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Abstract 
 
Introduction: Coronary heart disease (CHD) is the leading cause of death 
worldwide with 3.8 million men and 3.4 million women dying globally each year. 
Although existing myocardial reperfusion strategies such as thrombolysis and 
percutaneous coronary intervention (PCI), if applied in a timely manner, limit 
myocardial infarct size, the mortality and morbidity remains significantly high. 
Ischaemic preconditioning (IPC) may offer the potential to attenuate myocardial 
ischaemia/reperfusion injury through cardioprotective signaling pathways which is 
recruited at the time of myocardial reperfusion, thereby improving clinical 
outcomes in patients with coronary artery disease. 
 
Ischaemic preconditioning is a phenomenon whereby short intermittent episodes 
of coronary occlusion followed by reperfusion protect the myocardium against a 
subsequent period of sustained ischaemia. This protection is reflected in the 
limitation of infarct size and improved functional recovery of the ischaemic heart 
during reperfusion. Despite intensive research efforts, the promise of an effective 
cardioprotective strategy using the endogenous protective mechanisms of the 
heart which underlies IPC, has not yet been materialized. Although progress has 
been made in terms of signaling mechanisms in the preconditioned heart, the 
identification of the myocardial reperfusion phase as the critical “window” for 
cardioprotection, requires the elucidation of the signal transduction pathways 
during the reperfusion phase after IPC. 
 
In view of the above, the aims of the present study were to investigate: 
 
i. the involvement of the RISK pathway and p38 MAP kinase pathway in IPC 
during early  and late reperfusion 
ii. the involvement of heat shock protein-27 (HSP-27), heat shock protein-70      
(HSP-70), GSK-3β, CAMKII, AMPK and the transcription factor CREB in 
the context of IPC during early reperfusion 
iii. the involvement of autophagy and apoptosis during early and late 
reperfusion after IPC 
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iv. the correlation of the protein kinases with the hemodynamic parameters of 
the heart 
v. the mechanism of IPC by means of two-dimensional (2D) proteomics  
 
Methods: The isolated perfused working rat heart model was used with 
functional recovery as end-point. Hearts were preconditioned (IPC) for 3x5 min 
global ischaemia, alternated with 5 min reperfusion. Hearts were subjected to 25 
min sustained global ischaemia, followed by 5, 10, 15 or 30 min reperfusion when 
hearts were snap-frozen for western blotting analysis. Alternatively, hearts were 
reperfused for 30 min to record hemodynamic parameters and measure 
functional recovery. Non-preconditioned (Non-IPC) hearts were stabilized for 30 
min and subjected to 25 min sustained global ischaemia followed by 5, 10, 15 or 
30 min reperfusion when hearts were snap-frozen. Alternatively Non-IPC hearts 
were reperfused for 30 min to serve as control for the 30 min reperfused IPC 
group. Activation of the protein kinases was determined by western blotting 
analysis. 
 
For the proteomic study mitochondrial and cytosolic proteins were isolated from 
heart tissue and separated in the first dimension by isoelectric focusing, followed 
by separation in the second dimension by two dimensional gel electrophoresis. 
The PD Quest software programme was used to identify significantly expressed 
protein spots. Protein spots of interest were excised and subjected to in-gel 
digestion and the resulting peptides were analysed by mass spectrometry. 
Proteins were identified by Mascot and the Swiss Prot database. 
 
Results: Western blotting analysis demonstrated that the RISK pathway and p38 
MAPK are activated very early in reperfusion, but the activation is not sustained 
during the reperfusion period. Autophagy is also upregulated during this early 
reperfusion phase; it is attenuated in the middle reperfusion phase and increase 
for a second peak of upregulation in the late reperfusion phase. In addition, we 
identified CAMKII as a novel marker of functional recovery in IPC after 
reperfusion.  
 
The proteomic analysis identified twenty differentially expressed mitochondrial 
and thirty six differentially expressed cytosolic proteins between Non-IPC and 
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IPC hearts. Functions ascribed to the majority of these individual proteins were 
directly related to cardiac metabolism.  
 
Conclusion: Activation of the majority of the protein kinases investigated in the 
present study is associated with the hemodynamic parameters of the heart 
instead of functional recovery. Results indicated that the variable signaling 
patterns could be attributed to differences in heart rate and the effect thereof 
(ejection fraction, minimum and maximum rate of contraction), as a result of 
sympathetic stimulation due to psychological stress in the animals before 
slaughtering. Proteomics results demonstrated that IPC hearts which failed after 
ischaemia /reperfusion are metabolically compromised and “worse off” compared 
to non-IPC hearts. 
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Uittreksel 
 
Inleiding: Koronêre hartsiekte is die vernaamste oorsaak van sterftes wêreldwyd 
met 3.8 miljoen mans en 3.4 miljoen vrouens wat jaarliks sterf. Alhoewel 
bestaande miokardiale herperfusie strategieë soos trombolise en perkutane 
koronêre intervensie (PKI), wanneer betyds toegepas, miokardiale infarktgrootte 
beperk, bly mortaliteit en morbiditeit steeds hoog.  Isgemiese prekondisionering 
(IPK) beskik oor die potensiaal om miokariale isgemie/herperfusie skade te 
verminder deur beskermende seinoordragpaaie tydens miokardiale herperfusie te 
aktiveer en sodoende die pasiënte wat aan koronêre arterie siekte ly, se 
prognose te verbeter. 
 
Isgemiese prekondisionering verwys na die verskynsel waartydens kort episodes 
van isgemie opgevolg deur herperfusie, die miokardium teen ‘n daaropvolgende 
langdurige isgemiese insident beskerm. Hierdie beskerming word gereflekteer in 
die beperking van infarktgrootte en verbeterde funksionele herstel van die 
isgemiese hart tydens herperfusie. Ten spyte van intensiewe navorsingspogings 
is die presiese meganisme van endogene beskerming tydens IPK nog nie ten 
volle ontrafel nie. Die identifisering van die miokardiale herperfusie fase se 
kritiese “vensterperiode” van beskerming, noodsaak ‘n volledige analise van die 
seinoordragpaaie wat geaktiveer word tydens die herperfusie fase na IPK. 
 
In die lig van bogenoemde, was die doel van die huidige studie om die volgende 
te ondersoek: 
 
i. die betrokkenheid van die RISK seinoordragpad en p38 MAP kinase 
tydens vroeë en laat herperfusie na IPK 
ii. die betrokkenheid van “heat shock protein-27” (HSP-27), “heat shock 
protein- 70” (HSP-70), GSK -3β, CAMKII, AMPK en die transkripsie faktor, 
CREB, in die konteks van IPK tydens vroeë herperfusie 
iii. die betrokkenheid van outofagie en apoptose tydens vroeë en laat 
herperfusie na IPK  
iv. die korrelasie van die proteïenkinases met die hemodinamiese parameters 
van die hart 
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v. die meganisme van IPK deur middel van twee dimensionele proteomika 
 
Metodes: Die geïsoleerde werkende rothart model, met funksionele herstel as 
eindpunt, is gebruik. Harte is geprekondisioneer (IPK) met 3x5 min globale 
isgemie, afgewissel met 5 min herperfusie. Daarna is harte blootgestel aan 25 
min volgehoue globale isgemie, gevolg deur 5, 10, 15 of 30 min herperfusie, 
waartydens harte gevriesklamp is. Alternatiewelik, is harte blootgestel aan 30 min 
herperfusie ten einde funksionele herstel te meet en hemodinamiese parameters 
te registreer. Nie-geprekondisioneerde (Non-IPK) harte is gestabiliseer vir 30 
min, waarna dit onderwerp is aan 25 min volgehoue globale isgemie, gevolg deur 
5, 10, 15 of 30 min herperfusie, waartydens harte gevriesklamp is vir westelike 
klad analise. Alternatiewelik, is Non-IPK harte onderwerp aan 30 min herperfusie 
om te dien as kontrole vir die 30 min IPK groep. Aktivering van die 
proteïenkinases is bepaal deur westelike klad analise. 
 
Vir die proteomiese studie, is onderskeidelik mitokondriale en sitosoliese 
proteïene geïsoleer en geskei in die eerste dimensie met behulp van iso-
elektriese fokusering, gevolg deur skeiding in die tweede dimensie met behulp 
van twee dimensionele gel elektroforese. Die PDQuest sagteware program is 
gebruik om proteïenkolle te identifiseer wat statisties beduidende verskille toon. 
Proteïenkolle van belang is uitgesny en onderwerp aan in-gel tripsinering en die 
peptiede wat sodoende verkry is, is deur middel van massa spektrometrie 
geanaliseer. Proteïene is geïdentifiseer deur Mascot en die Swiss Prot databasis. 
 
Resultate: Westelike klad analise het aangetoon dat die RISK pad en p38 MAPK 
geaktiveer is tydens vroeë herperfusie, maar die aktivering word nie volgehou 
tydens die hele herperfusie periode nie. Outofagie word gestimuleer tydens die 
vroeë herperfusie fase; dit word onderdruk in die middel herperfusie fase en 
bereik ‘n tweede piek van stimulering in die laat herperfusie fase. Die 
proteomiese analise het onderskeidelik twintig differensieel gereguleerde 
mitokondriale proteïene en ses en dertig differensieel gereguleerde sitosoliese 
proteïene geïdentifiseer tussen Non-IPK en IPK. Die grootste persentasie van 
hierdie proteïene is direk betrokke by miokardiale energie metabolisme. CAMKII 
is geidentifiseer as ‘n unieke merker van funksionele herstel in IPK tydens 
reperfusie. 
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Gevolgtrekking: Aktivering van die meeste van die proteïenkinases wat 
ondersoek is in die huidige studie, is geassosieer met die hemodinamiese 
parameters van die hart, in plaas van funksionele herstel. Die resultate het 
aangetoon dat die varierende patrone van kinase aktivering toegeskryf kan word 
word aan verskille in harttempo en die effek daarvan (ejeksie fraksie, minimum 
en maksimum tempo van kontraksie), as gevolg van simpatiese stimulasie 
toegeskryf aan sielkundige stres in die diere voor slagting. Proteomiese analise 
het getoon dat IPK harte wat faal na isgemie/reperfusie metabolies 
gekompromiseer is en “slegter daaraan toe” is, in vergelyking met Non-IPK harte.       
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Abbreviation List 
 
Units of measurement: 
 
%    percentage 
 
µl    microliter                                         
 
µg    microgram 
 
ml    milliliter                    
 
g    gram 
 
M    molar 
 
Min   minute 
 
hr    hour 
 
mM   millimole 
 
µM   micromole 
 
Chemical compounds: 
 
Ca2+   calcium 
 
CO2   calcium chloride 
 
H2O   water 
 
K+    Potassium 
 
KCL   Potassium chloride 
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MgSO4   Magnesium sulphate 
 
NaCl   Sodium chloride 
 
NaHCO3   Sodium hydrogen carbonate 
 
O2              Oxygen 
 
Tris   tris(hydroxymethyl) aminomethane hydrochloride 
 
 
Other abbreviations: 
 
Non-IPC   Non preconditioning 
 
IPC   Ischaemic preconditioning 
 
SWOP   second window of protection 
 
HF   heart failure 
 
Ado   adenosine 
 
ACs   adenylyl cyclases 
 
cAMP   cyclic adenosine monophosphate 
 
cGMP   cyclic guanosine monophosphate 
 
PKA   protein kinase A 
 
PKC   protein kinase C 
 
PKG   protein kinase G 
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PI3-K   phosphoinositide 3-kinase  
 
PKB/Akt   protein kinase B 
 
MAPK   Mitogen-activated protein kinase 
 
ERK   extracellular signal-regulated kinases 
 
JNK   c-Jun amino-terminal protein kinase 
 
NOS   nitric oxide synthase 
 
eNOS   endothelial nitric oxide synthase 
 
NO   nitric oxide 
 
ROS   Reactive Oxygen Species 
 
HSP   heat shock protein 
 
RISK   Reperfusion Induced Salvage Kinases 
 
mito KATP channels mitochondrial KATP channels 
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Introduction to the study and statement of the problem   
 
Introduction 
Ischaemic preconditioning (IPC) is a phenomenon whereby brief episodes of 
ischaemia and reperfusion protect the heart against a subsequent prolonged 
ischaemic insult. This protection is associated with a decrease in infarct size and 
improved functional recovery during reperfusion. Despite intensive research 
efforts the precise mechanism of IPC still remains elusive. It is proposed that 
events during the brief preconditioning ischaemic episodes, trigger signaling 
pathways which converge at the level of the mitochondria.  
Although IPC is a powerfull protective strategy, it could not be effectively 
employed in patients during acute myocardial infarction, since IPC has to be 
introduced before the onset of ischaemia and it is impossible to predict the time 
of infarction. Emerging studies suggest that events occurring during the post-
ischaemic reperfusion phase, underlie the mechanism of IPC-induced protection.  
 
Objectives and statement of the problem 
Research efforts to elucidate the mechanisms whereby IPC protects the heart 
have been hampered by the opposing results obtained by different research 
groups. This phenomenon has been attributed to differences in species (rabbits 
vs rats vs mice), models (Langendorff vs working heart mode), experimental 
protocols (single vs multi-cycle) and severity of ischaemia (global vs regional).  
 
Of major concern are the conflicting data regarding kinase activation in the same 
species and model. Furthermore, researchers often report only one time point of 
kinase activation during reperfusion and then associate it with protection. We, 
therefore, hypothesize that kinase phosphorylation at reperfusion after IPC is a 
time dependent, dynamic process which correlates with different functional 
parameters. 
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The aims of this study therefore were: 
 
1) to characterize the activation patterns of the various kinases at different time 
points during reperfusion after IPC and to compare it with non-preconditioned 
hearts (Non-IPC) at the same time points during reperfusion after global 
ischaemia; 
2) to assess autophagy at these different time points during reperfusion after 
IPC and to compare it with non-IPC hearts at the same time points during 
reperfusion after global ischaemia; 
3) to assess apoptosis after 30 minutes of reperfusion after IPC and to compare 
it with non-IPC hearts at the same time point during reperfusion after global 
ischaemia; 
4) to identify the underlying mechanisms involved contributing to poor 
functional recovery of the IPC hearts during early (15 min) reperfusion, by 
employing 2D proteomics; 
5) to assess whether activation of the various kinases and heat shock proteins 
correlate with functional recovery and/or other haemodynamic parameters of the 
heart; i) before and after sustained ischaemia,  ii) after the IPC protocol (3xIPC) 
and also iii) after IPC during early (5 min and 10 min ) and late (30 min) 
reperfusion;  
6) to identify the kinase(s) of which the activation patterns do correlate with 
functional recovery of the ischaemic heart after IPC during 30 min reperfusion. 
 
Plan of study  
As a background to the study a broad and thorough overview of the current 
literature on IPC and the signaling of IPC is provided in Chapter 1. Following this, 
the basic materials used and methods employed during the research project are 
outlined in Chapter 2. The experiments have been presented in three separate 
chapters. Each chapter has its own introduction, results and discussion section. 
Despite being separate chapters cognizance must be taken of the fact that the 
data is still closely related and supporting the universal goal of the study. The 
central theme of Chapter 3 was to assess kinase profiles through western blots 
while Chapter 4 examines the different protein expression profiles by means of 
proteomics between IPC and Non-IPC hearts. In chapter 5 the aim was to 
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correlate kinase activation with the haemodynamic parameters of the heart. The 
final conclusion and future directions were discussed in Chapter 6.  
Conclusion 
Activation of the majority of the protein kinases investigated in the present study 
was associated with the hemodynamic parameters of the heart instead of 
functional recovery. Although the kinases play a major role in the protection 
elicited by IPC during the reperfusion phase, proteomic data also revealed an 
important role for proteins related to cardiac metabolism. 
 
Ethical approval 
The study (project number: P09/05/009) has been approved by the Research 
Ethics Committee: Animal Care and Use (REC: ACU) of the University of 
Stellenbosch. Animals were handled according to the guidelines “for accepted 
standards for the use of animals in research and teaching”, as reflected in the 
South African National Standards (SANS 10386:2008) document.  
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Chapter 1 
 
Introduction 
 
Cardiovascular disease remains a leading cause of morbidity and mortality. 
Regardless of the latest advances in the prevention and management of heart 
disease, the World Health Organization predicts that it will be the major cause of 
death globally by the year 2020 [Murray et al., 1997], which will place an  
enormous economic burden on healthcare resources. As a result of this, there is 
continued interest in finding new drugs or developing novel interventions that will 
limit cardiac damage. 
 
In the clinical setting, coronary reperfusion has proven to be the only means to 
reduce infarct size, after coronary artery occlusion. Reperfusion is a pre-requisite 
to salvage the ischaemic heart; however it is well established that reperfusion is 
accompanied by detrimental processes associated with reperfusion injury 
[Braunwald et al., 1985], which make the applications of cardioprotective 
strategies possible at this time. Consequently, numerous studies have 
investigated the potential of cardioprotective drugs or interventions administered 
at the onset of reperfusion to limit infarct size, such as thrombolysis or primary 
angioplasty.  
 
Thrombolysis as reperfusion strategy in acute myocardial infarction involves the 
intravenous application of streptokinase or tissue plasminogen activator [Hartzler, 
1983]. Direct primary percutaneous intervention, also known as coronary 
angioplasty, is the primary reperfusion therapy for acute myocardial infarction 
[Meyer et al., 1982]. Other interventions which can modify reperfusion injury  
include administration of Na+-H+ exchange inhibitors [Karmazyn, 1988], 
transforming growth factor-β1 (TGF-β1) [Lefer et al., 1993], fibroblast growth 
factor-2 (FGF-2) [Cuevas et al., 1999], cardiotrophin-1 (CT-1) [Cai et al., 1999], 
Insulin growth factor-1 [Buerke et al., 1995], activation of kinases [Hausenloy et 
al., 2004], perfusion with erythropoietin [Hanlon et al., 2005]. These have been 
reported to protect the myocardium when administered during reperfusion. 
However, results from failed clinical trails [Bolli et al., 2004; Flaherty et al., 1994] 
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indicated that the window of opportunity during reperfusion is very limited. 
Therefore candidate treatments or agents would need to be very effective when 
administered during reperfusion. 
 
Injury to the myocardium also occurs during ischaemia of which the proportion 
depends on the duration of the ischaemic event. In vivo studies with rabbits 
demonstrated that infusion of a glucose/insulin/potassium (GIK) cocktail 30 min 
before ischaemia continuing throughout the reperfusion phase elicited protection 
against ischaemia/reperfusion injury [Zhang et al., 2004]. A study by Jonassen 
and coworkers 2009, demonstrated that pre-treatment with insulin before 
ischaemia reduces infarct size in langendorff-perfused rat hearts.  
 
Results from a pilot clinical study indicated that administration of GIK reduced 
mortality in patients with acute myocardial infarction undergoing reperfusion [Diaz 
et al., 1998]. This clinical study was supported by experimental in vivo studies 
with rats, which demonstrated that GIK infusion at reperfusion reduces infarct 
size [Jonassen et al., 2000]. A later study by the same group, demonstrated that 
infusion of insulin at the onset of reperfusion had the same protective effects of 
GIK treatment and reduced infarct size in langendorff-perfused rat hearts 
[Jonassen et al., 2001]. 
 
Even though several attempts [Hartzler, 1983; Meyer et al., 1982; Karmazyn, 
1988; Lefer et al., 1993; Cuevas et al., 1999; Cai et al., 1999; Buerke et al., 1995; 
Hausenloy et al., 2004; Hanlon et al., 2005] to protect the ischaemic heart from 
lethal reperfusion damage have been intensively studied, the results were mostly 
controversial and unsatisfactory. Only a few of these results have been 
reproducible and none has been translated into clinical therapies [Bolli et al., 
2004]. However, in 1986 it was discovered that the heart has an endogenous 
protective mechanism, known as ischaemic preconditioning or IPC [Murray et al., 
1986].           
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1.) The phenomenon of ischaemic preconditioning (IPC) 
 
Ischaemic preconditioning (IPC) is a phenomenon in which brief episodes of 
ischaemia and reperfusion protects the heart against a subsequent prolonged 
ischaemic insult [Murry et al., 1986]. This protection is reflected as a decrease in 
infarct size and an increase in functional recovery of the ischaemic heart after 
reperfusion [Shiki & Hearse, 1987]. Ischaemic preconditioning has been 
acknowledged as the “strongest” form of in vivo protection against myocardial 
ischaemic injury, apart from early reperfusion [Kloner et al., 1998]. This 
phenomenon has evoked much attention and has been the object of major 
scientific investigations, aiming at elucidating the mechanism of IPC, which could 
lead to the development of pharmacological interventions to be used in a clinical 
setting. IPC has been observed in a variety of organs including the bladder, the 
brain, the gut, the kidney, the liver, the retina, skeletal muscle and the skin 
[Hausenloy et al., 2008; Yellon & Downey, 2003]. IPC was shown to occur in all 
species tested including canine [Przyklenl et al., 1995], mice [Miller & Winkle, 
1999], pigs [Valhaus et al., 1996], rabbit [Liu et al., 1991] and rat [Liu & Downey, 
1992]. It was also demonstrated that functional recovery in isolated human atrial 
trabeculae was greatly enhanced after an extended period of hypoxia by earlier 
hypoxic preconditioning [Speechly-Dick et al., 1995]. Despite the ability to 
demonstrate the occurrence of IPC in different animal models, the translation to 
the human clinical setting has been largely disappointing [Andrew et al., 2010].  
 
IPC occurs in two phases. The first phase, or classical preconditioning, is also 
known as the “early phase” or the “first window” of protection. The first phase is 
short-lived and cardioprotection wanes after 1-2 hours [Murray et al., 1986]. The 
second (late) phase or “delayed preconditioning”, also termed the “second 
window of protection” (SWOP), appears 12-24 hours after the IPC protocol and 
lasts for 48-72 hours [Marber et al., 1993; Yang et al., 2010].    
 
Although, IPC is a powerful protective strategy, it could not be effectively 
employed in patients during acute myocardial infarction, since IPC has to be 
introduced before the onset of ischaemia. It is impossible to predict the time of 
infarction, but if IPC exerts its protective effect at reperfusion, then clinical 
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therapeutic salvage could still be possible by implementing protective strategies 
at reperfusion. 
 
The signal transduction pathways of IPC can be divided into triggers, mediators 
and end effectors of protection. It has become an important objective to identify 
the triggers, mediators and end effector of IPC. Triggers are activated during the 
ischaemia/reperfusion cycle of the preconditioning phase, before the onset of 
sustained ischaemia. Inhibition of the triggers’ action during the preconditioning 
phase will block or abolish its cardioprotective effect. Mediators are important 
during the period of sustained index ischaemia and during the first few minutes of 
reperfusion after sustained ischaemia. Similarly, inhibition of a mediators’ action 
during this time will abolish the cardioprotection afforded by IPC. Elucidation of 
the signaling mechanisms involved in the cardioprotective effect of 
triggers/mediators in IPC can result in the development of pharmacological 
mimetics to be used in clinical therapy. 
 
1.1) Signaling pathways involved in ischaemic preconditioning 
(Fig.1.1) 
 
It is generally believed that simultaneous stimulation of the adenosine-, 
bradykinin- and opioid receptors in combination with the release of reactive 
oxygen species (ROS) during the short episodes of ischaemia/reperfusion all 
contribute to the triggering of IPC. It was hypothesized that the resulting signaling 
cascade requires convergence of all stimuli on a common distal pathway. This 
pathway is thought to involve protein kinase C (PKC), since inhibition of PKC 
inhibit the cardioprotective effects of ROS [Baines et al., 1997], adenosine 
[Sakamoto et al., 1995], the opioid receptors [Miki et al., 1998] as well as 
bradykinin [Goto et al., 1995]. This hypothesis was supported by studies in the rat 
[Mitchell et al., 1995] and in the rabbit [Ytrehus et al., 1994] which concluded that 
PKC activation plays a crucial role in IPC-induced protection.   
 
Adenosine, bradykinin and the opioids act via their corresponding G-protein 
coupled receptors to activate very divergent signaling cascades, which converges 
on a final common pathway. It is generally believed that adenosine receptors can 
activate PKC via phospholipases which produce diacylglycerol from membrane 
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phospholipids [Cohen et al., 2001]. Opioid receptors trigger through PI3-K 
activation and are dependent on transactivation of the epidermal growth factor 
receptor (EGFR) by metalloproteinases [Cohen et al., 2007]. Bradykinin is also 
dependent on PI3-K activation for its triggering action, but it occurs through an 
EGFR independent mechanism [Cohen et al., 2007]. The steps downstream in 
the signaling pathway through PI3-K appear to be the same for both bradykinin 
and the opioids, with subsequent phosphorylation of PKB/Akt through 
phospholipid dependent kinases.  Activation of PKB/Akt results in the activation 
of eNOS, leading to the production of NO. NO stimulates guanylyl cyclase to 
produce cGMP, which in turn activates PKG [Cohen et al., 2001; Oldenburg et 
al., 2004]. 
 
Several other substances were also found to trigger IPC through PKC activation, 
including angiotensin II [Liu et al., 1995], the catecholamines [Banerjee et al., 
1993] and endothelin [Wang et al., 1996]. However, these substances are not 
released in sufficient quantities during ischaemia to play a major role in IPC. 
 
It is well documented that reactive oxygen species (ROS), previously categorized 
as a receptor independent trigger, can stimulate IPC-induced protection by 
transient exposure of the heart to ROS generating systems [Yang et al., 2012]. 
Several studies demonstrated that cardioprotection induced by IPC could be 
blocked by ROS scavengers [Tritto et al., 1997; Baines et al., 1997]. In addition, 
cardioprotection induced by ROS could be blocked by inhibition of PKC, 
indicating that ROS signaling occurred upstream of PKC [Kuno et al., 2008].  
 
The source of ROS is thought to be the mitochondria. The mitochondrial KATP 
channel (mito KATP) is located in the mitochondrial inner membrane and has been 
shown to play an important role in IPC-induced cardioprotection [Liu et al., 1998; 
Garlid et al., 1997]. Opening of the mito KATP channel results in influx of K+ which 
is balanced by electrogenic H+ efflux driven by the respiratory chain, resulting in 
the increased production of ROS [Pain et al., 2000; Forbes et al., 2001].  ROS 
has been shown to induce the activation of PKC-ε [Yue et al., 2002; Schultz et 
al., 2003]. It has been proposed that activation of PKC is associated with the last 
step of the trigger phase as well as with the first step of the mediator phase 
[Downey et al., 2008].  
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The target of PKC however, remains unclear. It has been shown that PKC-
induced protection could be blocked by an adenosine receptor inhibitor [Philipp et 
al., 2006]. Since PKC inhibition does not affect protection mediated by the 
adenosine A2B receptor [Kuno et al., 2007], it is believed that the A2B receptor is 
located downstream of PKC. It is believed that PKC sensitizes the adenosine 
receptor to the heart’s endogenous adenosine. PKC thus plays a major role in 
IPC and can also directly or indirectly modulate several components which are 
associated with mitochondrial membranes. These include the mito KATP channel, 
BAX, BAD, Bcl-2 and also the mitochondrial permeability transition pore (MPTP) 
[Murphy 2004; Costa et al., 2005 & 2006], which are important modulators of cell 
survival/death. 
 
It is generally believed that IPC protects the heart by activating the ERK p44/p42 
MAPK- and PI3-K/PKB/Akt signaling pathways at reperfusion [Hausenloy et al., 
2005]. These pathways combined are denoted as the “Reperfusion Injury 
Salvage Kinase” or RISK pathway. Inhibition of either of these pathways during 
early reperfusion abolishes the protection afforded by IPC. Therefore, it is 
proposed that IPC exerts its protection during early reperfusion, after the period 
of lethal ischaemia [Hausenloy et al., 2005]. This finding provided enormous hope 
for implementing IPC in the clinical setting, particularly when blood supply to the 
ischemic zone is restored after clinical procedures. In fact, since 2005 many 
pharmacological agents were tested and found to protect the myocardium when 
given during early reperfusion. These include insulin [Baines et al., 1999], the 
adenosine A1/A2 agonist, Bay 60-6583 [Xu et al., 2000], the adenosine agonist 
5’-(N-ethylcarboxyamido) adenosine (NECA) [Yang et al., 2004], bradykinin 
[Yang et al., 2004], cyclosporine A [Hausenloy et al., 2009], erythropoietin [Cai & 
Semenza, 2004], natriuretic peptide [Yang et al., 2006], transforming growth 
factor-β1 [Baxter et al., 2001] and urocortin [Schulman et al., 2002]. All of these 
agents, except cyclosporine A, depend on the activation of the RISK pathway to 
induce cardioprotection. 
 
The mitochondrial permeability transition pore (MPTP) is currently postulated to 
play a crucial role in determining cell death or survival [Vigneron et al., 2011]. It 
was found that the MPTP remained closed during ischaemia and open only 
during the first few minutes of reperfusion. It has been shown that activation of 
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the RISK pathway and other protective signals converge to phosphorylate 
glycogen synthase kinase-3β on Ser9, resulting in its inactivation and subsequent 
inhibition of MPTP opening which results in cardioprotection [Juhaszova et al., 
2004]. The immunosuppressant drug, cyclosporine A, also inhibited MPTP 
opening induced by oxidative stress, phosphatases and calcium [Crompton et al., 
1988].  
 
In summary, more than two decades after the description of ischaemic 
preconditioning (IPC) and despite all the intensive research efforts and 
knowledge gained, the exact mechanism of this endogenous protective 
phenomenon still remains to be fully elucidated.  
 
According to Downey and co-workers (2008), the events during the triggering 
phase of IPC are well mapped. Events during the reperfusion phase are less well 
defined. Therefore, the finding that IPC exerts its protection during early 
reperfusion by activation of the RISK pathway caused a paradigm shift and has 
led to increased focus on events during early reperfusion.  
 
A recurring theme throughout this literature review is the great controversy 
regarding the role of protein kinases as potential mediators of protection in the 
setting of IPC-induced protection. Many of the studies investigating the role of 
these kinases in IPC, followed a pharmacological approach. This has led to a 
variety of suggested receptors and signaling pathways that could possibly be 
involved in the mechanism of IPC. However, it is also believed that meticulous 
investigation of the events during an IPC protocol will identify the parameters 
crucial for cardioprotection. 
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Figure 1.1: A cartoon showing the sequence of signaling events involved in triggering 
the preconditioning state prior to the ischaemic insult (events above the dividing line) and 
those that mediate protection in the first minutes of reperfusion (events below the 
dividing line). See text for details. [Downey et al., 2008]. 
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1.2.)  Receptor dependent triggers of early preconditioning 
 
1.2.1.)   α- and β- Adrenoreceptors                             
 
Adrenergic receptors belong to the superfamily of G protein-coupled receptors 
(GPCR). They share the common feature of 7-transmembrane spanning domains 
and are involved in physiological responses to autocrine and neurotransmitters 
[Yarden et al., 1986]  
 
The β-adrenergic receptor (β-AR) is a typical G protein-coupled receptor (GPCR).  
Upon stimulation, via circulating catecholamines (sympathetic stimulation), it 
regulates a wide range of biological processes. These include myocardial 
contractility and relaxation, vascular and bronchial smooth muscle tone, 
pacemaker activity, cell growth, cell survival and cell death. It is also involved in 
metabolic regulation, such as glucose and lipid metabolism. Adrenergic receptors 
can be divided into α- and β- adrenergic receptors [Ahlquist,  1948]. By using the 
appropriate agonists and antagonists the adrenergic receptors were further 
classified into α1-, α2-, β1- and β2- adrenergic receptor subtypes [Lands et al., 
1967; Ablad et al., 1974]. The β3 receptor was identified at a later stage [Emorine 
et al., 1989]. 
 
All three β-AR subtypes are found in a variety of tissue. They form a central part 
of membrane proteins located in the hearts of different species [Bylund et al., 
1998]. Sympathetic stimulation of the β-adrenergic receptor by catecholamines 
(norepinephrine and epinephrine) functions as a powerful regulatory system to 
enhance cardiac output as a consequence of stress, injury or exercise [Hata et 
al., 2004; Lohse et al., 2003]. Sympathetic stimulation increases the release of 
norepinephrine and epinephrine from the adrenal medulla to all areas of the 
heart, whereas the parasympathetic nervous system normally opposes its effects 
to maintain blood pressure within the normal range. The parasympathetic 
nervous system acts via the vagal nerve to release acetylcholine to control blood 
pressure [Opie, 1998].  
 
A G-protein coupled receptor (GPCR) is characterized by a glycosylated amino 
(N) terminus and an intracellular carboxyl (C) terminus region with serine and 
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threonine residues which are potential phosphorylation sites. The seven 
transmembrane domains (TD) are linked by three extracellular loops and three 
intracellular loops [Yarden et al., 1986]. Ligand binding triggers a conformational 
change in the GPCR with subsequent disruption of ionic interactions between the 
third cytoplasmic loop and the sixth transmembrane segment. This allows 
coupling with the heterotrimeric guanine-nucleotide regulatory proteins (G-
proteins) [Han et al., 1998; Wess, 1997]. The phosphorylation sites of protein 
kinase A (PKA) is situated on the third intracellular loop of the receptor. It is 
therefore thought that PKA plays an important role in agonist induced uncoupling, 
subsequent rapid desensitization and downregulation of the receptor [Benovic et 
al., 1985].  
 
The β1-AR and β2-AR coexist in cardiomyocytes of many mammalian species 
[Xiao et al., 1999], including in the human heart where the β1-AR is the 
predominant receptor. It is equally distributed in all parts of the heart [Brodde, 
1991]. The human heart expresses β1-AR and β2-AR at a ratio of about 70-80%: 
30-20% in the ventricles and 60-70%:40-30% in atria [Brodde, 1991]. The β1-AR 
stimulates cardiac muscle and contributes to the relaxation of blood vessels, 
whereas the β2-AR relaxes smooth muscle and contributes to cardiac contractility 
[Lands et al., 1967; Brodde, 1991].  
 
The β3-AR subtype is expressed in a variety of tissues and is found to a large 
extent in the coronary vascular bed [Strosberg, 1997]. The β3-AR subtype 
stimulates the L-type calcium current in human atrial myocytes [Skeberdis et al., 
1999] and reduces contractile force in human ventricular muscle [Gauthier et al., 
1989]. β3-adrenergic receptors are also expressed in adipose tissue [Emorine et 
al., 1989]. It also mediates lipolysis in white adipose tissue and thermogenesis in 
brown adipose tissue [Arch, 1989]. 
 
Signaling by cardiac β-adrenergic receptors has been studied in great detail and 
it is generally accepted that the β-AR subtypes have different affinities for their 
ligands, resulting in the activation of distinct signaling pathways [Lohse et al., 
2003]. It is proposed that spatial segregation of receptors allows their 
involvement with other segregated proteins, resulting in the formation of 
signalosomes [Lohse et al., 2003]. 
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β-AR signaling is initiated by binding of the agonists (catecholamines) to the 
receptor, followed by a subsequent conformational change, resulting in the 
activation of the classical Gs-adenylyl cyclase (AC)-cAMP-PKA signaling 
pathway. PKA, which is the primary target of cAMP, phosphorylates several 
proteins that are essential for cardiac function, including L-type calcium channels 
[Zhao et al., 1994], phospholamban [Simmerman et al., 1998], ryanodine 
receptors [Marx et al., 2000], troponin 1 [Sulakhe et al., 1995] and myosin binding 
proteins [Kunst et al., 2000]. This affects cardiomyocyte contractility by increasing 
the Ca2+  influx  through the L-type channel and increasing Ca2+ re-uptake into the 
sarcoplasmic reticulum (phospholamban/SERCA) and modulating myofilament 
Ca2+ sensitivity (troponin I, myosin binding protein-C) [Lohse et al., 2003]. 
 
It is also well known that catecholamines act through α-adrenergic receptors (α-
AR). Two classes of α-AR have been identified, α1-AR and α2-AR [Shannon & 
Chaudhry, 2006]. The α1-AR can be further classified into three subtypes; α1-A, 
α1-B and α1-D with distinct physiological roles. The α1-AR plays an adaptive role 
in the heart and has been shown to protect against the development of heart 
failure in contrast with the detrimental effects of chronic β-AR stimulation. The 
beneficial effects of the myocardial α1-AR subtype have been confirmed by 
studies using knockout (KO) mice models [Simpson, 2006]. These studies 
demonstrated that KO of the two main myocardial α1-AR subtypes, α1-A and α1-
B, resulted in the impairment of normal post-natal myocardial growth. 
Consequently, this resulted in severe dilated cardiomyopathy and death after 
pressure overload [O’Connell et al., 2003 & 2006]. This data obtained from KO 
studies suggested that the α1-AR is cardioprotective [Huang et al., 2007; 
O’Connell et al., 2006], whereas the role of the α1-AR appears to be associated 
with physiological cardiac hypertrophy [Vecchione et al., 2002; Rodrigo et al., 
2005]. All three α-AR subtypes can cause constriction of peripheral arteries 
[Vecchione et al., 2002], whereas the cardiac α1-AR stimulates coronary 
vasoconstriction [Turnbull et al., 2003]. Studies demonstrated that α1-A, α1-B and 
α1-D are all present in the human heart [Jensen et al., 2009]. In addition, the α1-
AR subtype expression was shown to be similar to the mouse heart with α1-A and 
α1-B in the myocardium and the α1-D subtype in the coronary arteries. The α1-AR 
mRNA’s are not repressed in heart failure and α1-AR are not downregulated in 
contrast with β-AR subtypes [Jensen et al., 2009]. 
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 A large percentage of studies proposed that activation of the α- [Hu et al., 1995; 
Tsuchida et al., 1994] and β- adrenoreceptors [Spear et al., 2007; Tong et al., 
2005] can act as triggers of IPC. This was based on the findings that IPC-induced 
cardioprotection was attenuated when these receptors were blocked. Other 
contradictory reports showed that neither depletion of intramyocardial 
catecholamine storage and release [Ardell et al., 1996] nor specific 
catecholamine receptor antagonists [Thornton et al., 1993] could block the 
protection afforded by IPC. It was, however, shown that exogenous 
catecholamines or adrenoreceptor agonists could precondition the heart where 
direct involvement of the α1-A and α1-B-receptors during IPC was suggested 
[Thornton et al., 1993 & Tsuchida et al., 1994].  Another study however, 
suggested the involvement of the α1-A-, rather than the α1-B receptor 
[Rorabaugh et al., 2005].  
 
Activation of the β2-adrenoreceptor was also reported to be important in IPC-
induced cardioprotection [Tong et al., 2005]. Β1-adrenoreceptor activation also 
confered protection during the preconditioning period, but activation was shown 
to be deleterious after reperfusion [Spear et al., 2007]. 
 
Although the α1-adrenergic receptor was proposed to play a role in IPC-induced 
cardioprotection, our laboratory could not find evidence for this receptor in the 
mechanism of IPC [Moolman et al., 1996].  
 
In addition, the steps during an IPC protocol were meticulously investigated in our 
laboratory to serve as a guide to direct future research [Moolman et al., 1996]. 
The finding that cAMP increased in a cyclic manner at the end of each IPC 
episode suggested a potential role for β-adrenergic receptor signaling as trigger 
in the IPC process [Lochner et al., 1998 & 2000]. It was first reported by Asimakis 
et al. [1994] that pharmacological preconditioning with isoproterenol induced 
protection against ischaemia. Subsequently it was reported that transient β-AR 
stimulation with agents such as dobutamine and isoproterenol could mimick IPC 
and offer protection against a subsequent period of sustained ischaemia 
[Miyawaki & Ashraf, 1997; Lochner et al., 1999]. This phenomenon is known as 
β-preconditioning. 
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1.2.2.)   Adenosine, Bradykinin and the opioids 
 
Adenosine is an ubiquitous nucleoside which is continuously produced 
intracellularly and extracellularly under normal conditions. It is maintained at low 
intracellular levels (100-300 nM) by the enzymes adenosine kinase and 
adenosine deaminase. Adenosine is released by metabolically active and 
stressed cells (oxygen deprivation) in which case the levels can increase up to 10 
µM [Zetterstrom et al., 1982; Hagberg et al., 1987]. Adenosine plays a major role 
in the cardiovascular system [Baines et al., 1999], the central nervous system 
[Fredholm et al., 1995], the gastrointestinal tract [Linden, 1994; Marquardt, 1998], 
the immune system [Cronstein, 1994], cell growth, proliferation and apoptosis 
[Burnstock, 2002] under normal and stressful situations. 
 
In the heart, adenosine has the following electrophysiological effects; transient 
reversible slowing of heart rate (negative chronotropic effects), anti-arrhythmic 
effects and impairment of atrioventricular conduction (negative chronotropism) 
[Drury & Scent-Gyorgi, 1929; Belardinelli et al., 1989]. Adenosine mediates two 
types of actions in the heart, those that are cAMP dependent (direct effects) and 
also those that are cAMP independent (indirect effects). 
 
In addition, adenosine has an essential function in the regulation of the 
myocardial oxygen supply, known as demand balance.  This is achieved by 
increasing the oxygen supply through coronary vasodilation and reducing the 
oxygen demand by decreasing myocardial contractility. Adenosine also 
attenuates the effects of the catecholamines and thereby suppresses conduction 
inside the sinoatrial (SA) and atrioventricular (AV) nodes [Belardinelli et al., 
1989]. Adenosine also inhibits oxygen metabolite production by activated 
neutrophils [Pelleg, 1985; Belardinelli et al., 1989], attenuates the release of 
norepinephrine from nerve terminals and activates glycolysis [Pelleg, 1985; 
Belardinelli et al., 1989]. The cardiac actions of adenosine were shown to be 
surprisingly similar to that of acetylcholine (Ach) [Belardinelli & Isenberg, 1983]. 
Therefore, it appears as if Ach and adenosine act in parallel to antagonize the 
effects of cardiac sympathetic stimulation.    
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Adenosine mediates its effect via activation of cell surface receptors namely A1, 
A2A, A2B and A3 adenosine (AdoRs) receptors. These receptors belong to the G-
protein-coupled superfamily of receptors [Auchampach & Bolli, 1999; Olah & 
Stiles, 1995].  
 
The A1-AdoR is the most extensively studied adenosine receptor in the setting of 
cardioprotection. Several studies reported the involvement of the A1-AdoR with 
signaling cascades such as the DAG/IP3/PLC cascade and PKC, MAPKs, PI3-
kinase and PKB/Akt [Buck, 2004; Mubagwa & Flemming, 2001; Headrick et al., 
2003]. Activation of the mito KATP channel and PKC also play a role in A1-AdoR 
mediated cardioprotection [Peart & Headrick, 2003]. 
 
Liu and co-workers (1991) discovered that activation of the Gi-coupled adenosine 
A1 receptor triggered IPC’s protection [Liu et al., 1991]. It has thus become clear 
that IPC in the heart was receptor mediated and the result of signal transduction 
pathways.  
 
It was also reported that the A2A-AdoR protected against ischaemia/reperfusion 
injury by limiting the damaging effects of neutrophil activation [Lasley et al., 
2001]. These receptors have also been shown to play a role in the 
cardioprotection afforded by postconditioning [Kin et al., 2005]. Activation of the 
A2A-AdoR has been shown to limit infarct size during reperfusion in the isolated 
rabbit heart and this cardioprotection was linked to activation of ERK p44/42 [Kis 
et al., 2003]. 
 
The A2B-AdoRs are less well studied in the setting of myocardial 
ischaemia/reperfusion [Kilpatrick et al., 2002]. However, the A2B-Ado has been 
shown to play a role in the infarct limiting effects of postconditioning in the rabbit 
heart. This protection implicated the involvement of PKC [Phillip et al., 2006]. The 
cardioprotective role of the A2B-Ado was also demonstrated in IPC induced 
protection during reperfusion [Solenkova et al., 2005].  
Overexpression of the A3-AdoR enhances ischaemic tolerance and significantly 
limits ATP depletion during ischaemia [Gross et al., 2002]. This is consistent with 
adenosine dependent increase of myocardial energy state [Fralix et al., 1993]. 
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The A3-AdoR was shown to be involved in delayed preconditioning in a similar 
fashion to the A1-AdoR [Takano et al., 2001].  
 
Studies followed that indicated involvement of bradykinin B2 [Wall, et al., 1994] 
and opioid-δ-receptors [Schulz et al., 1995] in IPC-induced protection. These 
substances can act as triggers of IPC by binding to their corresponding G-protein 
coupled receptors. This lead to the activation of signaling pathways that is 
thought to converge on a common target, possibly protein kinase C (PKC), since 
inhibition of PKC attenuated the protection afforded by IPC [Yang et al., 2010].  
 
It was also shown that adenosine [Sakamoto et al., 1995], bradykinin [Goto et al., 
1995] and the opioids [Miki et al., 1998] are released in sufficient quantities by 
ischaemia to act as endogenous triggers of IPC. Opioid receptor signaling is 
suggested to depend on transactivation of the epidermal growth factor receptor 
(EGFR), which activates PI3-kinase [Cohen et al., 2007]. This process is 
metalloproteinase-mediated and the EGFR tyrosine kinase auto-phosphorylates 
its tyrosine residues when bound to its triggering growth factor. Bradykinin’s 
triggering action is also dependent on PI3-kinase activation, but it appears to be 
independent of EGFR. For both the opioids, as well as bradykinin, the steps 
downstream of PI3-kinase appear to be similar. PI3-kinase causes 
phosphorylation of PKB/Akt, which in turn activates endothelial nitric oxide 
synthase (eNOS) to produce nitric oxide (NO). NO stimulates guanylyl cyclase 
(GC) to produce cyclic guanosine monophosphate (cGMP), which stimulates 
protein kinase G (PKG) [Oldenburg et al., 2004]. 
 
There is evidence that cyclooxygenases may act as triggers of IPC in rats [Chen 
et al., 1999] and mice [Gabel et al., 2001]. Norepinephrine, angiotensin, 
prostaglandins and endothelin are also released during the brief periods of 
ischaemia/reperfusion during IPC. Endogenous prostaglandins however, do not 
act as triggers of IPC in the rat [Li et. al., 1992] or rabbit [Liu et al., 1992]. 
Agonists such as norepinephrine, endothelin and angiotensin can precondition 
the heart when administered exogenously, but are not released in sufficient 
quantities during ischaemia to act as endogenous triggers of IPC [Tanno et al., 
2000; Wang et al., 1996; Moolman et al., 1996]. 
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1.3.)  Receptor independent triggers: 
 
1.3.1.)  Reactive oxygen species (ROS) 
 
Biological systems are extremely capable to tolerate the production of ROS under 
normal conditions and to maintain this well balanced system. However, during 
ischaemia/reperfusion this balance becomes disturbed as cellular antioxidant 
defense mechanisms are attenuated during ischaemia. The ability of elevated 
hydrogen peroxide (H2O2) to produce the destructive hydroxyl radical (.OH) 
becomes more favorable under these conditions [Hess & Manson, 1984].  
 
ROS are extremely reactive molecules and include superoxide anion (O2-) and 
the hydroxyl radical (OH.). However, H2O2, which is not considered a free radical, 
is often discussed in combination with ROS, since it is also very active. Free 
radicals originating from the reaction of oxygen with nitrogen are considered a 
subclass of free radicals and are known as reactive nitrogen species (RNS). RNS 
include nitric oxide (NO) and peroxynitrite (ONOO-). ROS and RNS are the 
products of several enzymes and biochemical processes. Biological systems 
have several defense mechanisms against reactive oxygen species under normal 
conditions. These protective mechanisms, known as anti-oxidants may be 
enzymatic or non-enzymatic. Anti-oxidants could also function as triggers of 
signaling cascades in the cell [Marczin et al., 2003].  
 
The main source of ROS in the myocardium is located in the mitochondria 
[Becker et al., 1999]. The production of ROS has been shown in isolated hearts 
and also in isolated cardiomyocytes during ischaemia. The levels of ROS 
generated during ischaemia are generally low and it is postulated to have an 
important role in cell signaling.  
 
ROS are produced in large quantities during the first few minutes of post-
ischaemic reperfusion and it is generally accepted that these high concentrations 
of ROS results in oxidative injury. At these high concentrations, ROS may 
damage myocytes by inducing lipid peroxidation of membranes, thereby altering 
the integrity, fluidity and permeability of membranes. Another target of ROS is the 
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membrane proteins, which are involved in ion transport and responsible for 
maintaining cellular ionic homeostasis [Schulz et al., 2001].  
 
It is now clear that low concentrations of ROS and RNS play a crucial role in 
signaling pathways necessary for several biological processes, including 
cardioprotection. It is generally believed that cells are protected against 
ischaemia/reperfusion damage when they maintain the delicate equilibrium 
between the protective anti-oxidant signaling and harmful effects of ROS.  
 
It was demonstrated in several studies that ROS production plays an essential 
role in IPC-induced protection [Baines et al., 1997; Tritto et al., 1997] and it was 
also postulated that it is the ischaemia-generated ROS that triggers IPC [Van den 
Hoek et al., 1998]. One of the proposed mechanisms of IPC induced 
cardioprotection is the opening of the mitochondrial KATP (mito KATP) channel, 
located in the inner mitochondrial membrane [Garlid et al., 2003]. This 
cardioprotection involves stabilization of the mitochondrial inner membrane and 
the prevention of mitochondrial uncoupling [Halestrap et al., 2009]. Since 1997, 
several publications have implicated opening of the mito KATP channel as the 
main trigger and /or end effector of IPC [Garlid et al., 2003; Gross & Peart, 2003]. 
Diazoxide has been reported to be a specific activator (opener) of the mito KATP 
channel and is therefore able to trigger IPC pharmacologically. The fatty acid, 5-
Hydroxydecanoate (5-HD), has been reported to be a specific inhibitor of the mito 
KATP channel [O’Rourke, 2004]. However, diazoxide and 5-HD have various mito 
KATP channel independent actions and experimental proof that these channels 
play an essential role in IPC induced protection remains inadequate [Hanley & 
Daut, 2005].  
 
The ability of ROS to modulate the mito KATP channel has been reported [Forbes 
et al., 2001; Pain et al., 2000]. ROS primarily formed by mitochondria is 
superoxide (O2.-) [Murphy et al., 2009], while secondarily generated ROS 
includes hydrogen peroxide (H2O2) or lipid peroxides [Kowaltowski et al., 2009]. 
Both O2.- and H2O2 have been shown to induce opening of the mito KATP channel 
[Zhang et al., 2001; Costa et al., 2008]. In addition, it was suggested that opening 
of the mito KATP channel by H2O2 may occur via a PKC-ε dependent mechanism 
[Costa et al., 2008]. Another source of ROS in the heart is NADPH oxidase and it 
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is postulated that it may also be involve or contribute to the ROS that trigger IPC. 
A recent study demonstrated that NADPH almost completely inhibited mito KATP 
channel activity [Queliconi et al., 2011], suggesting that this channel may play a 
role in sensing both redox status and energy metabolism [Cardoso et al., 2010]. 
ROS can also modulate intracellular calcium homeostasis [Feissner et al., 2009]. 
The transient increase in ROS through the increase in NO levels can trigger both 
early [Nakano et al., 2000] and late phases [Sun et al., 2005] of ischaemic 
preconditioning.  
 
1.3.2.) Nitric oxide 
 
Nitric oxide (NO), a simple diatomic gas (structural formula:  N=O) and free 
radical, was originally regarded as an atmospheric pollutant and a component of 
exhaust fumes and cigarette smoke [Singh & Evans, 1997]. The idea that NO 
could be endogenously produced in the body was not considered until the 
concept of “nitrovasodilators” and their role in smooth muscle relaxation was 
introduced in the early 1980’s [Furchgott  & Zawadzk, 1980; Murad,1998].  
 
The first known physiological interaction described for NO, was the discovery that 
NO could activate soluble guanylate cyclase (sGC) [Murad 1994; 1998]. 
Activation of sGC by NO results in the conversion of guanosine triphosphate 
(GTP) to cyclic monophosphate (cGMP) [Denninger & Marletta, 1999]. This 
reaction is the trigger of NO’s signaling cascade with cGMP as second 
messenger, leading to smooth muscle relaxation. NO plays a key role in the 
regulation of  vascular homeostasis.  
 
NO is synthesized by enzymes called nitric oxide synthases (NOS) which are 
expressed in a variety of tissues. It is particular highly expressed in the nervous- 
and cardiovascular system [Schulz et al., 2004]. NOS consists of three known 
isoforms; neuronal NOS (nNOS, NOS-1), inducible NOS (iNOS, NOS-2) and 
endothelial NOS (eNOS or NOS-3). All three isoforms are expressed in the heart 
[Ballgand & Cannon 1997]. eNOS expression is most prominent in endothelial 
and cardiac microvascular endothelial cells while iNOS expression has been 
shown to be relatively higher in cardiomyocytes.  
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Cardiomyocytes express all three isoforms of NOS. NOS-1 and -3 are 
constitutively expressed, while NOS-2 is not usually expressed in 
cardiomyocytes. The expression of NOS-2 is induced during the inflammatory 
response and is associated with heart failure [Ziolo et al., 2001]. 
 
The expression of iNOS is dependent on cytokine stimulation such as TNF-α  
[Balligand & Cannon, 1997] and it is also known that iNOS generates up to 1000-
fold more NO than eNOS [Singh & Evans, 1997]. iNOS derived NO can be 
potentially harmful due to the sudden, robust generation of NO. It can react with 
the super-oxide radical (O2-) leading to the formation of the highly reactive and 
harmful radical, peroxynitrite (ONOO.). The biological effects of NO in the heart 
depend on which NOS isoform is activated and also the amount of NO released  
[Strijdom et al., 2009]. 
 
NO is regarded as an important mediator of biological processes in the heart and 
is reported to play an important role in cardioprotection [Boengler et al., 2000]. 
The sources of NO can both be exogenous or endogenous. Endogenous NO can 
be generated by activated endothelial NO synthase (eNOS) or upregulated by 
inducible NOS (iNOS). However, the role of endogenous NO in IPC still remains 
somewhat controversial [Nakano et al., 2000a]. Results from one study indicated 
that inhibition of NO synthase attenuates the protective effect of IPC in rats, 
thereby suggesting a trigger function for nitric oxide in early IPC [Lochner et al., 
2000]. Conversely, several other studies indicated that nitric oxide is not a trigger 
of early IPC [Nakano et al., 2000; Post et al., 2000].  
 
Recent studies however, demonstrated that the cardioprotective properties of NO 
are partly cGMP dependent [Otani, 2009] and are attributed to the vasodilatory 
and anti-inflammatory effects of cGMP [Costa et al., 2008]. NO also has direct 
cardioprotective properties which are cGMP independent. It is also suggested 
that the direct effects of NO largely target mitochondria. It was further 
demonstrated that NO can confer protection long after the triggering signal 
[Boengler et al., 2000]. These studies support the idea that NO works as a signal 
mediator and end effector of protection, rather than a trigger [Kitakaze 1998; Liu 
et al., 1991].  
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Another aspect of NO in late IPC is its dual role as both a trigger and mediator, 
which involve two different NOS isoforms [Boli, 2001]. It is thought that during the 
triggering phase of IPC, brief episodes of ischaemia activates eNOS to release 
NO, which in turn induces the expression of iNOS and a subsequent second 
burst of NO release [Boli, 2001].  
 
However, the induction of NO synthesis colocalizes with the site where calcium 
and ROS are exerting their actions. While NO confers many protective functions 
in the heart, it could be detrimental when simultaneously exposed to excessive 
oxidative stress. This may result in the generation of further oxidative/nitrosative 
stress [Costa et al., 2008]. 
 
1.3.3.) The role of calcium 
 
Calcium, like ROS serve as a signaling mediator under physiological conditions, 
but the time period, dose and location are critical [Feissner et al., 2009]. It is 
widely recognized that intracellular calcium overload causes cellular damage 
because of ischaemia/reperfusion injury, especially when it is intense and for a 
prolonged period. However, short and transient exposure to calcium, like ROS, is 
beneficial because both of them have been reported to trigger IPC [Node et al., 
1997; Sun et al., 1996]. Intracellular calcium is required to activate protein kinase 
C (PKC) during IPC [Node et al., 1997]. Furthermore, the calcium-activated K+ 
channel has been reported to protect the myocardium when it is activated at 
reperfusion [Sato et al., 2005; Shintani et al., 2004].  
 
1.4.)    Mediators of ischaemic preconditioning 
 
Mediators exert their actions during the period of sustained ischaemia and the 
first few minutes of reperfusion after sustained ischaemia. Inhibition of a 
mediator’s action during this time will abolish the cardioprotective effect of IPC. 
Identification and subsequent elucidation of the signaling pathways involved in 
the cardioprotective effects of mediators in IPC could result in the development of 
novel pharmacological interventions to be used in clinical therapy. 
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1.4.1)  Protein kinase C (PKC)                              
 
The PKC family consists of at least 12 serine/threonine kinases. Many of these 
PKC isoforms are present in the rabbit heart. The most important PKC-isoforms 
in the rat heart are the α-, δ- and ε isoforms. Studies conducted in the rabbit 
[Ytrehus et al., 1994] and rat [Mitchell et al., 1995] support a central role for PKC 
as mediator of IPC. Furthermore, studies in different species indicated that PKC 
epsilon (PKC-ε) is the main isoform of PKC involved in IPC [Vondriska et al., 
2001; Jennings et al., 1997].  
 
The function of PKC-δ in IPC is controversial. Some studies indicated that it has 
a protective role in IPC [Kawamura et al. 1998; Mayr et al. 2004], while other 
studies showed that the expression of PKC-δ peptides have no protective role in 
IPC and even worsens ischaemia/reperfusion injury  [Chen  et al., 2001]. 
 
Other researchers also indicated that PKC on its own do not play a role in the 
protection afforded by IPC, however, simultaneous activation of both PKC and 
tyrosine kinase play a role in the protective response elicited by IPC [Masaya et 
al. 2000; Fryer et al]. It is thus suggested that PKC is not the only mediator of 
IPC, but that co-mediation with tyrosine kinase (Src and Lck) is likely to occur 
[Vahlhaus et al.1998]. It is probable that PKC and tyrosine kinase are two 
components of a much larger kinase cascade as their downstream targets are 
the mitogen activated protein kinases (MAPK’s). The MAPK family is one of the 
major kinase cascades in the mammalian heart and consists of four families, 
each of which has been suggested to play a role in cardioprotection (Discussed 
in section 1.5). 
 
Studies demonstrated that PKC is responsible for the generation of IPC- induced 
activation of 5’-nucleotidase (CD73), which would generate more protective 
adenosine from adenosine monophosphate [Kitakaze et al., 1995]. It was further 
proposed that the increase in extracellular adenosine activated the low affinity 
adenosine A2b receptor, which in turn is protective [Eckle et al., 2007].  
According to this hypothesis, IPC hearts should have a higher adenosine 
concentration than non-IPC hearts. This has been difficult to demonstrate as 
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most studies did not detect a difference in adenosine concentration between IPC 
and non-IPC hearts [Schulz et al., 1998].  
 
A minority of studies have shown an increase in adenosine levels in IPC hearts 
[Eckle et al., 2008], whereas some actually documented lower adenosine levels 
in IPC hearts [Goto et al.,1996; Harrison et al., 1998]. It was proposed that the 
activated Gi-PCR concentrate in caveolae during IPC where signalling enzymes 
are scaffolded into signalosomes which migrate to the mitochondria [Oldenburg 
et al., 2004]. The signalosomes interact with mitochondria through an unknown 
PKG mediated mechanism, resulting in the activation of two pools of PKC-ε, 1 
and 2 [Costa et al. 2008].  PKC-ε1 maintains ROS production, while PKC-ε2 
inhibits opening of the mitochondrial permeability transition pore (MPTP). The 
MPTP is a large conductance pore located in the mitochondria, which opens 
during reperfusion, resulting in cardiomyocyte death. Closure of the MPTP during 
reperfusion is cardioprotective (discussed in section 1.6.2).  
                    
1.4.2.)   Sphingokinase 
 
The activation of sphingokinase in the setting of IPC has been demonstrated to 
be dependent on the activation of PKC-ε. Sphingosine 1-phosphate, a lipid 
signalling molecule, generated by sphingokinase is implicated as a potential 
mediator of IPC-induced protection [Jin et al., 2004]. 
 
1.4.3.)  Protein kinase A (PKA)                                    
 
Protein kinase A (PKA) is a ubiquitous cellular kinase that phosphorylates serine 
and threonine residues in response to cAMP [Niswender et al., 2002]. The 
widespread expression of PKA subunits, together with the numerous 
mechanisms by which cAMP is regulated within the cell, suggests that the PKA 
signaling pathway is of importance in cellular function. PKA is a key regulatory 
enzyme in the catecholamine-mediated control of excitation-contraction coupling 
in the heart. It also plays an important role in the activation of transcription factors 
as well as the control of metabolic enzymes. The PKA enzyme is composed of 
two catalytic (Cα and Cβ) and one regulatory (R) subunit [Corbin et al., 1988]. 
Activation of the regulatory subunit by cAMP results in the release of the catalytic 
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subunits from the PKA holoenzyme. The free catalytic subunits (Cα and Cβ) can 
subsequently function as active holoenzymes. The Cα and Cβ subunits are 
believed to have different functions and have been shown to phosphorylate 
different targets [Yu et al., 2004]. 
 
The important role of β-adrenergic receptor stimulation and possible involvement 
of PKA in the pathogenesis and treatment of heart failure is well accepted [Lohse 
et al., 2003]. Excessive β-adrenergic receptor stimulation in heart failure can lead 
to adverse effects on myocardial function as has been demonstrated in the 
setting of ischaemia/reperfusion [Waldenstrom et al., 1978; Rona, 1985]. 
Ischaemia/ reperfusion in the heart is characterized by cAMP accumulation, 
accompanied by activation of PKA [Sakai et al., 1999], increased phosphorylation 
and opening of L-type calcium channels, resulting in the development of cytosolic 
calcium overload [Shine & Douglas, 1983; Du Toit & Opie, 1992].  
 
The role of PKA in the cardioprotection afforded by IPC is controversial. A study 
by Makaula and coworkers (2005) demonstrated that inhibition of PKA before 
sustained ischaemia enhanced the cardioprotection induced by IPC. These 
results suggest a harmful role for PKA in this regard. 
 
In contrast, it was demonstrated in a different study that intramyocardial 
accumulation of cAMP mimicked the cardioprotective effect of IPC. Inhibition of 
PKA attenuated the protective effect of IPC, suggesting a mediator function for 
PKA in the setting of IPC [Lochner et al., 1999]. Both elevated levels of cAMP 
and activation of PKA were shown to be independent of PKC [Sanada et al., 
2001; Sato et al., 2005]. It was reported that instead of PKC, the activation of p38 
could be involved as a downstream mechanism of protection [Sanada et al., 
2001]. It was also reported that Rho kinase play an important protective role 
downstream of PKA during sustained ischaemia [Sanada et al., 2004]. 
Importantly, apart from its protective effects, the RhoA/Rho-kinase mediated 
pathway plays a key role in vascular smooth muscle contraction, cell adhesion 
and motility, cytokinesis and gene expression. All of these processes are involved 
in the pathogenesis of atherosclerosis [Shimokawa, 2002].  
 
Stellenbosch University  http://scholar.sun.ac.za
  27
1.4.4.)   Protein kinase G (PKG) 
 
Protein kinase G (PKG) is a cGMP dependent serine/threonine protein kinase 
and forms part of the NO-sGC-cGMP pathway. This pathway is regarded as the 
predominant molecular mechanism of the actions of NO [Balligand & Cannon 
1997]. Activation of the NO-sensitive sGC generates cGMP from GTP, resulting 
in the activation of two cGMP-dependent protein kinases (PKG 1 and PKG II) 
[Schultz et al., 2004]. Phosphodiesterase II (PDE II) and phosphodiesterase III 
(PDE III) are second class molecular targets of cGMP. PDE II is activated by 
cGMP and PDE III is inhibited by cGMP [Schultz et al., 2004]. cGMP have also 
been demonstrated to regulate the activity of cGMP-regulated ion channels 
[Friebe & Koesling, 2003]. Together, these effectors are implicated in the 
regulation of a number of important physiological functions in the cardiovascular 
system. 
 
PKG was first implicated as a potential mediator of IPC, when studies indicated 
that cGMP levels were increased in IPC hearts [IIiodromitis et al., 1996]. Work 
done in Downey’s laboratory (2005) suggested that PKG-ε can mediate opening 
of the mito KATP channel during IPC-induced cardioprotection [Costa et al., 2005]. 
The mechanism of this activation was unknown, but it was suggested that ROS 
may be involved, since direct activation of PKG resulted in the production of 
ROS.  It was also reported that NO, guanylate cyclase, cGMP and PKG are the 
key role players in activation of the mito KATP channels. This protection elicited by 
the NO/PKG signaling pathway was associated with a decrease in LDH release 
and DNA damage. The protective effects induced by the NO/PKG pathway were 
blocked by the two inhibitors of the mito KATP channel, glibenclamide and 5-HD. 
These results suggested that NO, PKG and the mito KATP channel contribute to 
the mechanism involved in IPC induced cardioprotection [Cuong et al., 2005].  
 
1.5.)  Mitogen Activated Protein Kinases (MAPK’s) 
 
The MAP Kinase (MAPK) family is one of the major kinase cascades in the 
mammalian heart. MAPKs regulate diverse cellular processes including gene 
expression, differentiation, motility, mitosis, differentiation, metabolism, cell 
survival and apoptosis [Roux & Blenis, 2004].  MAPKs are serine/threonine 
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kinases which require dual phosphorylation on a Thr- and Tyr motive for 
activation [Boulton et al., 1990]. All eukaryotic cells possess multiple MAPK 
pathways of which the most extensively studied groups are the 44 and 42-kDa 
extracellular signal-regulated kinase family (ERK p44 and ERK p42 MAPK), Big 
Map Kinase 1 (BMK 1/ERK 5) and the two stress-activated MAPK families: the 
46- and 54-kDa c-Jun-NH2 amino- terminal kinase (JNK) and the 38 kDa, p38 
MAP Kinase family [reviewed by Roux & Blenis, 2004] (Figure 1.2).  
 
1.5.1.)   p44/p42 MAP Kinases (ERK 1 and 2)                          
 
The mammalian ERK 1 and 2 cascade is known as the classical mitogen 
activated protein kinase cascade and comprises of the MAPKKKs:  A-Raf, B-Raf 
and Raf-1; the MAPKKs, MEK1 and MEK2 and the MAPKs, ERK1 and ERK2 
(Figure 1.2). ERK 1 and ERK 2 have 83% amino acid homology and are 
expressed to various extents in quiescent cells in all tissues [Chen et al., 1992]. 
ERK 1 and 2 are potently stimulated by growth factors, serum and phorbol esters, 
but are minimally activated by ligands of heterotrimeric G-protein coupled 
receptors, cytokines, osmotic stress and microtubule disorganization [Lewis et al., 
1998].  
 
The observations that several growth factors with anti-apoptotic effects [Buerke et 
al., 2001], such as fibroblast growth factor [Htun et al., 1998], insulin-like growth 
factor [Buerke et al., 2001] and cardiotrophin-1 [Kuwahara et al., 2000] can 
activate ERK, suggested a cardioprotective role for ERK in cell survival. A major 
cardioprotective role for ERK p42 was demonstrated in opioid-induced 
cardioprotection in rats [Fryer et al., 2001].  It was indicated in several models 
that ERK signaling was activated during ischaemia in the rat [Miyakawa et al., 
2001], in vivo, in a pig model [Baracik et al., 1997] and in neonatal rat 
cardiomyocytes [Ye et al., 2000]. 
 
It was also reported in several studies that ERK activation is induced during 
ischaemia/reperfusion in rat, bovine, human and guinea pig hearts [Araujo et al., 
2001; Talmor et al., 2000], while other studies, on the other hand, failed to 
indicate involvement of ERK in the setting of ischaemia/reperfusion [Bogoyevitch 
et al., 1996; Clerk et al., 1998]. 
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Figure 1.2:   Signaling cascades leading to activation of the MAPK-activated protein 
kinases (MAPKs). Mitogens and cellular stresses lead to activation of the ERK1/2 and 
p38 cascades, which in turn phosphorylate and activate the five subgroups of MKs. MKs 
represents an additional enzymatic amplification step in the MAPK catalytic cascades.  
See text for details [Roux & Blenis, 2004] 
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Furthermore, it was also demonstrated by numerous studies that various MAPK 
cascades are involved in the setting of ischaemic preconditioning (IPC) - induced 
cardioprotection [Cohen et al., 2000]. In this context, activation of the ERK 
pathway was demonstrated after IPC, in an isolated working rat heart model. 
[Maulik et al., 1996]. The IPC protocol consisted of four cycles of 5 min ischaemia 
followed by 10 min reperfusion. Normothermic ischaemia was induced for 30 min, 
followed by 30 min reperfusion. ERK was activated after 30 min reperfusion. The 
contribution of ERK activation to protection was not tested in this study [Maulik et 
al., 1996]. Activation of ERK during IPC was also reported in an in vivo rat heart 
model [Fryer et al., 2001].  IPC was induced by one cycle of a 5 min coronary 
artery occlusion followed by 5 min reperfusion. Activation of ERK was increased 
during IPC after 5 min, 30 and 60 min of reperfusion compare to control. The 
ERK blocker, PD98059 abolished IPC-induced protection and activation of ERK 
[Fryer et al., 2001]. A study by Ping and co-workers [1999], ultilizing the 
conscious rabbit model of IPC, demonstrated activation of ERK directly after the 
IPC protocol. The IPC protocol consisted of 6 cycles of 4 min coronary occlusion 
followed by 4 min reperfusion. This activation of ERK was completely blocked by 
the PKC inhibitor chelerythrine, suggesting that PKC activates the ERK pathway 
in IPC [Ping te al., 1999]. A study by Hausenloy and co-workers [2005]  
demonstrated a biphasic activation of ERK in a rat heart Langendorf perfusion 
model with regional ischaemia. IPC hearts were subjected to two 5 min periods of 
global ischaemia followed by 10 min reperfusion, before 35 min of regional 
ischaemia. This was followed by 120 min reperfusion after which infarct size was 
measured. ERK was activated after the IPC stimulus and the second phase of 
ERK activation occurred after 120 min reperfusion. Inhibition of ERK activation 
with the MEK1/2 inhibitor PD98059 abrogated IPC-induced protection. 
 
The role of ERK in IPC was further emphasized when it was demonstrated that 
PKC-ε may act as an upstream activator of ERK 1 and 2 [Ping et al., 1999]. In 
addition, it was suggested that the generation of ROS in response to IPC is able 
to activate ERK 1 and 2 [Samavati et al., 2002]. The translocation of ERK 1 and 2 
to the nucleus [Ping et al., 1999], the intercalated discs [Da Silva et al., 2004], the 
cytosol [Fryer et al., 2001] and the mitochondria [Baines et al., 2002] were 
demonstrated after a preconditioning stimulus. ERK 1 and 2 has been 
demonstrated to activate NF-Kβ and AP-1 transcription factors in the nucleus 
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[Ping et al., 1999]. These transcription factors are implicated in delayed IPC. ERK 
1 and 2 can activate MAPKAP kinase 2 α and β, leading to phosphorylation of the 
small heat shock protein 2, which is important in stabilizing the integrity of the 
cytoskeleton during ischaemia, thus preserving cell viability [Chevalier & Allen, 
2001].  ERK 1 and 2 can phosphorylate p90RSK and inhibit GSK-3β leading to 
the inhibition of MPTP opening and cardioprotection [Eldar-Finkelman et al., 
1995; Frodin et al., 1999]. It was also suggested that hypoxia inducing factor-1α 
(HIF-1α) may be a potential downstream target of ERK 1 and 2 in IPC [Liu et al., 
2003]. HIF-1α is activated in response to hypoxia and is important in the 
regulation of genes concerned with cellular survival during hypoxia [Cai et al., 
2003].  
 
Although the majority of studies support a role for ERK in IPC, the role of ERK as 
a potential mediator of IPC has been controversial because several studies failed 
to demonstrate any activation of ERK during IPC. Kim and co-workers [1999], 
demonstrated ERK activation after post-ischaemic reperfusion in control as well 
as IPC hearts. IPC was induced in rabbit hearts with 5 min ischaemia followed by 
10 min reperfusion. Hearts were subjected to 30 min regional ischaemia followed 
by 2 hours reperfusion. Infarct size was measured as endpoint of functional 
recovery. In the IPC hearts infarct size was reduced after 2 hours reperfusion, 
compare to controls. Infusion of the MEK1/2  inhibitor PD98059 during ischaemia, 
however, did not abrogate IPC-induced protection. These results demonstrated 
that a reduction in infarct size by IPC was independent form ERK activation. A 
study by Mocanu and co-workers [2002], demonstrated that ERK was 
phosphorylated in response to IPC, but is not required for IPC-induced protection. 
In this study, rat hearts were preconditioned with two cycles of 5 min ischaemia 
and 10 min reperfusion on a Langendorff perfusion system. Hearts were 
subjected to 35 min regional ischaemia, followed by 120 min reperfusion prior to 
infarct size assessment.  Administration of the MEK inhibitor PD98059 during the 
IPC protocol had no effect on the reduction of infarct size, indicating that the ERK 
signaling pathway is not implicated in IPC [Mocanu et al., 2002]. Takeishi and co-
workers [2001] failed to demonstrate a role for ERK as mediator of IPC. Guinea 
pig hearts were perfused on a Langendorff apparatus with a saline-filled latex 
balloon attached to a catheter inserted into the left ventricle, through the mitral 
valve for pressure measurements. Hearts were preconditioned by 5 min global 
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ischaemia followed by 10 min reperfusion, prior to 20 min global ischaemia. 
Takeishi and co-workers [2002] could not detect any IPC–induced ERK activation 
during ischaemia and reperfusion in this study, suggesting that ERK may not play 
a role in IPC.  Mockridge and co-workers [2000] also failed to demonstrate a role 
for ERK as mediator of IPC in a cardiomyocyte model. Cardiomyocytes from rats 
were preconditioned and reperfused for 24 hours in this study.  Although ERK 
was activated during reperfusion with maximum activation at 10 min reperfusion, 
infusion of the MEK inhibitor PD98059 30 min before IPC did not block 
cardioprotection.  These results suggest that the protective effect of IPC was 
independent of ERK activation [Mockridge et al., 2000].  
 
1.5.2.)  p38 MAPK 
  
The p38 family consists of four isoforms, p38-α, p38-β, p38-γ and p38-δ of which 
the α- and γ isoforms are the most abundant in the myocardium [Saurin et al., 
2000]. p38 has two activation sites, a threonine residue at amino acid 180 and a 
tyrosine residue at site 182. Both activation sites must be phosphorylated for full 
activation to occur. p38 is activated by a MAP kinase kinase (MEK 3 or MEK 6), 
which itself has to be activated first by a MAP kinase kinase kinase (MAPKKK).  
 
It has been shown that the different isoforms of p38 mediate different biological 
functions [Michel et al., 2001]. In neonatal rat cardiomyocytes, p38-β is anti-
apoptotic, while p38-α mediates apoptosis [Wang et al. 1998]. Several studies 
demonstrated that p38 is phosphorylated within minutes during regional no-flow 
ischaemia and global ischaemia in isolated rat hearts [Bandyopadhyay et al., 
1997; Bogoyevitch et al., 1996]. This was also found in dog, pig and rat hearts in 
vivo.  
 
The activation of p38 during prolonged ischaemia is transient and the 
phosphorylation of p38 may be rapidly reduced towards pre-ischaemic values 
after prolonged ischaemia. Following this reduced activation of p38, it is once 
again increased upon reperfusion [Yin et al., 1997; Shimizu et al., 1998].  
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It was demonstrated that both PKC and tyrosine kinases are located upstream of 
p38 in the IPC signaling pathway, suggesting that they may act as activators of 
p38 [Weinbrenner et al., 1997].  
 
Potential downstream targets of p38 in IPC are myofilaments, the sarcolemma 
and also the nucleus [Da Silva et al., 2004]. Other studies have shown that p38 
forms signaling modules with PKC-ε at the level of the mitochondria in the setting 
of IPC [Baines et al., 2002]. Recent studies indicated co-localization of p38 with 
connexin-43. This was associated with an increase in p38 activation, suggesting 
that p38 may protect by reducing gap junction permeability [Schulz et al., 2003].  
 
MAPKAP kinase 2 is an important substrate and target of p38.  p38 has been 
shown to phosphorylate MAPKAP kinase 2, which in turn phosphorylates the 
small HSP-27, which protect cardiomyocytes against ischaemic damage [Rouse 
et al., 1994]. HSP-27 is highly abundant in cardiac and skeletal muscles and 
associates with actin [Efthymiou et al., 2004]. It is also vital to muscle assembly 
[Brown et al., 2007]. HSP-27 increases in response to stress to protect against 
insults such as ischaemia through stabilization of the actin cytoskeleton. HSP-27 
protects against ischaemia/reperfusion damage where it plays a key role in anti-
oxidant mechanisms. Studies have shown that hypoxic preconditioning resulted 
in translocation of HSP-27 from the cytosol to the cytoskeleton. This translocation 
was dependent on p38 activation [Armstrong et al., 1999]. 
 
Although the p38 signalling pathway in IPC has been extensively studied, 
published observations are inconsistent.  A majority of studies reported activation 
of p38 during the triggering phase of IPC, while inhibition of p38 during this phase 
of IPC substantially attenuated the protective effect of IPC as indicated by an 
increase in infarct size. These results imply a major role for p38 activation during 
the triggering phase in IPC induced protection [Nakano et al., 2000; Sakamoto et 
al., 2000 and Sanada et al., 2001]. The study by Nakano and co-workers [2000] 
investigated p38 activation in isolated rabbit hearts. The Langendorff perfusion 
system was used with infarct size as endpoint. IPC was induced by a single cycle 
of 5 min ischaemia, followed by 10 min reperfusion prior to 20 min global 
ischaemia. These results demonstrated that IPC activates p38 during the 
triggering phase of IPC. The potent blocker of p38, SB203580, blocked the 
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protection afforded by IPC as measured by infarct size [Nakano et al., 2000]. The 
study by Sakamoto and co-workers [2000], used the Langendorff perfusion model 
with a latex balloon inserted in the left ventricle connected to a pressure 
transducer to monitor the heart rate and left ventricular pressure (LVP). Rat 
hearts were preconditioned by a single cycle of 5 min ischaemia, followed by 5 
min reperfusion. Subsequently hearts were subjected to 40 min global ischaemia, 
followed by 50 min reperfusion. These results demonstrated p38 activation during 
the triggering phase of IPC to be protective as blockade with SB203580 inhibited 
IPC-induced protection [Sakamoto et al., 2000]. The study by Sanada and co-
workers [2001], utilized an in vivo canine heart model with infarct size as endpoint 
to investigate p38 activation. IPC was induced by 4 cycles of 5 min coronary 
occlusion, followed by 5 min reperfusion. Subsequently the coronary artery was 
occluded for 90 min (sustained ischaemia) followed by 6 hours of reperfusion. 
These results demonstrated p38 activation during the triggering phase of IPC. 
Inhibition of p38 during IPC using SB203580, completely reverses the infarct size 
limitation by IPC, suggesting that activation of p38 during this phase is protective 
[Sanada et al., 2001].  
 
On the other hand, several studies indicated that the activation of p38 during the 
sustained ischaemic period was increased after IPC and that p38 may act as a 
mediator of IPC [Schulz et al., 2002; Nakano et al., 2000; Weinbrenner et al., 
1997 and Eaton et al., 2002]. Schulz and co-workers [2002], utilized an in vivo 
swine heart model of IPC. Pig hearts were preconditioned by 10 min ischaemia 
followed by 15 min reperfusion, prior to 90 min sustained ischaemia followed by 
120 min reperfusion. These results demonstrated that p38 was phosphorylated 
during sustained ischaemia in the IPC hearts. Blockade of p38 with SB203580 
before sustained ischaemia attenuated the infarct size reducing effect of IPC 
[Schulz et al., 2002]. The study by Nakano and co-workers [2000] utilized an 
isolated rabbit heart model, using the Langendorff perfusion system with infarct 
size as endpoint. IPC was induced by 5 min ischaemia, followed by 10 min 
reperfusion prior to 20 min global ischaemia. It was demonstrated that IPC 
activates p38 and also its downstream substrate MAPKAP2 during the sustained 
ischaemic period in IPC hearts. The p38 inhibitor SB203580, blocked the 
protection afforded by IPC as measured by infarct size, suggesting that p38 is a 
mediator of IPC in this model [Nakano et al., 2000]. Weinbrenner and co-workers 
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[1997] investigated p38 activation in an  isolated rabbit heart model. The 
Langendorff perfusion system was used with a saline filled latex balloon inserted 
into the left ventricle. IPC was induced by 5 min global ischaemia, followed by 10 
min reperfusion, before the onset of 30 min global ischaemia. It was 
demonstrated that IPC activated p38 after 10 and 20 min global ischaemia. The 
p38 blocker SB203580, attenuated the protective effect of IPC and also the 
activation of p38 during sustained ischaemia. These results suggest a mediator 
function for p38 in IPC [Weinbrenner et al., 1997]. Eaton and co-workers [2000] 
utilized the Langendorff perfused rat heart model of IPC. Ventricular function was 
assessed via a latex balloon which was inserted in the left ventricle connected to 
a pressure transducer. IPC was induced by three cycles of 5 min ischaemia ; 
followed by three cycles of 5 min reperfusion, prior to 20 min ischaemia and 60 
min reperfusion. p38 Activation was increased during the 20 min ischaemic 
period. Protection by p38 activation was not tested for by infusion of the p38 
blocker. 
 
In vitro studies indicated that IPC primarily prevents the activation of p38-α during 
sustained ischaemia in p38 α–transfected rat cardiomyocytes. p38-β was shown 
to be downregulated during sustained ischaemia in control and ischaemic 
preconditioned cells [Saurin et al., 2000]. IPC appears to require activation of the 
p38-α, but not the p38-β isoform [Sicard et al., 2010]. However other studies 
failed to show any contribution of p38 towards IPC [Ping et al., 1999; Barancik et 
al., 2000; and Gysembergh et al., 2001]. Ping and co-workers [1999] utilized an 
in vivo rabbit heart model of IPC. IPC was induced by 6 cycles of 4 min coronary 
occlusion followed by 4 min reperfusion. This study failed to show any 
contribution of p38 towards IPC-induced protection [Ping et al., 1999]. Barancik 
and co-workers [2000] investigated p38 activation in an in vivo swine heart model 
of IPC. The IPC protocol consists of 2 cycles of 10 min ischaemia followed by 10 
min reperfusion, prior to 40 min index ischaemia and 60 min reperfusion. The p38 
blocker SB203580 was administered 15 min before IPC and also during the IPC 
protocol. Inhibition of p38 did not influence the infarct size reduction by IPC, 
suggesting that p38 does not contribute to IPC-induced protection [Barancik et 
al., 2000]. The study by Gysembergh and co-workers [2001] utilized an isolated 
rabbit heart model of IPC. The Langendorff perfusion system was used with a 
balloon inserted in the left ventricle. IPC was induced by 2 cycles of 5 min 
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episodes of antecedent PC ischaemia. This study failed to show any contribution 
of p38 towards IPC-indiuced protection [Gysembergh et al., 2001]. 
 
Studies showing attenuation in p38 activation during the sustained ischaemic 
period after the IPC stimulus, suggest a detrimental role for p38 activation during 
sustained ischaemia [Kimura et al., 2005; Saurin et al., 2000; Rakhit et al., 2001; 
Fryer et al., 2001]. This finding was consistent with numerous other studies 
showing that inhibition of p38 during sustained ischaemia is protective against 
reperfusion damage [Mackay et al., 1999; Ma et al., 1999;  Kimura et al., 2005]. 
Therefore, the role of p38 as a mediator of protection in IPC remains 
controversial and since it has a major role in the triggering phase, it was 
suggested to act as a trigger rather than a mediator in IPC [Maulik et al., 1998]. 
The importance of p38 activation in the setting of cardioprotection thus remains 
controversial. 
 
1.5.3.)  JNK                                   
 
JNK 1, JNK 2 and JNK 3 (also known as SAPKα, SAPKβ and SAPKγ 
respectively), also known as stress activated protein kinases (SAPK) are 
ubiquitously expressed [Kyriakis et al., 1994].  JNK 3 is primarily expressed in the 
brain, whereas JNK 1 (46 kDa) and JNK 2 (54 kDa) are expressed in the heart.  
In contrast to ERK 1 and 2, the JNK’s are strongly activated by cellular stresses 
such as heat, osmotic shock, UV irradiation, endotoxins and cytokines and to a 
lesser extent by serum and growth factors [Kyriakis & Avruch, 1990]. JNK 
requires dual phosphorylation on tyrosine and threonine residues within a 
concerved Thr-Pro-Tyr motif and are activated by the upstream MAPKKs, MKK4 
and MKK7, which are activated by several MAPKKKs, including MKK1-4, MLK2 
and -3, TPL-2, DLK, TAO1 and-2, TAK 1, ASK 1 and -2 [Kyriakis & Avruch, 1990] 
(Figure 1.2.).  MKK7 is capable of activating both p38 as well as JNK, whereas 
MKK4 is specific for JNK. Both JNK isoforms are significantly activated upon 
reperfusion, but are not affected by ischaemia alone.  
 
Studies have demonstrated that ROS mediated the activation of JNK at 
reperfusion [Knight et al., 1996]. Others have indicated that hypoxic 
preconditioning-induced activation of JNK is dependent on PKC-ε [Ping et al., 
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1999]. JNK can also be activated by Gq-coupled receptors and subsequent 
activation of PKC. 
 
Once activated, JNK rapidly phosphorylates the transcription factor c-Jun within 
its N-terminal domain. It was also reported that overexpression of PKC-ε 
activated the transcription factors NF-Kβ and AP-1, which is important mediators 
of delayed IPC - this was shown to be dependent on the activation of JNK [Li et 
al., 2000]. Over-expression of active PKC-ε in murine myocytes resulted in the 
formation of signalling modules, comprising JNK, ERK 1 and 2 and also p38, at 
the level of the mitochondria [Baines et al., 2002]. It is possible that the brief 
episodes of ischaemia/reperfusion, as seen in IPC, could activate the JNK 
pathway. Some studies suggested a potential role for JNK as mediator of 
protection in IPC. Activation of JNK 46 during ischaemia was reported to be 
mediated by PKC. Inhibition of JNK 46 with curcumin blocked the infarct size 
reduction of IPC in isolated rat heart, thereby supporting a mediator function in 
IPC. Other studies could not confirm the mediator function of JNK in IPC induced 
protection. Several studies however, indicated activation of JNK during the 
triggering phase of IPC [Haq et al., 1998], suggesting that JNK mediates the 
protective effect of IPC [Sato et al., 2000]. Some studies however, demonstrated 
JNK activation in response to an IPC stimulus but failed to indicate a contribution 
to protection [Iliodromitis et al., 2002]. Therefore the role of JNK in IPC remains 
controversial. 
 
1.5.4.)   Phosphatidylinostitol 3- kinase (PI3-K) and PKB/Akt         
                                                                                                                                                       
Phosphoinositide 3-kinase (PI3-Ks) forms part of a unique family of enzymes with 
the ability to function as both lipid- as well as protein kinases. Based on their 
substrate specificity, molecular structure and mode of action, mammalian PI3-Ks 
are divided into three classes (I, II and III) [Oudit et al., 2004]. Upon activation 
PI3-Ks phosphorylate the plasma membrane lipid phosphatidyl-inositol-4,5-
biphosphate (PIP2) to form phosphatidyl-inositol-3,4,5- triphosphate (PIP3). PIP3 
acts as a second messenger by recruiting a variety of different downstream 
components such as phosphoinositide-dependent kinase-1 (PDK1) and 
phosphoinositide-dependent kinase-2 (PDK2) which phosphorylates and 
activates various protein kinases [Burgering & Coffer, 1995]. Akt, also known as 
Stellenbosch University  http://scholar.sun.ac.za
  38
Protein Kinase B (PKB), is one of the targets of the phosphatidylinositol 3-kinase 
(PI3-K)-related signalling pathway.  
 
Class I PI3-K can be divided into two subclasses, namely Class I A PI3-K and 
Class 1B PI3-K, which are the main isoforms expressed in cardiomyocytes [Naga 
Prasad et al., 2003]. Class I PI3-K’s are heterodimers of a 110-kDa catalytic 
subunit (p110-α, p110-β and p110-δ) and a regulatory subunit of 85 or 55 kDa 
(p85/p55). Class I PI3-Ks are stimulated by receptor tyrosine kinase cascades 
and modulate cardiac growth [Luo et al., 2005].  
 
Class 1B PI3-K consists of a p110γ catalytic subunit and a p101 regulatory 
subunit. It has been shown to couple to GPCR and has the ability to modulate 
cAMP metabolism in ventricular myocytes and is an important regulator of 
cardiac contractility [Patrucco et al., 2004; Crackower et al., 2002]. In addition, 
PI3-K-γ has been shown to play a critical role in the induction of fibrosis, cardiac 
hypertrophy and cardiac dysfunction as a consequence of long term β-AR 
stimulation [Oudit et al., 2003].  
 
The serine/threonine protein kinase PKB/Akt is the main effector of the PI3-K-
related signalling pathway and plays a central role in the regulation of cellular 
growth, survival and metabolism across many species [Jian-Zhi et al., 2012]. 
PKB/Akt exists as 3 isoforms (Akt-1, Akt-2 and Akt-3) in the mammalian heart. 
The Akt-1 isoform predominates in the heart and it has an important role in 
protecting the myocardium against ischaemia/reperfusion injury [Shiraishi et al., 
2004]. Expression of Akt-2 also occurs in the heart, whilst Akt-3 phosphorylation 
is upregulated in diseased hearts [Taniyama et al., 2002]. PKB can be 
phosphorylated at two sites (serine 473 and threonine 308) [Alessi et al., 1996]. It 
has been suggested that full activation of PKB requires phosphorylation at both 
sites, therefore it requires two phosphorylation events [Tsurutani et al., 2006].  
 
PKB/Akt is activated in response to growth factors and hormones including 
insulin, insulin growth factor-1 (IGF-1), as well as through β-adrenergic 
stimulation and plays an important role in the regulation of cardiac hypertrophy, 
angiogenesis and apoptosis [Oudit et al., 2004]. Activated PKB results in a signal 
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transduction cascade, leading to the inhibition of apoptosis and thereby 
promoting cell survival [Davidson et al., 2006].  
  
It was first demonstrated in 2000 [Tong et al., 2000] that IPC protects the heart by 
activating PI3-K-Akt. This study was conducted in a Langendorff perfused rat 
heart model of IPC. A latex balloon connected to a pressure transducer was 
inserted in the left ventricle to monitor left ventricular developed pressure (LVDP). 
IPC was induced by 4 cycles of 5 min ischaemia and 5 min reperfusion. The PI3-
kinase inhibitor wortmannin (WM) was administered for 5 min before and 
throughout IPC. It was demonstrated that WM treatment blocked the protective 
effect of IPC and also the IPC-induced increase in PKB/Akt [Tong et al., 2000]. 
This finding was confirmed in subsequent studies, suggesting that Akt may act as 
a mediator of IPC induced protection. Mocanu and co-workers [2002]  
investigated the activation of PKB/Akt in an isolated rat heart Langendorff 
perfusion model. A latex balloon was inserted in the left ventricle to monitor 
LVDP. The IPC protocol consisted of two cycles of 5 min global ischaemia, 
followed by 10 min reperfusion, prior to 35 min regional index ischaemia and 120 
min reperfusion. The PI3K inhibitor, wortmannin (WM) was administered 
throughout  the IPC protocol. It was demonstrated that blockade of IPC with WM 
resulted in only partial attenuation of protection [Mocanu et al., 2002]. In a study 
by Hausenloy and co-workers [2005], the isolated rat heart Langendorff model of 
IPC was used with functional recovery as endpoint. IPC was induced by two 5 
min periods of global ischaemia, followed by 10 min reperfusion, prior to 35 min 
regional ischaemia and 120 min reperfusion. The PI3K inhibitor LY294002 was 
infused into the perfusate for the first 15 min of reperfusion. IPC induces a 
biphasic response in PKB/Akt phosphorylation. The first phase occurred 
immediately after the IPC stimulus, whereas the second phase occurred at 
reperfusion. The PI3K inhibitor attenuated this biphasic activation of PKB/Akt and 
abrogate the IPC mediated reduction in infarct size [Hausenloy et al., 2005]. 
 
However, several other studies failed to demonstrate a role for Akt as a mediator 
of IPC [Budas et al., 2006; Lecour 2009]. Some studies failed to show any 
contribution of PKB/Akt towards IPC-induced protection.  Button and co-workers 
investigated PKB/Akt activation in adenosine receptor mediated IPC. Right 
ventricular strips were isolated from adult wistar rats and mounted between 
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platinum electrodes and isometric force transducers. Hypoxic IPC was induced 
by 10 min hypoxia, followed by 20 min reoxygenation prior to 30 min hypoxia 
followed by 30 min reoxygenation. Wortmannin (WM) was added 30 min before 
hypoxic IPC or treatment with adenosine receptor agonist and removed before 30 
min hypoxia. It was demonstrated that although the selective adenosine receptor 
agonist induced IPC in the right ventricular strips, the effect is independent of 
PI3K- PKB/Akt dependent signaling pathways [Button et al., 2005].  Germack and 
co-workers [2005] investigated the activation of PKB/Akt in neonatal ventricular 
myocytes prepared from 1-4 days old Wistar rats. Cells were pre-treated for 15 
min with adenosine before 4 hours of hypoxia followed by 18 hours of 
reoxygenation. Cell viability was assessed using the sodium 3’ –[1-
[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulfonic 
acid hydrate assay (XTT assay) and Lactate dehydrogenase (LDH) release. The 
PI3K inhibitor Wortmannin (WM) was administered 15 min before adenosine 
treatment, followed by 4 hours of hypoxia. WM did not reverse the 
cardioprotection of adenosine IPC, suggesting that the PI3K-PKB/Akt pathway is 
not involved [Germack et al., 2005].        
 
Tyrosine kinase is a known upstream activator of PI3-K-Akt [Cantley et al., 2002]. 
Studies have demonstrated that the tyrosine kinase Src is located upstream from 
PI3-K-Akt activation in the IPC signaling pathway [Krieg et al., 2002]. It was 
further demonstrated that both eNOS and PKC-ε are located downstream of Akt 
in the IPC signalling pathway. This finding has been confirmed by other studies 
[Krieg et al., 2003 & 2004; Costa et al., 2005]. PI3-K /Akt are reported to induce 
NO production upon IPC and reperfusion [Tong et al., 2000]. 
 
The majority of the downstream targets phosphorylated by PKB/Akt activate 
various anti-apoptotic pathways [Hausenloy et al., 2004]. It is suggested that 
PKB/Akt may protect the myocardium against ischaemia/reperfusion injury, by 
acting at the level of the mitochondria, through the inhibition of GSK-3β and 
subsequent inhibition of the mitochondrial permeability transition pore [Davidson 
et al., 2006].  
 
However, chronic activation of the PKB/Akt pathway may lead to cardiac 
hypertrophy. It appears that a fine balance has to be maintained between the 
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potential beneficial effects of activating this pathway and the potentially 
detrimental effects of sustained activation of this pathway [Franke et al., 2003]. 
 
1.5.5.) The involvement of PKB/Akt and ERK p44/p42 MAPK in 
           cardioprotection     
 
Lethal reperfusion injury or ischaemia/reperfusion damage specifically refers to 
the component of cell death occurring as a consequence of reperfusion, following 
a transient period of ischaemia [Piper et al., 1998]. However, it is well established 
that activation of the prosurvival kinases,  PKB/Akt and ERK p44/p42 MAPK 
a.k.a. the Reperfusion Injury Salvage Kinase (RISK) pathway, at the onset of 
reperfusion, lead to myocardial protection against ischaemia/reperfusion (I/R) 
damage [Hausenloy & Yellon, 2004]. An earlier study by                      
Hausenloy and co-workers, utilizing the isolated perfused rat heart model, 
indicated that IPC results in phosphorylation of both Akt and ERK 1 and 2 after 
15 min reperfusion. Inhibition of either PKB or Akt activation at 15 min reperfusion  
abolished protection, indicating that phosphorylation of both these kinases was 
essential to mediate the protection induced by IPC [Hausenloy et al., 2003].  
 
A later study reported that signaling through the PKB/Akt and ERK p44/p42 
pathways can mediate cellular survival by an anti-apoptotic mechanism. This is 
achieved by phosphorylation and subsequent inactivation of a distal target, the 
pro-apoptotic protein BAD [Inamura et al., 2010]. 
 
Investigation into the downstream targets of PI3-K has focused on the role of 
GSK-3β inhibition in the cardioprotection by ischaemic preconditioning [Tong et 
al., 2002]. GSK-3β is inactivated through phosphorylation by PI3-K and is a 
critical downstream mediator of IPC. This kinase serves as a downstream 
effector of the Wnt/Frizzled pathway-induced cardioprotection [Barandon et al., 
2005].  
 
The mitochondrial outer membrane (OM) contains a channel protein known as 
the voltage-dependent anion channel (VDAC). It is the most abundant protein of 
the OM and allows non-specific small substances of less than 5 kDa into the 
intermembrane space and cytosol. Opening of VDAC is a regulated process, 
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since the channel exhibit some degree of specificity in the mitochondrial 
import/export of molecules such as ATP, calcium and other ions. The role of 
VDAC in apoptosis was first demonstrated by Shimizu and co-workers in 1999. 
Results from this study demonstrated that the pro-apoptotic proteins Bax and Bak 
accelerate opening of VDAC. This was accompanied by cytochrome c release 
from the mitochondria and Bax/Bak-induced loss of mitochondrial membrane 
potential [Shimizu et al., 1999]. A later study by the same group demonstrated 
that the anti-apoptotic proteins BcL-2 and BcL-XL, prevented VDAC opening  and 
cytochrome c release [Shimizu et al., 2001]. Taken together, the results from 
these studies suggest that the BcL-2 family of proteins regulate the mitochondrial 
membrane potential and cytochrome c release from the mitochondria, through 
binding to VDAC to inhibit apoptosis.  
 
The mitochondrial inner membrane is less permeable and allow only small 
molecules like H2O, O2, CO2 or NH3 to enter/exit. The mechanism that induces 
the release of larger molecules by the mitochondria, such as cytochrome c, is  
known as the mitochondrial permeability transition (MPT). It is proposed that the 
mitochondrial permeability transition pore (MPTP) is composed of adenine 
nucleotide translocase, a mitochondrial phosphate carrier, and cyclophilin D 
[Halestrap et al., 2004]. Calcium overload and ROS induces opening of the 
MPTP which changes the membrane potential across the mitochondrial inner 
membrane, consequently resulting in mitochondrial swelling and subsequent 
apoptosis [Saotome et al., 2009].  
 
It is reported that IPC prevents opening of the MPTP during ischemia /reperfusion 
downstream of GSK-3β [Juhaszova et al., 2004] or PKC-ε [Baines et al., 2003]. 
Glycogen synthase- 3β (GSK-3β) signaling is also implicated in the regulation of 
cardiac hypertrophy and ventricular remodeling. Two isoforms (GSK-3A and 
GSK-3β) exist and are equally expressed in cardiomyocytes, but it is the β 
isoform which is considered important in pathological hypertrophy [Matsuda et al., 
2008]. The role of GSK-3β in cardiomyocyte hypertrophy has been thoroughly 
studied [Dorn et al., 2005]. GSK-3β is active in unstimulated cells. After 
stimulation it can be inhibited by two different mechanisms. One mechanism 
involves activation by growth factors and hypertrophic stimuli, which lead to the 
phosphorylation of a specific residue, the N-terminal serine 9 on GSK-3β. Unlike 
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most protein kinases, phosphorylation leads to inhibition of GSK-3β.  Several 
kinases are capable of serine 9-induced phosphorylation and inhibition of GSK-
3β, including p70S6 kinase, protein kinase A, protein kinase B and the protein 
kinase C family. Protein kinase B/Akt is the primary kinase responsible for 
phosphorylation and inhibition of GSK-3β after stimulation of cardiomyocytes with 
pro-hypertrophic agonists such as isoproterenol, phenylephrine and endothelin-1 
[Goode et al., 1992; Cross et al., 1995]. The Wnt pathway is also implicated in 
the inhibition of GSK-3β. This pathway does not use serine-9 phosphorylation, 
but involves proteins called dishevelled and axin. This mechanism appears to 
sequester GSK-3β, limiting its access to the key downstream effector of the Wnt 
pathway, B-catenin.  
 
1.5.6.)  Heat shock protein-70   (HSP-70) 
 
The cytoplasm of mammalian cells contain several families of molecular 
chaperones, including HSP-90, HSP-70, chaperone containing TCP1 (CCT, also 
called TCP1 – ring complex TRIC) and the small HSP (sHSP) family of proteins. 
The latter was discussed in section 1.5.2. The HSP-70 chaperone family 
consists of six member proteins. They are located in the cytosol and include 
HSP-70 and its cognate, HSc-70 [Daugaard et al., 2007]. HSP-70 proteins are 
highly abundant in the absence of stress, but are also inducible with stress. They 
are functionally highly homologous and are able to recognize hydrophobic 
surfaces of unfolded proteins and also partially folded intermediates. Their activity 
is controlled by their ability to bind ATP [Mayer et al., 2005]. HSP-70 proteins 
inhibit protein aggregation, thereby promoting productive folding of proteins 
[Young et al., 2010].  
 
Various studies indicate that HSP-70 is protective against ischaemia/reperfusion 
injury. Expression of HSP-70 in rabbit hearts resulted in a reduction of 
ischaemia/reperfusion injury [Okubo et al., 2001].  Results from at least four 
studies demonstrated that transgenic overexpression of HSP-70 in mice hearts 
significantly protected against ischaemia/reperfusion injury [Marber et al., 1995; 
Plumie et al., 1995; Trost et al., 1998].  
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Many of the HSP’s are regulated by the HSF family of transcription factors. HSF-
1 expression can upregulate HSP expression and thereby protect against 
ischaemia/reperfusion injury [Zou et al., 2003]. Cardiac HSF-1 can be induced by 
transgenic overexpression of calcium/calmodulin-dependent kinase II (CAMK II), 
which is important in protecting the heart against ischaemia/reperfusion damage. 
CAMK II regulates calcium handling and regulates cell death in response to 
ischaemia/reperfusion injury. Expression of CAMK II protects against oxidative 
stress, hypoxia and angiotensin II induced apoptosis [Peng et al., 2010]. This 
cardioprotection is a result of increasing HSP-70 through phosphorylation of 
HSF-1. These studies suggest that HSF-1 may be a common regulator by which 
the cell induces a number of HSP’s to protect against ischaemia/reperfusion 
injury.  
 
At least 13 chaperones and co-chaperones assist HSP’s with protein folding 
and/or targeting damaged proteins for degradation by the ubiquitin proteasome 
system in a process called protein triage [Arndt et al., 2007]. Increased 
expression of co-chaperones in the heart is associated with cardioprotection  
during ischaemia. A number of co-chaperones have been identified in the heart 
which control the activity of the chaperones, namely  Bcl2-associated athanogene 
1 protein (BAG-1) [Heymann, 2006], the carboxyl-terminus of HSP70 interacting 
protein (CHIP) [Zhang et al., 2005], the HSP-70/HSP-90 organizing protein 
(HOP) [Heymann, 2006] and the Heat Shock Protein- 40 family of proteins (DnaJ) 
[Qiu et al., 2006]. Studies have demonstrated that BAG-1 has the ability to inhibit 
apoptosis and to induce autophagy (discussed in section 2.1.) to protect 
myocytes. BAG-1 isoforms (BAG-1s and BAG-1L) are rapidly induced after 
ischaemia with the increase in BAG-1 being sustained after reperfusion [Towsend 
et al., 2004]. The interaction of BAG-1 with HSP-70 increases after 
ischaemia/reperfusion injury. Increasing BAG-1s and BAG-1L in cardiomyocytes 
reduce apoptosis after ischaemia/reperfusion injury. These studies demonstrated 
a cardioprotective role for BAG-1 with a critical component related to its 
interaction with HSC70/HSP-70. It has been demonstrated that autophagy plays 
an important role in the adaptation to ischaemia/reperfusion injury in association 
with BAG-1 [Gurusamy et al., 2009]. BAG-1 associates with the autophagosomal 
membrane protein LC3-II and may induce autophagy using HSc-70 [Gurusamy et 
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al., 2009]. BAG family members may shuttle damaged or oxidized proteins into 
the autophagy pathway to improve cell survival.  
 
CHIP acts as a co-chaperone regulating HSP-70 in the folding system and is also 
important in the ubiquitin-proteasome system as an ubiquitin ligase. It has the 
ability to ubiquitinate proteins that the chaperone/co-chaperone complex is 
unable to refold. CHIP plays an important role in the heart in 
ischaemia/reperfusion injury [Zhang et al., 2005] and has a critical role in 
shuttling damaged and oxidized proteins into the autophagic pathway after 
iscahemia/reperfusion. CHIP increases in the heart in response to high glucose 
levels and is responsible for the degradation of the pro-hypertrophic transcription 
factor, GATA4 [Kobayashi et al., 2007]. Chaperones and co-chaperones are thus 
important regulators of protein quality control in the heart. 
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1.6)  Modalities of Post- Reperfusion Cell Death 
 
Three major forms of cell death exist in the myocardium: apoptosis, necrosis 
and autophagy. The majority of cardiomyocyte death (adding to the final infarct) 
occurs during ischaemia and the first few minutes of reperfusion [Zhao et al., 
2001]. Unfortunately, cell death does not stop there and can continue in the post-
ischaemic zone from days to even weeks, post-reperfusion [Zhao et al., 2000].  
 
All three modalities of cell death may contribute to the continued loss of 
cardiomyocytes in the post-ischaemic zone or the reperfused area. The following 
mechanisms can contribute to the continuous myocyte death that makes up the 
final infarct: (i) myocytes which have been irreversibly damaged despite 
reperfusion; (ii) continued dysfunction of the coronary microvasculature; and (iii) 
the infiltration of inflammatory cells [Baines et al., 2011). These processes 
(shown in Figure 1.3) can lead to myocyte death as a result of elevated 
myocardial concentrations of ROS [Zweier et al., 2006], activation of Toll-like 
receptors [Kim et al., 2009; Chao et al., 2009], secretion of toxic cytokines 
[Vinten-Johansen et al., 2004; Zang et al., 2006] and activation of the 
complement cascade [Vinten-Johansen et al., 2004; Frangogiannis et al., 2002].  
 
The end result of myocardial ischaemia is energy stress. Reperfusion however, is 
accompanied by sudden ionic shifts and substantial oxidative stress. After acute 
ischaemia/reperfusion injury the myocardium is subjected to biomechanical 
stress and inflammation. Some cells die by apoptotic- and necrotic pathways, 
while the surviving cells are subjected to metabolic and functional changes 
[Gottlieb et al. 2011]. The goal of cardioprotection is to prevent cell death during 
acute ischaemia/reperfusion injury and to modulate metabolic and functional 
changes after the injury to sustain healthy mitochondrial function. 
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Figure 1.3: Mediators of post-reperfusion cardiomyocyte death. A variety of                    
humoral and cellular factors are released from dying cardiac myocytes and inflammatory 
cells during reperfusion that are cytotoxic. The 5 main factors are: 
 reactive oxygen species (ROS);   
 inflammatory cytokines such as tumor necrosis factor-α (TNF-α);  
 heat shock proteins (HSPs) which activate Toll-like receptors; 
 secretion/release of enzymes such as secretory phospholipase A2 (sPLA2) 
which directly attacks myocyte membranes; and 
 activation of the complement cascade leading to the formation of the cytolytic  
membrane attack complex [Baines et al., 2011]  
 
Stellenbosch University  http://scholar.sun.ac.za
  48
The functional status of cardiomyocytes is dependent on mitochondria, capable 
of producing ATP, which is essential for the energy needs and calcium 
homeostasis of the cell. The cardiac mitochondrion acts as a global signal 
integrator of cellular homeostasis and is the key determinant of cardiomyocyte 
fate, as shown in Figure 1.4. [Gottlieb et al., 2011]. Poorly functional 
mitochondria can determine the fate of the cell through activation of either 
apoptotic or necrotic cell death [Gottlieb et al., 2011].  
 
The signals that destabilize mitochondria include reactive oxygen species (ROS), 
PKC-δ, JNK and pro-apoptotic members of the Bcl-2 family (Bax/Bak and a BH3 
–only family member such as Bid, Bnip3, Nix) [Logue et al., 2005; Gustafsson et 
al., 2006].  The combined effect of calcium overload and ROS production can 
lower the threshold for the activation of mitochondrial iPLA2, resulting in the 
production of arachidonic acid and plasmalogens which are detrimental to 
mitochondria [Ford et al., 1991]. In contrast, signals that promote stabilization of 
mitochondrial function, as summarized in Figure 1.4, include PKB/Akt and its 
downstream targets, PKC-ε and the pro-survival members of the Bcl-2 family 
[Gustafsson et al., 2006].  
 
1.6.1.)  Apoptosis 
 
One of the most widely recognized biochemical features of apoptosis is the 
activation of a class of cysteine proteases known as caspases [Thornberry & 
Lazebnik, 1998]. Caspases are present in the cell as inactive procaspases that 
are cleaved and activated in response to apoptotic stimuli. Initial activation of 
caspases may involve transduction of a signal from membrane death receptors 
belonging to the tumor necrosis factor receptor (TNF) family, such as Fas and 
TNF receptor 1 (TNFR1) [Ashkenazi & Dixit, 1998], or may be mediated by a 
mitochondrial pathway [Green & Reed, 1998].  
 
Stimulation of death receptors results in the activation of caspase-8, which goes 
on to activate caspase-3, a key effector protein of the apoptotic machinery. 
Release of cytochrome c from the mitochondria, on the other hand, leads to 
activation of caspase-9 through formation of a cytosolic complex and subsequent 
activation of caspase-3. 
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Unlike necrosis, apoptosis is energy dependent and highly regulated. Apoptosis 
is controlled by the complex interaction of numerous prosurvival and prodeath 
signals. These include the Bcl-2 family of proteins, which may be antiapoptotic 
(Bcl-2, Bcl-XL) or proapoptotic (Bad, Bid), and exerts its effects primarily at the 
level of mitochondria [Adams & Cory, 1998]. Other important regulators of 
apoptosis act at the level of caspases. Such proteins include cellular FADD-like 
inhibitory protein (cFLIP) and the inhibitor of apoptosis (IAP) family [Rasper 
et al., 1998; Uren et al., 1998]. There are also proteins that counteract the effect 
of the caspase inhibitors themselves such as Smac/DIABLO, a mitochondrial 
protein that, when released, binds and neutralizes IAPs, thus promoting caspase 
activity [Srinivasula et al., 2000]. Several other factors are also believed to be 
involved in the regulation of apoptosis including, growth factors, mitogen 
activated protein kinases (MAPKs), PKB/Akt, calcium, and oxidants. The 
complex interaction of all these molecules determines the ultimate fate of the cell: 
life or death.  
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Figure 1.4: Mitochondria integrate the signals of ischaemia/reperfusion injury. 
Mitochondria respond to a variety of inputs, both good and bad, including ROS, 
phospholipases, kinases, phosphatases, Bcl-2 family members (both pro- and anti- 
apoptotic), calcium, and the pH of the cytosol and mitochondrial matrix. See text for 
details [Gottlieb, 2011]. 
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1.6.1.1 Caspases, the proteases of the apoptotic pathway 
 
As stated before, a key phenomenon of apoptotic cell death is the activation of a 
unique class of aspartate-specific proteases known as caspases.  All caspases 
are composed of a prodomain and an enzymatic region. Heterogeneity among 
the proteases exists regarding the structure of the prodomain, suggesting that 
this region may define important functional differences between caspases. 
Caspase-1, -2, -4, -5, -8, -9, and –10 contain a long prodomain of 15 to 25 kDA 
compared with <5 kDA in caspases-3, -6, and –7. For activation, the caspase 
proform has to be cleaved into a large subunit and a small subunit within the 
enzymatic domain that finally reassociate to form a complex comprising two small 
and two large subunits. The prodomain is not necessary for the proteolytic 
activity once the caspase is activated. Interestingly, all activating cleavages occur 
after an aspartate residue. Since this cleavage site is a unique characteristic of 
caspases (with the serine protease, granzyme B, being the only exception), 
activation can occur only through auto activation or cleavage by another 
caspases or granzyme B.  
 
Cells possess multiple caspases, which may work in a cascade fashion. The 
redundancy may serve to amplify and accelerate the response, as well as to 
provide multiple mechanisms to complete the process. Indeed, the redundancy is 
apparent in the phenotypes of knockout mice in which the deletion of a single 
caspase is associated with a relatively unimpressive phenotype. Deletion of 
caspase-1 or caspase-11 does not result in dramatic phenotypic changes; thus 
the roles for these caspases are less clear [Li et al., 1997; Wang et al., 1998]. 
However, deletion of caspase-3 results in a failure of neuronal apoptosis, and the 
mice are born with abnormally large brains and die soon after birth [Kuida et al., 
1996].  
 
Substrates for caspases comprise many different proteins, including nuclear 
proteins, proteins involved in signal transduction, and cytoskeletal targets 
[Cardone et al., 1997; Kothakota et al., 1997; Sakahira et al., 1998]. Most of 
these protein substrates appear to be cleaved by caspases-3 and –7.  
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In summary, caspases can be grouped into an upstream (caspases -1, -2, -4, -5, 
-8, -9, -10)  and downstream (caspases -3, -6, -7) subgroup. Upstream caspases 
are characterized by long prodomains that appear to contain essential regulatory 
proteins. Most of the activity that finally leads to the lethal proteolytic breakdown 
of cellular target proteins is exerted by downstream caspases sensitive to DEVD 
(aspartate-glutamine-valine-aspartate) oligopeptides (caspase-3 and caspase-7). 
 
1.6.1.2 Mechanisms of caspase activation 
 
Once downstream caspases are activated, cell death appears to be inevitable. 
Therefore, understanding the mechanisms that initiate proteolytic activation of 
these caspases is a crucial step in defining targets that allow for the modulation 
of apoptotic cell death. Recent data suggest that activation of caspases may take 
place either within death receptor complexes of the cytoplasmic membrane or 
by a mitochondrion-dependent mechanism within the cytosol. 
 
1.6.1.2 (a) Death- and decoy receptor pathway 
 
The best characterized pathways for the initiation of apoptosis involves the 
binding of extracellular death signal ligands (FasL and TNF) to receptors that 
belong to the TNFR gene superfamily [Smith et al., 1994]. The cytoplasmic 
sequence divides the TNFR superfamily into two main subgroups of receptors 
that either possess or lack a ‘death domain’ (DD) [Tartaglia et al., 1993; Itoh & 
Nagata, 1993]. The death-domain-containing receptors, or ‘death receptors’ (DR) 
include TNFR1, Fas (Apo1/CD95), DR3 (Apo3), DR4 (TRAIL-R1), DR5 (TRAIL-
R2) and DR6. The death receptors interact via their DD with intracellular DD-
containing adaptors, such as FADD (Fas-associating protein with DD) and 
TRADD (TNF receptor-associated death domain), and recruit these adaptors to 
the cell membrane. Thus, binding of Fas ligand to the Fas receptor leads to 
clustering of the Fas receptor’s DD. The adapter, FADD, then binds through its 
own DD to the cluster receptor DD. FADD also contains a ‘death effector domain’ 
(DED) that binds to an analogous domain within the pro-caspase-8 protein. Upon 
recruitment by FADD, pro-caspase-8 oligomerization drives its own activation (to 
caspase-8) through self-cleavage. Caspase-8 then activates downstream effector 
caspases, such as caspase-3, thereby initiating apoptosis. Signaling induced by 
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activation of TNFR1 or DR3 diverges at the level of TRADD [Hsu et al., 1995]. On 
the one hand, nuclear translocation of the transcription factor nuclear factor B 
(NFB) and activation of c-Jun N-terminal kinase (JNK) are initiated [Chinnaiyan 
et al., 1996; Hsu et al., 1996; Yeh et al., 1997]. On the other hand, TNF- 
signaling is linked to Fas signaling pathways through interaction of TRADD with 
FADD. Surprisingly, FADD knockout mice exhibit a phenotype of ventricular 
thinning and poorly developed trabeculation of the heart [Yeh et al., 1998]. An 
additional death domain-containing protein, receptor-interaction protein (RIP), 
was also shown to interact with the cytoplasmic domain of TNFR1 [Stanger et al., 
1995; Hsu et al., 1996]. Caspase-2 can be recruited to RIP through an adaptor 
protein called RIP-associated ICH/Ced-3-homologous death domain protein 
(RAIDD) [Duan et al., 1997]. 
 
Another subgroup of TNFR-homologues consists of decoy receptors, which 
function as inhibitors, rather than transducers of signaling. This subgroup 
includes decoy receptor (DcR)1 and DcR2 (both of which are cell-surface 
molecules) as well as osteoprotegerin (OPG) and DcR3 (both of which are 
secretory, soluble proteins). 
 
1.6.1.2 (b) Mitochondrial pathway  
 
The other well-characterized pathway to caspase activation involves participation 
of the mitochondria. In 1997, Zou and co-workers showed that cytochrome c 
participates in caspase activation, in concert with other proteins that were 
subsequently identified as caspase-9 and Apaf-1. Apaf-1 contains a region 
shared with other caspases and may be required for protein-protein interaction. 
In addition, it has a binding site for ATP (or dATP), and a series of 12 WD-40 
repeats, which may be involved in binding cytochrome c [Zou et al., 1997]. Apaf-1 
interacts with cytochrome c and dATP to activate caspase-9 [Li et al., 1997]. The 
activated and processed caspase-9 then cleaves caspase-3 to generate the 
active enzyme, which is the effector protease that proceeds to degrade most of 
the cellular targets.  
 
This pathway requires cytochrome c to be released from the mitochondria, where 
it is normally sequestered in the intermembrane space. Thus, agents affecting 
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mitochondrial integrity may lead to cytochrome c release and activation of 
caspases. Little information is available explaining how cytochrome c release is 
controlled, or even if this is a nonspecific event accompanying general loss of 
mitochondrial integrity or a regulated release of a single protein. It appears to 
occur before loss of mitochondrial membrane potential [Kluck et al., 1997], but 
may represent generalized leakage of intermembrane space constituents. Adachi 
and co-workers (1998) have shown that loss of outer membrane integrity is a 
rather late event, but far earlier, cytochrome c has become unavailable for 
electron transport, although still present in the intermembrane space. This 
suggests its interaction with other protein(s) that eventually may all be released 
from the mitochondria when the outer membrane ruptures. One postulated 
mechanism for the rupture of the outer mitochondrial membrane to occur is 
swelling of the matrix [Vander Heiden et al., 1997]. Since the inner membrane is 
heavily folded, it can tolerate swelling in response to ion fluxes without rupture, 
however, as it swells, it will stretch and eventually rupture the outer membrane. 
Disruption of mitochondrial calcium homeostasis, leading to the formation of the 
permeability transition pore, may also result in mitochondrial matrix swelling and 
rupture [Crompton, 1999].  
 
A widely recognized target of caspases is the enzyme poly-(ADP-ribose) 
polymerase (PARP).  PARP was the first cellular protein to be identified as being 
specifically cleaved in apoptosis [Kaufmann, 1989], and its cleavage 
subsequently was shown to be a universal phenomenon occurring in apoptosis 
induced by a variety of stimuli [Kaufmann et al., 1993]. Specific proteolysis of 
PARP occurs in the DNA binding domain and as a result, two polypeptides of 24 
and 89 kDa are formed, thereby abolishing PARP’s catalytic activity [Nicholson et 
al., 1995; Tewari et al., 1995]. An apparent active role for PARP in apoptosis 
came from studies using human osteosarcoma cells that undergo spontaneous 
apoptosis. Smulson  and co-workers (1997) observed transient PARP activation 
in the early phase of apoptosis, prior to caspase-mediated cleavage and 
inactivation of PARP protein. This transient burst of poly-(ADP-ribosyl)ation of 
nuclear proteins was subsequently detected at an early stage of induced 
apoptosis in other cell types [Simbulan-Rosenthal, 1998]. These findings suggest 
that PARP and poly-(ADP-ribosyl)ation may trigger an important step of early 
apoptosis. However, treatment of PARP-/- fibroblasts with TNF-, anti-Fas and IL-
Stellenbosch University  http://scholar.sun.ac.za
  55
3 withdrawal [Menissier-de Murcia et al., 1997; Wang et al, 1997], and of 
thymocytes with -irradiation, dexamethasone, ceramide and etoposide induces 
normal apoptotic responses [Leist et al., 1997; Wang et al., 1997]. Moreover, 
PARP-/- primary neurons and hepatocytes undergo apoptosis normally in 
response to a variety of stimuli, including potassium withdrawal, staurosporine, 
and colchicine [Leist et al., 1997]. These results indicate that at least in certain 
cell types, PARP does not actively participate in the apoptotic cascade. Despite 
the above-mentioned discrepancies, most studies point out that PARP is 
specifically cleaved during apoptosis, and that massive DNA damage activates 
PARP, before or in parallel to caspase activation, leading to necrosis. Therefore, 
it remains to be elucidated whether the activation and/or cleavage of PARP has a 
specific role in the “decision-making” phase or activating phase of programmed 
cell death. 
 
An important question, which is often raised, is why must PARP be cleaved in 
cells destined to die?  It has been postulated that PARP cleavage occurs in order 
to prevent depletion of energy pools required for later stages of apoptosis 
[Earnshaw, 1995]. Transient transfection of cells with non-cleavable PARP 
delays apoptosis induced by anti-Fas, as judged by morphological criteria such 
as cell shrinkage and nuclear condensation. The authors claimed that PARP 
cleavage facilitates cellular disassembly ensuring cell death completion [Olivier, 
1998].  However, in two other studies, cell lines stably expressing non-cleavable 
PARP exhibit increased apoptosis in response to TNF- and staurosporine, as 
determined by extensive morphological analyses [Herceg & Wang, 1999; 
Boulares et al., 1999].  It was hypothesized that mutant PARP accelerates 
apotosis through compromised energy metabolism and the mitochondrial 
permeability transition (MPT) [Nicholson & Thornberry, 1997], or by shifting 
caspase-3 activation to an earlier time point [Boulares et al., 1999]. Alternatively, 
poly(ADP-ribosyl)ation of histones and other nuclear proteins by non-cleavable 
PARP could also substantially contribute to unwinding of chromatin structures 
thereby facilitating access to apoptotic DNAase(s). The apparent discrepancy of 
the results between the above-mentioned studies using non-cleavable PARP can 
be attributed to the technical means by which the mutant PARP was introduced 
into the target cells, i.e. transient versus stable transfection. More importantly, the 
observed induction of massive necrosis coupled with NAD+ and ATP depletion in 
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mutant PARP expressing cells [Herceg & Wang, 1999], strongly argues that 
PARP cleavage plays an important role in ensuring the normal speed and order 
of apoptotic events, and prevention from necrosis in cells undergoing apoptosis. 
Since massive activation of PARP leads to necrotic cell death, cells that die via 
apoptosis must block PARP-mediated necrosis by cleaving PARP. Together, 
these findings fit well with the proposal that PARP cleavage has a function in the 
prevention of necrotic death that would otherwise lead to pathological 
inflammatory responses [Earnshaw, 1998]. This theory is also supported by 
several other studies demonstrating that PARP activation is involved in 
inflammatory responses [Szabo et al., 1997, 1998; Cuzzocrea et al., 1999; Olivier 
et al., 1999]. Moreover, streptozotocin-induced disruption of pancreatic -cells 
underlines PARP activation and energy depletion as a cause of necrotic cell 
death in this cell type [Burkart et al., 1999]. 
 
1.6.1.3 Regulatory proteins 
 
In apoptosis, protein-protein interactions are the underlying theme in both 
mitochondria and death receptor pathways. A sophisticated and tightly controlled 
network of protein-protein interactions exists to ensure the accuracy of the cell-
death machinery.  
 
The Bcl-2 family is a large key group of apoptosis regulators which, through the 
diverse interactions among themselves and with other proteins, control the 
release of apoptogenic factors needed for caspase activation [Adams & Cory, 
1998; Chao & Korsmeyer, 1998]. The IAP (Inhibitor of apoptosis protein) 
family is another family of proteins that inhibits apoptosis through physically 
interacting with caspases and thereby directly inhibiting their function.  
 
1.6.1.3 (a) Bcl-2 Protein Family 
 
Members of the Bcl-2 family include both anti-apoptotic proteins, exemplified by 
Bcl-2, Bcl-XL, Mcl-1, Bcl-w and A-1, and pro-apoptotic proteins exemplified by 
Bax, Bak, Bik, Bad and Bid. In terms of sequence, Bcl-2 family proteins share at 
least one of four homologous regions termed Bcl homology (BH1 to BH4). Based 
on sequence homology, a subclass of pro-apoptotic proteins termed “BH3-only” 
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can be classified that share sequence homology only in the BH3 domain. While 
all of the pro-apoptotic members use the BH3 domain to interact with anti-
apoptotic proteins, BH3-only proteins, including Bad and Bid, appear to act 
mainly as antagonists of anti-apoptotic members such as Bcl-2 and Bcl-XL. In 
contrast to the opposing biological functions and wide differences in amino-acid 
sequences, experimentally determined crystal structures of Bcl-2 [Petros et al., 
2001] and  Bcl-XL [Muchmore et al., 1996; Aritomi et al., 1997], vs Bax [Suzuki et 
al., 2000] and Bid [McDonnel et al., 1999; Chou et al., 1999] are surprisingly 
similar. 
 
The mechanism by which Bcl-2 family proteins regulate apoptosis has been a 
subject of intensive research. Currently it remains controversial and several 
models have been proposed. An attractive mode of action is the 
heterotrimerization between anti-apoptotic and pro-apoptotic Bcl-2 family 
members [Oltvai et al., 1993; Yang et al., 1995; Reed et al., 1996]. Some 
information about the structural basis of these interactions is provided by the 
three-dimensional structure of Bcl-XL in complex with a peptide derived from the 
BH3 domain of Bak [Sattler et al., 1997]. The structure reveals a hydrophobic 
surface pocket on Bcl-XL formed by the BH1-3 domains bound by the Bak BH3 
domain peptide in helical conformation. Since the BH3 domain is buried in the 
structure of pro-apoptotic proteins Bid [McDonnel et al., 1999; Chow et al., 1999] 
and Bax [Suzuki et al., 2000], this raises the speculation that conformational 
changes are necessary for the exposure of the BH3 domain of a pro-apoptotic 
protein and its inhibition of the functional pocket on the anti-apoptotic partner. In 
the cell environment, pro-apoptotic Bcl-2 family members are suggested to 
undergo such conformational changes [Desagher et al., 1999] triggered by 
dephosphorylation [Zha et al., 1996] or proteolytic cleavage by caspases (such 
as the cleavage of Bid to generate tBid [Slee et al., 2000; Li et al., 1998; Luo et 
al., 1998].  
 
1.6.1.3 (b) IAP (Inhibitor of apoptosis protein) family 
 
The Bcl-2 and IAP families are regulators of caspases at two different levels: the 
Bcl-2 family controls signaling events upstream of caspases, while the IAP family 
directly binds and inhibits caspases. The human IAP family contains eight distinct 
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cellular members including X-IAP (X-linked IAP), c-IAP1, c-IAP2, and survivin 
[Devereaux et al., 1999]. In humans, IAPs such as X-IAP, c-IAP1, and c-IAP2 
selectively inhibit caspase-3, -7 and –9 through direct molecular interactions but 
not caspase-1, -6, -8, -10. In addition, IAPs can interact with Smac/DIABLO, 
which is released from the mitochondria together with cytochrome c upon death 
stimuli. The binding of Smac/DIABLO removes IAPs from their association with 
caspases and thus relieves their caspase-inhibiting function [Devereaux et al., 
1997; Roy et al., 1997]. 
 
In the human heart, cardiac failure is characterized by the progressive death of 
myocytes [Olivetti et al., 1997]. It was always believed that all adult 
cardiomyocyte cell death was caused by necrosis. However, Narula et al. [1996] 
and Olivetti et al. [1997] provided the first evidence that apoptosis occurs in the 
myocardium of patients with end-stage dilated cardiomyopathy. Similarly, Saraste 
et al. [1997] demonstrated the presence of apoptotic cells in the infarct and peri-
infarct regions of myocardium obtained from patients dying from a recent 
myocardial infarction. Probably the best information about apoptosis in the heart 
has been derived from studies of experimental ischaemia/reperfusion. Kajstura 
and co-workers [1996], have shown that apoptosis is the predominant mode of 
cell death in ischaemia-reperfused tissue.  
 
Since the significance of cell death by apoptosis to cardiac pathology has been 
established, there is still great interest in the field. This is because unlike 
necrosis, which is thought to be an essentially irreversible process, the step-by-
step nature of apoptosis suggests it may be amenable to therapeutic 
intervention. 
 
1.6.2.)  Autophagy 
 
Autophagy is a catabolic process which degrades long-lived proteins and 
organelles, thereby maintaining cardiac structure and function and inhibiting 
cardiac abnormalities. It is an evolutionary conserved lysosomal pathway, 
involving the degradation of damaged cytoplasmic proteins, macromolecules and 
organelles such as ribosomes, the endoplasmic reticulum, Golgi-apparatus and 
mitochondria. The term autophagy is derived from the Greek language “auto” 
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(self) and phagy (to eat) and means self-digestion. It is a highly regulated, 
physiological process, initiated by starvation (amino acid and nutrient deficiency), 
hypoxia and metabolic stress. Self-digestion provides a means of recycling 
extracted amino acids and fatty acids for ATP production via the TCA cycle and 
thereby supplying an alternative energy source which may serve as a temporary 
survival mechanism. 
 
It is therefore a protective cell survival mechanism against environmental and 
cellular stress. However, if the cellular stress leads to continuous or excessively 
induced autophagy, cell death may occur. This type of cell death is referred to as 
type II programmed cell death (CPD-type II) [Mizushima et al., 2008].  Autophagic 
cell death is caspase-independent and does not involve classic DNA laddering 
[Kirisako et al., 1999].  
 
The process of autophagy consists of four stages; induction, nucleation, 
expansion and maturation/retrieval of autophagosomes [He et al., 2009; Levine et 
al., 2004].  Induction and nucleation involves the formation of an isolation 
membrane known as a phagophore from the source which can be the 
endoplasmic reticulum or mitochondria [Axe et al., 2008]. Phagophores migrate 
to the phagophore assembly site (PAS), where the factors involved in the 
autophagic process are recruited. Phagophores undergo expansion at the PAS 
site, after which they engulf the damaged cytosolic components (cargo), and 
subsequently develop into mature autophagosomes. Mature autophagosomes 
bind to microtubules and are transported to lysosomes for fusion. 
Autophagosome formation is regulated by the autophagy-related genes (ATG).  
Phagophore induction and expansion are mostly triggered by the class-III 
phoshoinositide 3-kinase, Vps34, which forms a multi-protein complex with 
Beclin-1, Atg14 and Vps150, leading to the formation of phosphatidylinositol 3-
phosphate (PtdIns3P). The latter is necessary for recruitment of other regulatory 
proteins at the phagophore assembly site to facilitate the expansion of the 
phagophore. Phagophore formation is also induced by a macromolecular 
complex formed by Atg13, Unc-51-like kinase 1 (Ulk 1, a homologue of the yeast 
Atg1) and Ulk 2, which phosphorylates the focal adhesion kinase family 
interacting protein 200 (FIP200), which triggers initiation of autophagy. 
 
Stellenbosch University  http://scholar.sun.ac.za
  60
The elongation phase involves two parallel ubiquitin ligase-like systems. Firstly, 
Atg12 must be conjugated onto Atg5 in a reaction catalyzed by Atg7 and Atg10. 
This is a pre-requisite step for the subsequent conjugation of LC3 onto 
phosphatidylethanolamine in the growing autophagosomal membrane 
[Gustafsson et al., 2008]. These two systems act in parallel and are well 
coordinated, thus enabling the formation of autophagosomes which are recruited 
to engulf targets through the action of an adaptor protein, such as p62. The 
Atg12-Atg5 complex binds to the phagophore membrane and promotes its 
elongation. Subsequently, Atg7, Atg3 and the Atg12-Atg5 complex modulate the 
conjugation of the lipidated form of LC3 known as LC3-II. L3-II is crucial for 
autophagosome expansion, including membrane tethering and hemifusion as 
well as controlling the size of the autophagosome by regulating the membrane 
curvature. Once autophagosomal formation is accomplished, L3-II is released 
into the cytosol after its Atg4-mediated cleavage from phosphatidylethanolamine. 
The mature autophagosome transports its cargo to the lysosome for degradation. 
The degradated products which include amino acids, carbohydrates, nucleic 
acids and fatty acids are eventually exported by the lysosome.  
 
Studies demonstrated that autophagy can be induced by cytotoxic signals in cells 
that are resistant to apoptosis, such as those lacking Bax or Bad or those 
expressing high levels of Bcl-2 or Bcl-XL [Shimizu et al., 2004]. Furthermore, 
apoptosis and autophagy are intertwined (shown in Figure 1.5) and linked by the 
following effector proteins; Bcl-2, Bcl-XL, Mcl-1, ATG5 and p53 [Shimizu et al., 
2004; Pattingre et al., 2005; Yosefi et al., 2006; Lockshin et al., 2007; Akar et al., 
2008].  Apoptosis and autophagy share some common signal transduction 
pathways, such as PI3-K/AKT/mTOR, NFқB, and ERK p44/p42 MAPK pathways 
[Dalby 2010]. 
 
Despite the enormous advances in the elucidation of the mechanism of 
autophagy, the signal transduction pathways that regulate autophagy are still not 
clear [Xie et al., 2007].  Mechanistic evidence exists however, which links the 
kinases to known regulators of autophagy (Figure 1.6).  AMPK has been shown 
to inhibit the phosphatidylinositol kinase homolog; mammalian target of 
rapamycin (mTOR) under conditions of energy stress, thereby induces a 
protective autophagic response [Papandreou et al., 2008].  mTOR is activated by 
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nutrients and amino acids and is an important negative regulator of autophagy 
[Meijer et al., 2004].  JNK has been shown to increase the expression of Beclin-1 
in a c-Jun dependent way [Li et al., 2009]. Beclin-1 has an important role in 
autophagy where it is recruited to the protein complex containing the lipid kinase, 
Vps34, which triggers nucleation of autophagosomes [Liang et al., 2006; 
Takahashi et al., 2007]. JNK further promotes autophagy by inducing the release 
of Beclin-1 from an inhibitory Bcl-2-Beclin-1 complex [Wei et al., 2008 & 2009]. 
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Figure 1.5: Regulation of autophagy and apoptosis is intertwined. Downstream targets 
of mTOR, EF2K (a.k.a.CAMK-III) and P70S6K, play a role in the regulation of translation 
and autophagy (see text for details) [Dalby, 2010]. 
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The protein serine/threonine kinase, eEF2K, is negatively regulated by mTOR 
and promotes autophagy during periods of cell stress. These studies suggest a 
possible link between the inhibition of protein synthesis and the induction of 
autophagy [Hait et al., 2006; Wu et al., 2006 & 2009].  Autophagy can also be 
induced by PKC and NO but the mechanisms involved are currently unknown 
[Huang et al., 2010]. 
 
It has been recognized since 1980, that autophagy occurs in cardiac tissue 
[Decker et al., 1980].  Autophagy could be detected under basal conditions in the 
heart and deletion of Atg5 in adult mice hearts rapidly induced cadiac 
hypertrophy, left ventricular dilatation and contractile dysfunction. This was 
associated with an increase in protein ubiquitination and aggregation, 
disorganized sarcomere structure, endoplasmatic reticulum stress and 
mitochondrial dysfunction [Nakai et al., 2007]. Autophagy is also essential for 
maintaining normal cardiac function during aging. Deletion of Atg5 in the mouse 
heart during aging resulted in cardiac dysfunction and aging cardiomyopathy  
[Taneike et al., 2010]. These results demonstrated that a certain level of 
autophagy is a requirement for normal cardiac structure and function. A modest 
increase of autophagy under stress conditions appears to be protective. A 
massive activation however, may be detrimental to the heart [Nishida et al., 2009; 
Wang et al., 2011].  
 
The initial studies, conducted in 1980, demonstrated that induction of autophagy 
correlated with functional recovery of the rabbit heart after ischaemia/reperfusion 
[Decker et al., 1980]. The same study demonstrated that prolonged ischaemia 
impair the autophagosome-lysosomal pathway, which is associated and 
correlated with contractile dysfunction and irreversible damage. Another study 
reported the expression of several autophagy-related genes during a period of 
prolonged ischaemia [Vatner et al., 2005]. Autophagy is stimulated during 
hypoxia and/or ischaemia in the heart, when the energy reserves is rapidly 
depleted [Nishida et al., 2009]. The decrease in cellular ATP content during 
ischaemia stimulates AMPK, which acts as an energy sensor for energy 
deprivation. Activation of AMPK during ischaemia is required for induction of 
protective autophagy, since inhibition of AMPK during sustained ischaemia 
significantly suppresses autophagy [Matsui et al. 2007]. 
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Figure 1.6: Protein kinase signaling pathways implicated in the regulation of                    
autophagy. JNK-1 activates autophagy by promoting the expression of the autophagy 
related genes (indicated by the light arrow). Phosphorylation of BCL-2 by JNK-1 disrupts 
the Beclin-1 BCL-2 complex and the inhibiting BCL-2 is released from the complex 
(darker arrow) and Beclin-1 is recruited to the Vps34 complex and autophagy is initiated 
(light block arrow,  ). Inhibition of a particular kinase or kinases may help blocking 
induction of protective autophagy. AMPK is activated by nutrient deprivation (indicated 
by dark arrow          ), and inhibits mTOR (indicated by dark arrow         ), which 
negatively regulates autophagy. Inhibition of mTOR by AMPK induces protective 
autophagy. eEF2K is negatively regulated by mTOR. DAPK promotes autophagy and is 
activated by MAP1B. Inhibition of some kinases, such as PKCδ, may lead to autophagic 
cell death. See text for details [Dalby, 2010]   
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Inhibition of autophagy was accompanied by enlargement of the infarction 
[Takagi et al., 2007]. Further studies support these findings that activation of 
autophagy during ischaemia is generally protective and essential for cell survival 
and also for maintenance of cardiac function [Matsui et al., 2007].  
 
The level of autophagy further increases during reperfusion and the production of 
ROS was suggested to be the main inducer of autophagy during reperfusion  
Production of ROS was accompanied by a robust activation of the autophagic 
mediator, Beclin-1, during reperfusion [Hariharan et al., 2011].                      
In a different study, Beclin-1 was also upregulated during reperfusion and this 
was associated with increased autophagy as measured by LC3 puncta. Mice with 
reduced levels of Beclin-1 had smaller infarcts after 24 hours of reperfusion 
[Matsui et al., 2007; Hariharan et al., 2011]. These results suggest that enhanced 
autophagy during reperfusion is detrimental in the heart [Matsui et al., 2007]. It 
would appear that the “good” autophagy is AMPK dependent, while the “bad” 
autophagy is dependent on Beclin-1 [Matsui et al., 2007]. 
 
Subsequently, it was demonstrated by several laboratories that autophagy 
increased in the setting of IPC [Yitzhaki et al., 2009; Yan et al., 2009]. This 
involvement of autophagy with IPC has been suggested to serve a protective 
function [Gurusamy et al., 2009; Park et al., 2009]. A recent study also 
demonstrated that IPC induces autophagy [Huang et al., 2010]. Using the rat 
Langendorff perfusion model, the results indicated that the autophagy marker p62 
was downregulated after the IPC protocol, compared to control hearts. Results 
from the same study demonstrated that autophagy is required for 
cardioprotection by IPC. Langendorff-perfused rat hearts were pretreated with an 
inhibitor of autophagy, 15 min before the IPC protocol. These hearts presented 
with larger infarcts than non-IPC hearts at the end of 2 hours of reperfusion. 
These results suggest that autophagy may be a possible end effector of IPC 
[Huang et al., 2010]. 
 
1.6.3.)  Necrosis 
 
Mitochondria may also trigger cell death through another pathway, known as the 
mitochondrial permeability transition (MPT), first described in 1976 [Hunter et al., 
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1976]. This pathway involves opening of a large conductance pore, the 
mitochondrial permeability transition pore (MPTP), resulting in the rapid 
exchange of solutes up to 1.5 kDa in size. The resulting influx of cytosolic water 
causes matrix expansion, leading to outer membrane rupture with the release of 
pro-apoptotic factors from the intermembrane space. Due to energetic collapse 
and uncontrolled enzymatic processes caused by matrix swelling, cell death often 
occurs before apoptosis can proceed [Halestrap et al., 1998]. Further studies 
demonstrated that the MPTP remains close during ischaemia and open only 
during the first few minutes of reperfusion [Griffiths et al., 1995]. Phosphorylated 
GSK3-β was shown to play a pivotal role in the inhibition of MPTP [Juhaszova et 
al., 2004]. Some studies suggest that PI3-K/Akt may protect the myocardium 
against ischaemia/reperfusion injury by acting at the level of mitochondria 
through the activation of GSK-3β, thereby inhibiting the MPTP [Davidson et al., 
2006]. It was also shown that PKC-ε protects the heart against 
ischaemia/reperfusion injury by inhibiting the MPTP [Costa et al., 2008].      
 
1.6.4.)  Cell death cross talk in ischaemia/reperfusion 
 
There is a tendency to study different modalities of cell death as detached 
processes, but it has become more obvious that substantial cross talk occurs 
between autophagic, necrotic and apoptotic pathways. As indicated in Figure 
1.7, caspases can cleave Beclin-1 and receptor-interacting protein 1 (RIP1), 
which are two key mediators of autophagy and apoptosis respectively. Thus, 
apoptosis can suppress both autophagy and necrosis [Djavaheri-Mergny et al., 
2010; Lin, et al., 1999]. On the contrary, inhibition of the key autophagic protein 
Atg5 triggers apoptosis by a mechanism which is still unknown [Boya et al., 
2005].  Opening of the pro-necrotic MPTP in the mitochondrial inner membrane, 
will result in adenosine triphosphate (ATP) depletion, which in turn will inhibit the 
induction of ATP dependent autophagy and apoptosis. Alternatively, studies 
indicated that inhibition of apoptosis with caspase inhibitors, will trigger 
autophagic or necrotic cell death [Vandenabeele et al., 2006]. Thus care must be 
taken in developing pharmacological agents or interventions for the treatment of 
ischaemia/reperfusion injury. By selectively inhibiting necrosis during reperfusion, 
it is possible that cells will still die, but through apoptosis and/ or autophagy 
instead.  
Stellenbosch University  http://scholar.sun.ac.za
  67
               
 
 
 
 
 
  
 
Figure 1.7: Cross talk between apoptosis, autophagy, and necrosis.                       
Depiction of the mechanisms by which the 3 forms of cell death can influence one 
another: 
(1) Caspases can cleave beclin-1 and receptor-interacting protein 1 (RIP1), two key 
mediators of autophagy and necrosis, respectively. Thus, apoptosis                       
can suppress the two other modes of death.  
(2) The key autophagic protein, Atg5, suppresses apoptosis, although the exact 
mechanisms are still unknown.  
(3) Opening of the pro-necrotic mitochondrial permeability transition (MPT) pore will                      
lead to adenosine triphosphate (ATP) depletion, which in turn will inhibit the 
progression of both autophagy and apoptosis [Baines, 2011]. 
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      1.7)   The importance of perfusion models in IPC 
                                              
Research efforts to elucidate the mechanism of IPC have often been hampered 
by the opposing results obtained by different laboratories. This has been 
attributed to differences in species (rabbits versus rats), perfusion models (in vitro 
versus in vivo), the size of the ischaemic zone (global versus regional ischaemia), 
the duration of ischaemia or the endpoint of protection (functional recovery of 
infarct size). Of particular concern are the conflicting data obtained with minor 
differences in only the experimental model or protocol. The 2 most frequently 
used experimental models of the perfused rat heart are the Langendorff  
retrogradely perfused model and the working heart model.  
 
The Langendorff model is based on forcing blood or a fluid into the coronary 
arteries through a canula implanted in the aorta [Langendoff, 1895]. It does not 
permit the left ventricle to eject the perfusate (cardiac output) and is therefore a 
non-working heart model [Doring 1988]. The Langendorff model employ regional 
ischaemia and use infract size or the incidence of reperfusion-induced 
arrhythmias as endpoint. Protection by IPC against arrhythmias has conclusively 
been reported in studies using rats, but its protective effects in large animals is 
controversial [Ovize et al., 1995; Grund et al., 1997]. It also appears that in the 
same species, the triggers required to precondition the heart against necrosis 
and arrhythmias, may differ [Li et al., 1992]. When using infarct size as endpoint, 
the age of the animal is an important aspect that needs attention. Tani et al., 
1997 reported that with middle age rats (50 weeks), the protective effect of IPC 
was reversed compared to young (12 week old ) rats. Furthermore the choice of 
anaesthetic agent is an important aspect, since anaesthetic agents may affect the 
magnitude of protection. A study by Haessler et al., 1994 showed that using 
identical experimental protocols, protection in pentobarbital anaesthetized 
animals was significantly greater than in isoflurane or ketamine/xylazine –
anaesthetized animals. This observation was confirmed by later studies [Cope et 
al., 1997]. The duration of infarct size development is different in various species 
[Nienaber 1983]. The early response to ischaemia depends to a large extent on 
the existence of a collateral circulation [Harken et al., 1981]. Various studies have 
shown that differences exist in the extent of collateralization of the various 
species [Schaper, 1971; Schaper et al., 1967; Schaper et al., 1992]. Dogs have a 
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well-developed coronary collateral circulation, while collateral blood flow in pigs 
and baboons is extremly low [Schaper 1971; White & Bloor 1981; Shen et al., 
1996; Crozatier et al., 1978]. The collateral circulation in the rat is low and the 
rabbit show intraspecies differences [Schaper et al., 1992; Winkler et al., 1984]. 
IPC has been shown in animals with [Murry et al., 1986] and without [Schott et 
al.,1990] a collateral circulation, implying that IPC is independent of the extent of 
a collateral circulation. However, collateral blood flow is a major determinant of 
infarct size and in order to obtain an accurate assessment of infarct size, 
collateral blood flow should always be determined in species with a collateral 
circulation. Body temperature is another important determinant of infarct size 
development with the magnitude of the effect depending on the duration of the 
coronary artery occlusion [Chien et al., 1994; Duncker et al., 1996; Schwartz et 
al., 1997]. The majority of studies use the ratio of infarcted area (IA) and the area 
at risk (AR) to assess the reduction in infarct size by IPC [Verdouw et al., 1998]. 
In the further analysis it then assumed that this ratio is independent of the area at 
risk, i.e. the relation between AR and IA is proportional. This has been shown to 
be true for rats [Ytrehus et al., 1993] but not for pigs [Koning et al., 1995] and 
rabbits [Ytrehus et al., 1993]. The linear regression line relating to infarted area 
and area at risk has a zero-intercept on the AR-axis. This implies that the 
mathematical description of this relationship is IA=a*AR + b or IA/AR=a+ b/AR. 
Especially for small AR, IA/AR depends on AR. Thus unless AR exeeds 20% of 
the left ventricular mass, IA/AR should be used with care, in particular when 
studies are compared in which the areas at risk differ substantially [Verdouw et 
al., 1998]. 
 
Neely et al., 1967 was the first to develope a working performing isolated heart 
model some 40 years ago. The working heart model employ global ischaemia 
and  permits the left ventricle to eject perfusate (cardiac output). It therefore uses 
functional recovery as endpoint. The advantage of the working heart model is that 
it allows construction of cardac function curves under a wide variety of conditions, 
such as before and after the post-ischaemic recovery phase of the reperfusion 
period [Verdouw et al., 1998]. The working heart model is particular useful for the 
study of metabolic pathways because the content of the substrate in the 
perfusion solution can be altered. The metabolic products can be determined in 
the effluent. Furthermore, at the end of the experiment, myocardial tissue can be 
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utilized for biochemical and histological analysis. When using global ischaemia 
one eliminates the interaction between the myocytes of different regions of the 
heart, which may have an impact on the ultimate function of regionally ischaemic 
myocardium [Fan et al., 1997]. 
 
 
Many laboratories in the field of IPC use infarct size as endpoint. Reduction in 
infarct size is regarded by many as the “gold standard” for the evaluation of the 
protection afforded by IPC [Yellon et al., 1998]. It is however, not always 
associated with an improvement in functional recovery in rabbits, dogs and pigs 
in vivo [Schulz et al., 2001]. Accurate measurement of infarct size can be 
complicated by by the choice of staining and the degree of collateral flow [Shirato 
et al., 1998]. Functional recovery of the isolated working rat heart subjected to 
global ischaemia has been the method of choice in many studies [Cave & Hearse 
1992; Csonka et al., 1999; Goto et al., 1992; Volovsek et al., 1992]. A study by 
Lochner et al., 2003 showed that IPC-induced improved functional recovery was 
best demonstrated in the globally ischaemic working heart. Improved functional 
recovery was seen at all ischaemic time intervals studied in this model. It was 
only seen in one series of non-working retrogradely perfused hearts after 30 min 
global ischaemia.  
 
The majority of studies focus on only one relatively early time point of reperfusion 
and this has led to the dismissal of cell death during late-stage reperfusion. This 
highlight the need for studies investigating longer reperfusion times in order to 
ascertain whether a reduction in infarct size is associated with a decrease in cell 
death during reperfusion. Therefore, we need better longer-term studies 
examining the different modalities of cell death that occur during late-stage 
reperfusion, to be able to understand their role and contribution to cardiac 
dysfunction and the underlying mechanisms that drive them. 
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In view of the above, the overall aims of the present study were:     
 
1) to characterize the activation patterns of the various kinases at different time 
points during reperfusion after IPC and to compare it with non-preconditioned 
hearts (Non-IPC) at the same time points during reperfusion after global 
ischaemia; 
2) to assess autophagy at these different time points during reperfusion after 
IPC and to compare it with non-IPC hearts at the same time points during 
reperfusion after global ischaemia; 
3) to assess apoptosis after 30 minutes of reperfusion after IPC and to compare 
it with non-IPC hearts at the same time point during reperfusion after global 
ischaemia; 
4) to identify the underlying mechanisms involved contributing to poor 
functional recovery of the IPC hearts during early (15 min) reperfusion, by 
employing 2D proteomics; 
5) to assess whether activation of the various kinases and heat shock proteins 
correlate with functional recovery and/or other haemodynamic parameters of the 
heart; i) before and after sustained ischaemia,  ii) after the IPC protocol (3xIPC) 
and also iii) after IPC during early (5 min and 10 min ) and late (30 min) 
reperfusion;  
6) to identify the kinase(s) of which the activation patterns do correlate with 
functional recovery of the ischaemic heart after IPC during 30 min reperfusion. 
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Chapter 2 
 
Materials and Methods: 
 
2.1) Animals 
 
Male Wistar rats weighing 250 -300 gram (± 8 weeks of age) were used in all 
experiments. Animals were cared for in the Central Animal Facility (CRF), which 
is an “Association for Assessment and Accreditation of Laboratory Animal Care” 
(AAALAC ) accredited unit, until the day of experimentation. Rats were housed in 
a thermally controlled environment (± 210C) and had free access to food and 
water. The study (project number: P09/05/009) has been approved by the 
Research Ethics Committee: Animal Care and Use (REC: ACU) of the University 
of Stellenbosch. 
 
2.2) Isolated working heart perfusions (Fig. 2.1) 
 
Rats were randomly assigned to different experimental groups. Rats were 
anaesthetized by intraperitoneal injection with sodium pentobarbitone, at a 
dosage of 120 mg/kg body mass, i.e. approximately 30 mg/rat. Hearts were 
excised and arrested in cold (40C) Krebs-Henseleit Buffer containing 119 mM 
NaCl, 25 mM NaHCO3, 4.75 mM KCl, 1.185 mM KH2PO4, 0.6 mM MgSO4, 0.6 
mM NaSO4, 1.25 mM CaCl2.2H2O, 10 mM glucose. The buffer was gassed with 
95% O2 and 5% CO2 prior to and during the perfusion protocol. Isolated rat hearts 
were rapidly mounted on the aortic cannula of the Neely-Morgan working heart 
perfusion system and retrogradely perfused through the aorta at a preload of 100 
cm H2O for 15 min.  
 
After cannulation of the aorta, the left atrial cannula was inserted into the 
pulmonary vein to allow atrial perfusion at a preload of 15 cm H2O. Myocardial 
temperature was closely monitored for the duration of the whole experiment by 
placing a temperature probe inside the coronary sinus. Subsequent to the 
stabilization period of 15 min, the mode of perfusion was changed to working 
heart mode for 15 min. In the working heart mode, buffer enters the heart through 
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the left atrium through the pulmonary vein and is ejected by the left ventricle 
against a hydrostatic pressure of 100 cm H2O (afterload). This was followed by a 
retrograde perfusion episode of 30 min. Hearts were then subjected to global 
ischaemia as end-point of ischaemic damage. 
 
2.2.1) Global ischaemia 
 
Hearts were subjected to 25 min global ischaemia, (cessation of perfusate flow to 
the whole heart). Global ischaemic temperature was maintained at 36.50C. This 
was followed by 10 min retrograde reperfusion and 20 min working heart mode 
reperfusion.  
 
2.2.1.1) Mechanical functional recovery after global ischaemia 
 
Mechanical functional recovery was measured as an end-point in hearts 
subjected to global ischaemia. Coronary (Qe) and aortic (Qa) flow rates in ml/min 
were measured manually. A side branch of the aortic cannula was connected to a 
Viggo-spectramed pressure transducer, in order to obtain the aortic pressure 
(mmHg). The heart rate (HR), peak systolic pressure (PSP), diastolic pressure, 
mean blood pressure and ejection fraction (EF), were obtained from the 
recordings made. The maximum rate of left ventricular pressure (LVP) rise, 
(dP/dTmax) and fall (-dP/dTmin) were also obtained from the recordings made. 
The following parameters were calculated: 
 
 Cardiac output (CO) in ml/min =  Qa + Qe 
 Stroke volume (SV) ml/min = CO / HR 
 The mean external power (TW) produced by the left ventricle in mWatts = 
     0.002222(PAO – 11.25) (CO) where PAO =aortic pressure and CO = cardiac  
     output (Kannengieser, 1979). 
 
These measurements were made before global ischaemia (during the 
stabilization phase) and after global ischaemia, during reperfusion, as indicated 
by the arrows in Fig. 2.1.  Functional recovery of hearts was determined after 30 
min reperfusion, by expressing post-ischaemic aortic output as a percentage of 
pre-ischaemic aortic output. 
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 Basic perfusion protocol:      
     
 Retrograde     Working heart                 Retrograde                        Sustained ischaemia         Retrograde           Working heart   
    
Retrograde     Iscmic preconditioned hearts: 
 
    15 min          15 min                         30 min                                   25 min                    10 min                   20 min 
                                      Recordings                                                                                                                                                   Recordings 
        Stabilization                             Stabilization                  Global ischaemia                        Reperfusion 
 
Controls: 
 Retrograde     Working heart                 Retrograde 
 
            Stabilization                             Stabilization 
                                           Recordings 
 
 
 
 
 
Figure 2.1 Basic perfusion protocol for the isolated perfused working rat heart with global ischaemia. Mechanical functional 
recordings, were made after 15 min working heart and after 30 min reperfusion, as indicated by the dashed arrows (   ). 
For control hearts, functional recordings were made after 15 min working heart as indicated by the dashed arrows (   ).
0                  15                  30    35    40    45     50    55    60                                      85      90      95     100    105               115 
 
                                                                                     Time (Minutes)
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2.2.1.2)  Experimental Protocol (Fig. 2.2) 
 
(i) Controls: Hearts were stabilized for 30 min (15 min retrograde, 15 min 
working heart). Functional recordings were made after 15 min working heart (as 
indicated by the dashed arrows in Fig. 2.1 and Fig. 2.2) and hearts were 
retrogradely perfused for another 30 min. Hearts were then snap-frozen before 
sustained ischaemia for Western blotting analysis, as indicated by the solid 
arrows (Fig.2.2). Control hearts were thus not subjected to ischaemia/reperfusion 
or the IPC protocol, but perfused under oxygenated conditions. 
 
(ii) Non-preconditioning (Non-IPC): Hearts were stabilized for 60 min (15 min 
retrograde, 15 min working heart and 30 min retrograde). Functional recordings 
were made at 15 min working heart as indicated by the dashed arrows in Fig. 2.2. 
Hearts were subsequently subjected to 25 min sustained global ischaemia 
followed by 30 min reperfusion (10 min retrograde perfusion and 20 min working 
heart). After 30 min reperfusion, functional recordings were made (dashed 
arrows) and hearts were snap-frozen for Western blotting analysis, as indicated 
by the solid arrows (Fig. 2.2). Alternatively, when investigating shorter reperfusion 
times, hearts were snap-frozen at 5, 10  and 15 min reperfusion respectively, as 
indicated by the solid arrows in Fig. 2.2.  
 
(iii) Ischaemic preconditioning (IPC): Hearts were stabilized for 30 min (15 min 
retrograde, 15 min working heart). Functional recordings were made after 15 min 
working heart as indicated by the dashed arrows in Fig. 2.2. Hearts were then  
preconditioned by 3x5 min global ischaemia, alternated with 5 min reperfusion. 
Hearts were subjected to 25 min sustained global ischaemia, followed by 30 min 
reperfusion (10 min retrograde perfusion and 20 min working heart). After 30 min 
reperfusion, functional recordings were made (dashed arrows) and hearts were 
snap-frozen for Western blotting analysis, as indicated by the solid arrows (Fig. 
2.2). Alternatively when investigating shorter reperfusion times, hearts were 
snap-frozen at 5, 10 and 15 min reperfusion respectively, as indicated by the 
solid arrows in Fig. 2.2. 
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Non-preconditioned  hearts:   
           
 Retrograde     Working heart                Retrograde                          Sustained ischaemia         Retrograde            Working heart              
                                                                                                                                                                                          
: 
                                                                                                                                       Reperfusion                           Recordings 
                                         Recordings                              Control 
 
  
 Retrograde    Working heart               Preconditioning                     Sustained ischaemia          Retrograde           Working heart          
                                                                                                                                                             
 
                                                                                                                            Reperfusion                          Recordings                   
                                         Recordings 
 
 
 
 
 
Figure 2.2        Experimental protocol according to a timeframe indicating at which time intervals, indicated by the solid arrows (  ), 
hearts were snap-frozen for western blot analysis. Functional recordings were indicated by the dashed arrows (    ).                                                     
                                                                                                     
Ischaemic preconditioned  hearts: 
0                  15                  30    35    40    45     50    55    60                                      85      90      95     100    105               115 
 
                                                                                     Time (Minutes)
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2.3)  Western Blot analysis 
 
Hearts were snap-frozen at different time intervals as indicated in Fig.2.2 and 
stored in liquid nitrogen, before the preparation of tissue lysates for Western 
blotting analysis. The following phosphorylated- and appropriated total primary 
antibodies (Cell Signaling Technology, Massachusettes, United States) were 
used: phospho-p38 MAP Kinase (Thr 180/Tyr 182) and total p38 MAP Kinase; 
phospho ERK (p44/42) MAP Kinase (Thr 202/Tyr 204) and total ERK (p44/42) 
MAP Kinase; phospho PKB/Akt (Ser 473) and total PKB/Akt; phospho HSP- 
27(Ser 82) and total HSP-27 (Rodent Preferred); HSP-70 (D69); phospho CREB 
(Ser 133) and total CREB (48H2); phospho-CaMKII (Thr 286) and total CaMKII 
(pan); phospho AMPKα (Thr 172) and total AMPKα; phospho GSK-3β (Ser9) and 
total GSK-3β; Caspase-3; Cleaved PARP (Asp 214) rat specific antibody, Beclin-
1 and LC3B. Equal protein loading was assessed by probing membranes with β-
Tubulin antibody (Cell Signaling Technology, Massachusettes, United States). 
ECL anti-rabbit IgG horseradish peroxidase-linked species-specific whole 
antibody (from donkey) was used as secondary antibody (Amersham, GE 
Healthcare, UK.)  Protein bands obtained were analyzed using densitometry 
(UNSCAN-IT Software version 5.1; Silk Scientific Corporation, United States). 
 
2.3.1) Preparation of lysates from heart tissue 
 
Approximately 30 ug of tissue in 900 µl of lysis buffer containing 20 mM Tris-HCl, 
pH 7.5; 1 mM EGTA; 1 mM EDTA; 150 mM NaCl, 1 mM β-glycerophosphate; 2.5 
mM sodium pyrophosphate; 1mM sodium vanadate; 1% (v/v) Triton-X100; 10 
µg/ml leupeptin; 10 µg/ml aprotonin and 50 µg/ml phenylmethylsulfonylfluoride 
(PMSF) was used for the preparation of tissue lysates. Tissues were 
homogenized with a politron for 2 x 5 sec, maintaining the temperature at 40C 
throughout all procedures, after which it was transfered to microcentrifuge tubes. 
It was centrifuged at 14 500 rpm for 10 min at 40C and the resulting supernatant 
(total cell lysate) was transferred to a new tube. The pellet was discarded. The 
Bradford assay (Bradford, 1976) was used for determining the protein content of 
the samples. The protein concentration of all samples were adjusted and 
equalized to 25 µg/ 9 µl with lysis and sample buffer. Samples were boiled for 5 
min and stored overnight at -800C. 
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2.3.2) Electrophoresis 
 
Polyacrylamide gels, consisting of a 4% stacking gel and 12% separation gel, 
were prepared by the method of Laemmli (Laemmli, 1970).  Pageruler (Thermo 
Scientific, Bremen, Germany) was used as molecular weight marker. Samples 
were subjected to electrophoresis, using the standard Bio-Rad Mini Protean III 
system (Bio-Rad Laboratories Inc. Hercules, CA, United States). Gels were run at 
100 V for 10 min and a further 50 min at 200V. Alternatively, 4-15% CriterionTM 
TGXTM precast gels (midi-gels) were used, using the Bio-Rad Criterion gel 
system (Bio-Rad Laboratories, Inc. Hercules, CA, United States). Electrophoresis 
was carried out at 200 V for 50 min, using the Laemmli system with 
electrophoresis buffer containing 25 mM Tris, 200 mM Glycine and 0.1% (w/v) 
SDS (Laemmli, 1970). 
 
2.3.3) Western Blotting 
 
The separated proteins were transferred to a Polyvinylidene Difluoride (PVDF) 
membrane (Merck Millipore, Massachusetts, United states). The blotting step was 
carried out at 200A for 60 min with cooling, using the Bio-Rad Mini Trans-blot Cell 
(Bio-Rad Laboratories, Inc. Hercules, CA, United States). Alternatively, the 
blotting step for the Criterion (midi-gels) were carried out at 100V for 35 min with 
cooling, using the Criterion blotter with plate electrodes. Proper transfer and 
equal protein loading was assessed by staining the membrane with 5% (w/v) 
Ponceau-S. Non specific protein binding sites on the membrane were blocked 
with 5% (w/v) fat free milk in TBSTween (Tris buffered saline with 0.1% (v/v) 
Tween 20) for 2 hours at room temperature. Membranes were incubated with the 
primary antibody (phosphorylated or total antibody) of interest, overnight at 40C 
with gentle agitation. After thorough washing with TBSTween, membranes were 
incubated with the secondary antibody (Rabbit IgG Horseradish Peroxidase-
linked; Amersham, GEHealthcare, UK), for 60 min at room temperature.  
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2.3.4) Chemiluminescence 
 
After thorough washing of membranes with TBSTween, membranes were 
incubated with the chemiluminescent reagents (ECL detection system with 
luminol; Amersham, GE Healthcare, UK.) for 1 min at room temperature in the 
dark. Membranes were exposed to ECL Hyperfilm and a hypercassette 
(Amersham, GE Healthcare, UK), to visualize protein bands. Densitometry was 
used to scan and quantify the protein bands in order to perform the statistical 
analysis. 
 
 
2.4) Statistical analysis 
 
The total number of animals included in the study were 234. For perfusions, 
inclusion criteria applied were: AO of 36 ml/min and above; CF of 20 ml/min and 
below. Exclusion criteria applied were: AO below 36 ml/min; CF above 20 ml/min.  
 
For multiple comparisons one-way analysis of variance (ANOVA) was used with 
the Bonferroni correction as post-hoc test (GraphPad Prism software version 
5.0). For perfusions and western blotting analysis a minimum of 8 animals were 
used per experimental group and a maximum of 4 groups were included in each 
comparison.  When 2 groups were included in a comparison, data were analyzed 
using the independent Student t-test. Results obtained were expressed as mean 
± standard error of the mean (SEM). For correlation studies the Pearson test with 
a two tailed p value was utilized. Results were expressed as the Pearson 
correlation coefficient (r). A p value of <0.05 was considered significant in all the 
statistical analysis performed.  
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2.5.) Two- dimensional (2D) Proteomics  
 
2.5.1) Isolation of the mitochondrial fraction from heart tissue 
 
Mitochondria were isolated from Non-IPC and IPC hearts at the end of 15 min 
reperfusion, as indicated in figure 2.2, using a mitochondrial isolation kit  (Sigma-
Aldrich St. Louis, Missouri, United States). This kit enables the fast isolation of 
an enriched  mitochondrial fraction for proteomic studies [Lopez, 2000;  
Rabilloud, 1998]. The isolation procedure was performed at 40C.  
 
Approximately 120 mg tissue was weighed in an Eppendorf tube and cut with the 
aid of a scalpel and glass plate to even smaller slices. Tissues were suspended 
in 10 volumes of extraction buffer A (10 mM HEPES, pH 7.5, 200 mM mannitol, 
70 mM sucrose and 1 mM EGTA) containing 0.25 mg/ml trypsin in a 2 ml 
Eppendorf tube and incubated on ice for 3 minutes, followed by centrifugation 
(cooled Eppendorf centrifuge) for 15 seconds at 13 400 rpm. The supernatant 
was removed by aspiration and 8 volumes of extraction buffer A containing  0.25 
mg/ml trypsin was added to the tissue and incubated on ice for 20 minutes. An 
albumin solution was then added to a final concentration of 10 mg/ml to quench 
the proteolytic reaction followed by centrifugation for 15 seconds at 13 400 rpm. 
The supernatant was removed by aspiration and the pellet washed with 8 
volumes of extraction buffer A. The tissue was centrifuged for 15 seconds at 13 
400 rpm and the supernatant removed by aspiration. Eight volumes of extraction 
buffer A was added to the tissue, followed by homogenization using a 3 ml 
volume homogenizer (Potter-Elvehjem). Total homogenization of the tissue was 
ensured by moving the pestle up and down 20-30 times. The sample was 
centrifuged at 1000xg for 5 minutes, the supernatant removed and transfered to a 
new tube followed by centrifugation at 3500xg for 10 minutes. The mitochondrial 
pellet was resuspended in storage buffer containing 10 mM HEPES, pH 7.4, 
containing 250 mM sucrose, 1mM ATP, 0.08 mM ADP, 5 mM sodium succinate, 
2 mM K2HPO4 and 1 mM DTT. The protein concentration of the mitochondrial 
preparation was determined by the Quick StartTM Bradford Protein assay 
(Sedmak and Grossberg, 1977) with bovine serum albumin as standard (Bio-Rad 
Laboratories, Inc. Hercules, CA, United States).   
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2.5.2) Isolation of the cytosolic fraction of heart tissue 
 
The cytosolic fraction of Non-IPC and IPC hearts were isolated at the end of 15 
min reperfusion, as indicated in figure 2.2, using the Calbiochem ProteoExtract 
Subcellular Proteome Extraction kit (Merck, Darmstadt, Germany). This kit is 
designed for the reproducible extraction of subcellular proteomes from 
mammalian cells to yield 4 sub-proteome fractions which are enriched in 
cytosolic, membrane/organelle, nuclear and cytoskeletal proteins. The cytosolic 
fraction was used for the 2D proteomic study. 
 
2.5.3) Sample preparation prior to 2D Electrophoresis 
 
The ReadyPrep 2D CleanUp kit (Bio-Rad Laboratories Inc. Hercules, CA, United 
States), was used to concentrate the mitochondrial and the cytosolic fractions 
respectively and also to remove (by washing away) compounds which interfered 
with the isoelectric focusing (IEF) step. After precipitation, the proteins were 
washed and then resuspended in the IEF/2D-compatible sample buffer 
containing 8M urea, 2% (w/v) CHAPS, 50 mM DTT, 0.2% (w/v) Bio-Lyte 3/10 
ampholyte, 0.002% (w/v) bromophenol blue. Protein concentration was 
determined using the RC/DC Assay (Bio-Rad laboratories Inc, Hercules, CA, 
United states). This assay is based on the Lowry assay but has been modified to 
be reducing agent compatible (RC) as well as detergent compatible (DC). 
 
2.5.4) Two-dimensional (2D) Gel Electrophoresis  
 
Separation in the first dimension, using Iso-electric focusing (IEF), was performed 
using the PROTEAN- IEF cell (Bio-Rad Laboratories Inc. Hercules, CA, United 
States). Samples containing 100 µg mitochondrial and 150 µg of cytosolic 
proteins respectively, were loaded on 11cm immobilized pH gradient strips, pH 5-
8 (Bio-Rad laboratories, Inc. CA, United States).  
 
Three samples (n=3 animals) from each group (IPC) were run in triplicate against 
its respective control (Non-IPC). Two comparisons were done namely, (1) the 
mitochondrial fraction of IPC hearts were compared to the mitochondrial fraction 
of Non-IPC hearts (control). This experiment was repeated twice (n=3 
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experiments). Therefore a total number of 6 animals (18 strips/gels) in 3 different 
experiments were used for the mitochondrial proteomic study. (2) the cytosolic 
fraction of IPC hearts were compared to the cytosolic fraction of Non-IPC hearts 
(control). This experiment was repeated twice (n=3 experiments). Therefore a 
total number of 6 animals (18 strips/gels) were used in 3 different experiments for 
the cytosolic proteomic study.  
 
Strips were rehydrated under passive conditions for 12 h at 20 0C and focused at 
200 V for 20 min. The voltage was linearly increased over 2h to a maximum of 
8000 V and then run (rapid ramping) to accumulate a total of 40 000 V/h.  
 
Prior to the second dimension, the immobilized pH gradient strips were first 
equilibrated for 15 min in 0.375 M Tris-HCL, pH 8.8, 6M urea, 2% (w/v) SDS, 
20% (v/v) glycerol and 2% (w/v) DTT,  followed by equilibration for another 15 
min in 0.375 M Tris-HCL, pH 8.8, 6M urea, 2% (w/v) SDS, 20% (v/v) glycerol and 
2.5% (w/v) iodoacetamide.  
 
Strips were embedded in 0.5% (w/v) low melting point agarose containing 
0.003% (w/v) bromophenol blue on the top of Criterion XT 4-12% precast Bis- 
Tris gels (Bio-Rad Laboratories, Inc. Hercules, CA, United states), containing a 
4% stacking gel. The PeqGold protein marker II (Optima Scientific, Mississauga, 
Canada), was used as molecular weight ladder. Electrophoresis was performed 
at 200V, constant for 55 min. Gels were fixed in 40% (v/v) methanol and 7% (v/v) 
acetic acid for 60 min at room temperature and stained overnight with Brilliant 
Blue G-Colloidal Concentrate  (Sigma-Aldrich, St Louis, Missouri, United States) 
to visualize protein spots. Gels were subjected to a rapid destaining step, using 
40% (v/v) methanol and 10% (v/v) acetic acid for 60 sec at room temperature, 
followed by further destaining  in 25% (v/v) methanol.   
 
2.5.5) Identification of differentially expressed mitochondrial and  
          cytosolic proteins spots 
 
Gels were scanned with a GS-800 Calibrated Densitometer, using the Quantity 
One-4:5.2 (basic) software program (Bio-Rad Laboratories Inc. Hercules, CA, 
United States) to obtain gel images. The gels were washed with milli-Q water and 
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stored in 25% (w/v) ammonium sulphate until spots were excised. The gel  
images were analyzed using the PDQuest advanced version 8.1.1 software 
program (Bio-Rad Laboratories, Inc. Hercules, CA, United States). As this 
software program has a built-in statistical program, it was able to identify protein 
spots, that differ significantly in intensity between the three sets of triplicate gels 
(3x IPC mitochondrial versus 3x Non-IPC mitochondrial) and (3x IPC cytosolic 
versus 3x Non-IPC cytosolic), respectively. It only took spots in consideration that 
were present on all gels.  This was done to exclude any possible technical error 
or artefacts on the gels. Only spots that differed significantly (p<0.05) between 
the IPC and Non-IPC gels, as identified by PD Quest, were manually excised and 
prepared for liquid chromatography-mass spectrometry/mass spectrometry (LC-
MS/MS) analysis. These spots (spots of interest), were manually excised using a 
razor blade, cutting a section of gel no greater than 0.5 cm x 0.15 cm, which was 
then sliced into five equally sized pieces and placed in a 96-well plate.  
 
2.5.6) Trypsin digestion of mitochondrial and cytosolic proteins 
 
All reagents were prepared immediately prior to use. The acetonitrile was HPLC 
grade and the other reagents were the highest possible commercial grade 
available. Milli-Q water or 17 megaohm/cm Nanopure water was used in all 
components of the procedure. The MassPREP station (Waters MS Technologies, 
Manchester, UK ) in the Proteomics Facility , University of Warwick, was used for 
this method.  
 
Gel plugs were washed twice with 50% (v/v) acetonitrile in 50 mM ammonium 
bicarbonate and when fully destained rinsed with 100% (v/v) acetonitrile. Gel 
plugs were air dried for 10 min and proteins reduced for 30 min with 10 mM 
dithiothreitol (DTT), followed by alkylation with 55 mM iodoacetamide. Gel plugs 
were rinsed with 100% (v/v) acetonitrile and then 100 mM ammonium 
bicarbonate followed by 100% (v/v) acetonitrile for a further three times.  
 
For the in-gel digestion, a 25 µl aliquot of 6 ng/µl trypsin (Promega Corporation, 
Wisconsin, Madison, United States) was added to each sample and allowed to 
incubate at 370C for 4.5 hours. An aqueous solution of 30 µl, containing 2% (v/v) 
acetonitrile and 1% (v/v) formic acid was used to extract the resulting peptides. 
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The extracted peptides were placed in a cooled 96-well plate, while the second 
extraction was performed. For the second extraction, 15 µl of an aqueous 
solution containing 51% (v/v) acetonitrile and 0.5% (v/v) formic acid was used. 
The second extract was combined with the first extract in a cooled second 96-
well plate and stored at -800C prior to analysis by mass spectrometry.   
 
2.5.7) Peptide separation by in-line liquid chromatography (LC)  
           and electrospray ionisation (ESI) mass spectrometry 
 
The 96-well plate containing the extracted tryptic peptides was transferred to a  
Micromass modular CapLC and autosampler system (Waters MS Technologies, 
Mancester, UK ). LC solvents were supplied by Mallinckrodt Baker, Inc.  A 6.4 µl 
aliquot of each extract was mixed with 13.6 µl of 0.1% formic acid and loaded 
onto a 0.5 cm LC Packings C18, 5 µm, 100 A 300 µm id µ-precolumn cartridge. 
(Dionex Corporation, Sunnyvale, CA, United States). The following LC conditions 
were used: Solution A [95% water; 4.9% (v/v) acetonitrile and 0.1% (v/v) formic 
acid] and  Solution B [4.9% water; 95% (v/v) acetonitrile and 0.1% (v/v) formic 
acid].  Flushing the column with solution A desalted the bound peptides before a 
linear gradient of solution B at a flow rate of 200 nl min-1 eluted the peptides for 
further resolution on a 15 cm LC Packings C18, 5 µm 5 A 75 µm i.d. PepMap 
analytical column (Dionex Corporation, Sunnyvale, CA, United States). The 
gradient separations were 0.10 min (95% A: 5% B); 3 min (95% A: 5% B); 27.5 
min (60% A: 40% B); 28 min (5% A: 95% B); 31 min (5% A: 95% B); 31.5 min 
(95% A: 5% B); 40 min (95% A: 5% B).  The eluted peptides were analysed on a 
Micromass Quadrupole Time of Flight (Q-TOF) Global Ultima mass spectrometer 
(Waters MS Technologies, Manchester, UK ) fitted with a nano-LC sprayer with 
an applied capillary voltage of 3.5 kV. The instrument was calibrated against a 
collisionally induced decomposition (CID) spectrum of the doubly charged 
precursor ion of [glu1]-fibrinopeptide B, (GFP); Sigma-Aldrich, St Louis, Missouri, 
United States. A calibration was accepted when the error obtained on all 
subsequent acquisitions was < 20 ppm.  
 
Sensitivity was assessed by the detection of a 500 fmol injection of GFP, with a 
base peak signal:noise ratio of > 50:1 on the doubly charged ion. The sensitivity 
and calibration of the MS instrument, as well as the chromatographic resolution of 
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the GFP peak, were checked at regular intervals during the analysis. The 
instrument was operated in data dependent acquisition (DDA) mode over the 
mass/charge (m/z) range of 50-2000. During the DDA analysis, both MS and 
tandem mass spectrometry (CID) was performed on the most intense peptides as 
they eluted from the column. 
 
2.5.8) Data analysis: 
 
The uninterpreted data from the MS analysis were processed using the 
Micromass ProteinLynx Global Server version 2.3 software package (smoothed, 
background subtracted, centred and deisotoped). The processed data was mass 
corrected against the doubly charged GFP peptide and Peak list files (PKL’s) 
were created. The resulting Micromass PKL files were subjected to the MASCOT 
search engine (www.matrixscience.com), using MS/MS Ion search and the 
SwissProt database to identify proteins. Mammalia was used as subspecies and 
other search parameters specified for were: carbamidomethylated at cysteine 
residues (fixed modifications), oxidized at methionine residues (variable 
modifications) and 1 missed trypsin cleavage was allowed for. Peptide tolerance 
was set at 0.2 Da and MS/MS tolerance was 0.5 Da; peptide charge was set at 
+2 and +3. All protein identifications were significant according to the probability-
based MOWSE scores, which were reported as -10* Log10 (p), where p is the 
probalility that the observed score is a random event. 
  
2.5.9) Statistical analysis: 
 
A total number of 12 animals were used in the 2D proteomic study. 2D gels were 
analyzed by the PDQuest software program, version 8.1.1. (Bio-Rad 
Laboratories, Inc Hercules, CA, United States). The replicate group analysis was 
performed with Non-PC (triplicate gels) as control group and IPC (triplicate gels) 
as experimental group. The significance level was set as p<0.05 and data was 
presented in terms of fold decrease or fold increase compared to control. The 
Mascot search engine was used to identify peptide protein matches. The search 
algorithm uses the probability-based MOWSE scoring algorithm (Pappin et al., 
1993). Mascot reports a probability-based Ion Score for each peptide match, 
which indicates the statistical significance of the MS/MS spectral assignment. 
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Individual ion scores >39 indicate identity or extensive homology (p<0.05) and a 
positive identification was defined and reported when the MOWSE scores (>40) 
were significant (p<0.05). 
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Chapter 3 
 
Investigating the involvement of kinase activation and 
expression in IPC during reperfusion 
 
3.1) Introduction 
 
The isolated perfused rat heart is a very important tool in experimental heart 
research. The signal transduction pathways activated by the preconditioning 
stimulus during the pre-ischaemic phase have been extensively delineated 
[Yellon & Downey, 2003]. Currently, it is proposed that the secretion of autocoids 
such as adenosine and bradykinin in response to the preconditioning ischaemic 
episodes, bind to their respective receptors on the cardiomyocytes and trigger a 
signaling cascade which terminates at the level of the mitochondria [Costa et al., 
2005].  
 
Emerging studies suggest that events occurring during the post-ischaemic 
myocardial reperfusion phase may however, underlie the cardioprotection elicited 
by IPC [Hausenloy et al., 2005]. In this regard, IPC has been demonstrated to 
modify events occurring during the reperfusion phase such as activating the pro-
survival kinases of the RISK pathway [Hausenloy et al., 2005; Solenkova et al., 
2006], which include PKB/Akt, a downstream effector of the PI3-kinase pathway 
and ERK 1/2, a member of the mitogen activated protein kinase family (MAPK).  
 
Research efforts to elucidate the mechanisms whereby IPC protects the heart 
have been hampered by the opposing results obtained by different research 
groups. This phenomenon has been attributed to differences in species (rabbits 
vs rats vs mice), models (Langendorff vs working heart mode), experimental 
protocols (single vs multi-cycle) and severity of ischaemia (global vs regional). Of 
major concern are the conflicting data regarding kinase activation in the same 
species and model. Furthermore, researchers often report only one time point of 
kinase activation during reperfusion and then associate it with protection. We, 
therefore, hypothesized that kinase phosphorylation at reperfusion after IPC is a 
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time dependent, dynamic process which correlates with different functional 
parameters. 
 
The aims of this part of the study therefore were: 
 
1. to characterize the activation patterns of the various kinases at different 
time points during reperfusion after IPC and to compare it with non-IPC 
hearts at the same time points during reperfusion after global ischaemia 
2. to assess autophagy at these different time points during reperfusion after 
IPC and to compare it with non-IPC hearts at the same time points during 
reperfusion after global ischaemia 
3. to assess apoptosis after 30 minutes of reperfusion after IPC and to 
compare it with non-IPC hearts at the same time point during reperfusion 
after global ischaemia 
 
3.2)   Methods 
 
To establish the involvement of the different protein kinases in IPC during early 
(5, 10, 15 min) and late (30 min) reperfusion, the following experimental protocol 
was used:  
 
(i) Controls: Hearts were stabilized for 30 min (15 min retrograde, 15 min 
working heart). Functional recordings were made after 15 min working heart (as 
indicated by the dashed arrows in Fig. 2.1 and Fig. 2.2, Materials and Methods 
section, Chapter 2) and Fig. 3.1. Hearts were retrogradely perfused for another 
30 min. Hearts were then snap-frozen before sustained ischaemia for Western 
blotting analysis, as indicated by the solid arrows indicated in Fig.2.2 and Fig.3.1. 
Control hearts were thus not subjected to ischaemia/reperfusion or the IPC 
protocol, but perfused under oxygenated conditions. Western blotting data of all 
proteins were normalized and expressed as fold change to control. The results 
obtained for the different phosphoproteins were normalized against the results 
obtained for the corresponding total protein, with the exception of the 15 min 
reperfusion timepoint. Equal loading was controlled for by performing ponceau 
staining on each membrane or blotting for β-Tubulin on each set of lysates per 
timepoint. 
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(ii) Non-preconditioning (Non-IPC): Hearts were stabilized for 60 min (15 min 
retrograde, 15 min working heart and 30 min retrograde). Functional recordings 
were made at 15 min working heart as indicated by the dashed arrows in Fig. 2.2 
and Fig. 3.1. Hearts were subsequently subjected to 25 min sustained global 
ischaemia followed by 30 min reperfusion (10 min retrograde perfusion and 20 
min working heart). After 30 min reperfusion, functional recordings were made 
(dashed arrows) and hearts were snap-frozen for Western blotting analysis, as 
indicated by the solid arrows in Fig. 2.2 and Fig. 3.1. Alternatively, when 
investigating shorter reperfusion times, hearts were snap-frozen at 5, 10  and 15 
min reperfusion respectively, as indicated by the solid arrows in Fig. 2.2 and 
Fig.3.1.  
 
(iii) Ischaemic preconditioning (IPC): Hearts were stabilized for 30 min (15 min 
retrograde, 15 min working heart). Functional recordings were made after 15 min 
working heart as indicated by the dashed arrows in Fig. 2.2 and Fig.3.1. Hearts 
were then preconditioned by 3x5 min global ischaemia, alternated with 5 min 
reperfusion. Hearts were subjected to 25 min sustained global ischaemia, 
followed by 30 min reperfusion (10 min retrograde perfusion and 20 min working 
heart). After 30 min reperfusion, functional recordings were made (dashed 
arrows) and hearts were snap-frozen for Western blotting analysis, as indicated 
by the solid arrows in Fig. 2.2 and Fig.3.1. Alternatively when investigating 
shorter reperfusion times, hearts were snap-frozen at 5, 10 and 15 min 
reperfusion respectively, as indicated by the solid arrows in Fig. 2.2 and Fig.3.1. 
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Experimental protocol: (Fig.3.1) 
 
Non-preconditioned  hearts:   
           
 Retrograde     Working heart                Retrograde                          Sustained ischaemia        Retrograde            Working heart              
                                                                                                                                                                                          
: 
                                                                                                                                       Reperfusion                           Recordings 
                                         Recordings                              Control 
 
  
 Retrograde    Working heart               Preconditioning                     Sustained ischaemia         Retrograde           Working heart          
                                                                                                                                                             
 
                                                                                                                            Reperfusion                          Recordings                   
                                         Recordings 
 
 
 
 
 
Figure 3.1     Experimental protocol according to a timeframe indicating at which time intervals, indicated by the solid arrows (  ), 
hearts were snap-frozen for western blot analysis. Functional recordings were indicated by the dashed arrows (    ).               
Ischaemic preconditioned  hearts: 
0                  15                  30    35    40    45     50    55    60                                      85      90      95     100    105               115 
 
                                                                                     Time (Minutes)
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3.3) Results 
 
Table 3.1  The hemodynamic parameters of the isolated rat hearts were measured after 15 min working heart before the period of sustained 
ischaemia, indicated by           .  The % recovery after 30 min reperfusion is indicated by           .  
 
1 38 16 54 221.04 60.77 125 82.18 15.07 0.19 12.67 -13.42 0.244 21%
2 44 16 60 216.05 61.45 107.4 76.77 14.43 0.19 9.16 -9.45 0.277 27.27%
3 42 18 60 252.65 58.84 112.27 76.65 15.11 0.152 10.59 -10.82 0.237 28.57%
4 42 18 60 260.54 63.45 115.33 80.75 15.516 0.14 11.22 -10.13 0.23 38.10%
5 42 18 60 269.19 56.08 111 74.42 14.97 0.13 10.15 -9.98 0.223 38.10%
6 42 18 60 188 52.56 114.53 73.22 15.28 0.224 10.33 -11.46 0.32 42.86%
7 36 16 52 256.65 62.96 98.26 74.73 11.46 0.16 8.85 -7.82 0.203 44.44%
8 40 20 60 251.02 58.06 111.58 74.91 15 0.153 9.14 -10.44 0.24 45%
9 44 16 60 218.7 57 129 80 17.13 0.183 12.67 -13.82 0.274 50%
AVE 41.1 17.3 58.4 237.1 59.0 113.8 77.1 14.9 0.2 10.5 -10.8 0.2 37.25%
10 44 20 64 303.75 57.19 108.67 74.46 15.67 0.14 10.36 -9.02 0.21 0.00%
11 38 16 54 264.98 55.75 109 73.5 13.07 0.14 10.54 -10.26 0.204 0.00%
12 48 18 66 275.24 55.945 109.31 70.4 16.273 0.12 12.53 -11.57 0.24 0.00%
13 40 18 58 278.6 53.48 113.16 73.64 14.82 0.12 11.26 -11.82 0.21 0.00%
14 48 16 64 281.42 55.43 111.43 74.1 16.02 0.12 10.86 -11.43 0.22 0.00%
15 44 16 60 257.47 58.5 109.9 75.09 14.71 0.136 10.94 -12.03 0.233 0.00%
16 42 18 60 240.31 58.93 107 74.89 14.39 0.166 7.71 -11.01 0.253 0.00%
17 48 20 68 303.11 51.78 114 72.49 17.52 0.096 12.29 -12.29 0.224 0.00%
18 44 18 62 282.6 57.45 110.11 75 15.4 0.105 11.37 -10.77 0.22 0.00%
19 40 20 60 264.37 60.72 104.9 75.45 14.145 0.13 8.81 -9.36 0.23 0.00%
20 44 16 60 248.11 57 110.36 74.78 14.86 0.14 9.79 -10.94 0.24 0.00%
AVE 43.64 17.82 61.45 272.72 56.56 109.80 73.98 15.17 0.13 10.59 -10.95 0.23 0.00%
 dP/dTminSample CO (ml/min) Heart rate (beats /min)
Table 3.1 The haemodynamic parameters of isolated rat hearts after 15 min working heart (before sustained ischaemia)
%  Recovery 
Preconditioned hearts ( protected)
% Recovery 
Non-IPC  (failed )
Stroke volume (ml/min)Total work (mW)  Ejection fraction dP/dTmax
Stroke volume (ml/min)AO (ml/min)
Diastole (mmHg) PSP (mmHg) Mean BP (mmHg)
Sample Diastole (mmHg) PSP (mmHg)
AO (ml/min) CF (ml/min)
dP/dTmax  dP/dTminTotal work (mW)Mean BP (mm Hg)CF (ml/min) CO (ml/min) Heart rate (beats/min)  Ejection fraction
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3.3)   Haemodynamic parameters of the isolated rat hearts before   
          sustained ischaemia (Table 3.1) 
 
The haemodynamic parameters of the isolated rat hearts after 15 min working 
heart, before the period of sustained ischaemia are indicated in table 3.1. The       
data presented in Table 3.1 indicates that there was no statistical differences 
between the parameters of the different animals before the start of the 
experiment, which could influence functional recovery of the ischaemic hearts. 
The persentage recovery (%) of the IPC hearts indicates functional recovery at 
the end of 30 min reperfusion, whilst the non-IPC hearts failed.  
 
3.3.1 The effects of IPC on the activation of the RISK pathway 
(PKB/Akt and ERK) during reperfusion (Figures 3.3.1 a-c). 
 
Results from the present study demonstrated that PKB/Akt was significantly 
activated in IPC compared to non-IPC (4.741±0.3414 vs 3.404±0.2574; p<0.05) 
at 5 min reperfusion.  At 15 min reperfusion, activation of PKB/Akt was 
significantly decreased in IPC compared to non-IPC (2.892±0.2638 vs 
4.093±0.2086; p<0.05). At 30 min reperfusion, activation of PKB/Akt was also 
significantly lower in IPC compared to non-IPC (1.501±0.07889 vs 3.550±0.2426; 
p<0.05). ERKp44 was significantly increased in IPC compared to non-IPC 
(2.759±0.2107 vs 1.795±0.1207; p<0.05) at 5 min reperfusion. ERKp42 was also 
significantly increased in IPC compared to non-IPC (1.485±0.1859 vs 
0.9423±0.1112; p<0.05) at 5 min reperfusion. However, at 30 min reperfusion, 
ERKp44 was significantly decreased in IPC compared to non-IPC 
(1.344±0.07658 vs 3.063±0.1312; p<0.05). Similarly ERKp42 was also 
significantly attenuated in IPC compared to non-IPC (1.896±0.1168 vs 
3.958±0.1678; p<0.05).  
 
3.3.2 The effects of IPC on the activation of the stress kinase, 
p38 MAPK, during reperfusion (Figures 3.3.2 a-b). 
 
Interestingly, the stress kinase p38 MAPK was significantly activated in IPC 
compared to non-IPC (5.421±0.4415 vs 2.342±0.3440; p<0.05) at 5 min 
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reperfusion. Similarly, p38 MAPK was also significantly increased in IPC 
compared to non-IPC (7.140±0.6138 vs 5.010±0.7842; p<0.05) at 10 min 
reperfusion.  At 15 min reperfusion, p38 MAPK was significantly attenuated in 
IPC compared to non-IPC (3.350±0.5955 vs 5.757±0.2600; p<0.05). This was 
also the case at 30 min reperfusion, where p38 MAPK was significantly inhibited 
in IPC compared to non-IPC (1.015±0.05167 vs 2.662±0.1096; p<0.05).  
 
3.3.3 The effects of IPC on the activation of HSP-27 and HSP-70, 
substrates of p38 MAPK, during reperfusion (Figures 3.3.3 
a-b). 
 
HSP-27, the downstream target of p38 MAPK was significantly activated in IPC 
(1.191±0.03369 vs 0.9598±0.0434; p<0.05) compared to non-IPC at 5 min 
reperfusion. No significant differences were observed in HSP-70 between IPC 
and non-IPC at 10 min timepoint. 
 
3.3.4 The effects of IPC on the activation of CREB and GSK-3β, 
substrates of PKB/Akt, during reperfusion (Figures 3.3.4 
a-b). 
 
The transcription factor CREB, a downstream target of PKB/Akt, was significantly 
activated in IPC compared to non-IPC (1.592±0.1169 vs 1.062±0.05588; p<0.05) 
at 5 min reperfusion as well as at 10 min reperfusion (2.483±0.2273 vs 
1.558±0.2077; p<0.05). 
 
GSK-3β, another downstream target of PKB/Akt, was significantly activated in 
IPC compared to non-IPC (1.420±0.1909 vs 1.256±0.07675; p<0.05) at 10 min 
reperfusion. 
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3.3.5 The effects of IPC on the activation of AMPK during 
reperfusion (Figure 3.3.5). 
 
In the present study AMPK was significantly activated in IPC (1.395±0.1303; 
p<0.05) compared to non-IPC (1.141±0.04760; p<0.05) at 5 min reperfusion. 
Similarly, AMPK was activated in IPC (1.697±0.4142; p<0.05) compared to non-
IPC (1.126±0.06978; p<0.05). 
 
3.3.6 The effects of IPC on the activation of CAMKII during 
reperfusion (Figure 3.3.6). 
No significant differences were observed in CAMKII activation at 5 and 10 
minutes of reperfusion between IPC and non-IPC. 
 
3.3.7 The effects of IPC on autophagy during reperfusion 
(Figures 3.3.7 a&b). 
 
The autophagy marker, Beclin-1 was significantly activated in IPC compared to 
non-IPC (1.313±0.06631 vs 0.8700±0.04860; p<0.05) at 5 min reperfusion.  
Another marker of autophagy, LC3 was significantly activated in IPC compared to 
non-IPC (0.8019±0.05190 vs 0.6487±0.04898; p<0.05) at 5 min reperfusion. At 
10 min reperfusion however, LC3 was attenuated in IPC compared to non-IPC 
(1.293±0.08390 vs 1.778±0.09305; p<0.05). Interestingly, at 30 min reperfusion 
LC3 activation was again significantly increased in IPC (0.8531±0.04587 vs 
0.6065±0.08621; p<0.05) compared to non-IPC.    
 
3.3.8 The effects of IPC on apoptosis during reperfusion (Figures 
3.3.8 a&b). 
 
Activation of cleaved caspase-3 was significantly increased in IPC compared to 
non-IPC (0.8531±0.04587 vs 0.6065±0.08621; p<0.05) at 30 min reperfusion. No 
significant differences were observed in cleaved PARP at 30 minutes between 
IPC hearts and non-IPC hearts.   
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3.3)  Results 
 
 
3.3.1 Investigating the involvement of PKB/Akt expression and     
phosphorylation in IPC after 5 min (A) and 10 min (B) reperfusion. 
 
 
 
        A              phospho PKB/Akt                                    B             phospho PKB/Akt 
                                                                     
                                                                        
                                                                      
 
                                                                     
                
 
         
                                                           
 
 
 
 
               A                                                              B                                 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1(a) Activation of PKB/AKT during IPC and non-IPC at 5 min (A) and 10 min 
(B) reperfusion. 
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3.3.1 Investigating the involvement of PKB/AKT expression and      
phosphorylation in IPC after 15 min (C) and 30 min (D) reperfusion. 
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Figure 3.3.1(b) Activation of PKB/Akt during IPC and non-IPC at 15 min (C) and 30 
min (D) reperfusion. 
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3.3.1 Investigating the involvement of ERK (p44/p42) MAPK expression 
and phosphorylation in IPC after 5 min (A) and 10 min (B) 
reperfusion. 
 
   A                   Phospho  ERK                                 B                  Phospho ERK 
                                                                                  44 kDa 
                                                                                  42 kDa  
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                                                                                  4        42 kDa    
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Figure 3.3.1(c)  Activation of ERK (p44/p42) MAPK during IPC and non-IPC after 5 min 
(A) and 10 min (B) reperfusion. 
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3.3.1 Investigating the involvement of ERK (p44/p42) MAPK expression 
and phosphorylation in IPC after 15 min (C) and 30 min (D) 
reperfusion.                                                      
C                           Phospho ERK                                         D                                                                                    
                                                              
                         Ponceau                                                                               Total ERK 
                                                                              
 
                                                                                      D  
    
 
 
 
 
 
 
 
 
 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1(d) Activation of ERK (p44/p42) MAPK during IPC and non-IPC at 15 
min (C) and 30 min (D) reperfusion. 
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3.3.2 Investigating the involvement of p38 MAPK expression and 
phosphorylation in IPC after 5 min (A) and 10 min (B) reperfusion. 
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Figure 3.3.2(a) Activation of p38 MAP Kinase during IPC and non-PC after 5 min (A) and 
10 min (B) reperfusion. 
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3.3.2 Investigating the involvement of p38 MAPK expression and 
phosphorylation in IPC after 15 min (C) and 30 min (D) reperfusion. 
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     Figure 3.3.2(b) Activation of p38 MAPK during IPC and non-IPC at 15 min (C) and 30     
min (D) reperfusion.  
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3.3.3 Investigating the involvement of HSP-27 expression and 
phosphorylation in IPC after 5 min (A) and 10 min (B) reperfusion. 
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  Figure 3.3.3(a) Activation of HSP-27 during IPC and non-IPC at 5 min (A) and 10 
min (B) reperfusion. 
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3.3.3 Investigating the involvement of HSP 70 expression in IP after 5 
min (A) and 10 min (B) reperfusion. 
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Figure 3.3.3(b) Expression of HSP-70 in ischaemic preconditioning (IPC) and non-IPC at 
5 min (A) and 10 min (B) reperfusion.  
 
Co
ntr
ol IPC
No
n-I
PC
0.0
0.5
1.0
1.5
2.0
2.5
Ex
pr
es
si
on
 o
f H
SP
-7
0 
(F
ol
d 
in
cr
ea
se
)
Co
ntr
ol IPC
No
n-I
PC
0.0
0.5
1.0
1.5
2.0
2.5
Ex
pr
es
si
on
 o
f H
SP
-7
0 
(F
ol
d 
in
cr
ea
se
)
 β-Tubulin 
70 kDa
Control          IPC                 Non-IPC  control            IPC                 Non-IPC 
 β-Tubulin 
55 kDa
Stellenbosch University  http://scholar.sun.ac.za
  103
3.3.4 Investigating the involvement of CREB expression and      
phosphorylation in IPC after 5 min (A) and 10 min (B)                      
reperfusion. 
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     Figure 3.3.4(a) Activation of CREB during IPC and non-IPC at 5 min (A) and 10 min (B)                        
 reperfusion.    
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3.3.4 Investigating the involvement of GSK-3β expression and      
phosphorylation in IPC after 5 min (A) and 10 min (B) reperfusion. 
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 Figure 3.3.4(b)      Activation of GSK3-β in IPC and non-IPC at 5 min (A) and 10  
                                min (B) reperfusion. 
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3.3.5 Investigating the involvement of AMPK expression and    
phosphorylation in IPC after 5 min (A) and 10 min (B) reperfusion. 
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    Figure 3.3.5 Activation of AMP kinase during IPC and Non-IPC at 5 min (A)                    
and 10 min (B) reperfusion. 
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3.3.6 Investigating the involvement of CAMKII expression and 
phosphorylation in IPC after 5 min (A) and 10 min (B) 
reperfusion. 
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    Figure 3.3.6 Activation of CAMKII in IPC and non-IPC at 5 min (A) and 10 min (B) 
reperfusion. 
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3.3.7 Investigating the involvement of Beclin-1 activation in IPC after 5 
min (A), 10 min (B) and 30 min (C) reperfusion. 
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        Figure 3.3.7(a) Activation of Beclin-1 in IPC and non-IPC at 5 min (A),                         
10 min (B) and 30 min (C) reperfusion. 
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3.3.7 Investigating the involvement of LC-3 activation in IPC after 5 min 
(A), 10 min (B) and 30 min (C) reperfusion. 
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 Figure 3.3.7(b) Activation of LC-3 in ischaemic preconditioning (IPC) and                      
non-IPC at 5 min (A), 10 min (B) and 30 min (C) reperfusion. 
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 3.3.8 Investigating the involvement of caspase-3 activation and   
        PARP cleavage in IPC after 30 min reperfusion. 
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  Figure 3.3.8 Activation of caspase-3 and cleaved PARP in IPC and non-IPC at 30 min       
reperfusion. 
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3.4) Discussion 
 
One of the most challenging aspects of research on signal transduction pathways 
is the fact that the chemical signals are usually very compartmentalized. For 
example, phospholipid-activated PKC is known to attach to docking sites where 
PKC phosphorylates its substrates only in the vicinity of the docking sites 
(Mochly-Rosen et al., 1987). Furthermore, a very few signals are distributed 
globally within the cell. Some signals like phosphorylation of PKB/Akt and ERK 
are very robust and easy to measure, while others like PKC are very difficult 
since more than 10 isoforms can be activated independently by lipid cofactors.  
 
Another critical factor which should be considered is that several signaling 
pathways are activated simultaneously during the IPC protocol. The usual 
technique for identifying a critical step in the pathway is to inhibit that step and 
test whether the response has been eliminated. However, inhibitors are not 
always very specific and multiple signals may occur simultaneously, therefore 
results must be interpreted with caution. 
 
Another problem that confront researchers, is to decide when to measure the 
signal. Some investigators make biochemical measurements several hours after 
reperfusion so that the infarct size can be measured in the same heart. However, 
Downey and co-workers (2008) is of the opinion that any signal at such a late 
time point in reperfusion would be irrelevant. They also suggested that triggers 
should obviously be measured during the trigger phase, while mediator signals 
should be measured in the first minutes of reperfusion. Furthermore, many 
researchers just measure a signal at a single time point during reperfusion and 
then assumes that activation/inhibition of the signals are associated with IPC-
induced protection of the heart. Clearly, our understanding of events in the 
mediator phase is still limited; therefore there is a need for the characterization of 
the signaling mechanisms in the early reperfusion phase. 
 
In light of the above mentioned, the aim of this part of the study was to determine 
the role of possible mediators during different time points in reperfusion after IPC 
and to compare it with non-IPC hearts at the same time points. These activation 
patterns of the kinases after IPC were summarized in Table 3.2. 
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Table 3.2 A summary of the activation patterns of the kinases                
 during reperfusion after IPC compared to Non-IPC hearts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
Activation of the RISK pathway and p38 MAPK 
   PKB/Akt  ERK44  ERK42  p38 MAPK 
Reperfusion             
5 min     
10 min     
15 min     
30 min     
         
Activation of the heat shock proteins   
   HSP‐27  HSP‐70     
Reperfusion           
5 min       
10 min       
         
Activation of PKB/Akt substrates and AMPK   
   CREB  GSK‐3β  AMPK   
Reperfusion            
5 min      
10 min      
         
Activation of autophagy and apoptosis   
   LC‐3  Beclin‐1  Caspase‐3  PARP 
Reperfusion             
5 min         
10 min         
30 min     
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3.4.1 The RISK pathway and PKB/Akt substrates 
 
A significant increase in PKB/Akt was observed after 5 minutes reperfusion in the 
IPC hearts compared to the non-IPC hearts. This was however, a transient 
activation where no significant differences were observed at 10 minutes and 
where the signal was attenuated at 15 and 30 minutes reperfusion compared to 
non-IPC hearts. ERK44 and ERK42 were also significantly increased at 5 
minutes reperfusion, while no significant differences were observed at 10 and 15 
minutes. A significant decrease in ERK44 and ERK42 was also observed at the 
30 minute time point compared to the non-IPC hearts. Our results are in 
accordance with the literature where activation of PKB/Akt and ERK1/2 conferred 
powerful cardioprotection when activated early in reperfusion [Yellon & Baxter, 
1999; Housenloy & Yellon, 2004].  
 
PKB/Akt plays a dual role in the mechanisms of protection during IPC - during the 
triggering phase of protection (where receptor activation prepares 
cardiomyocytes for subsequent insults) and in the mediator phase (where 
protective mechanisms suppress concurrent ischaemia and/or reperfusion injury) 
[Downey et al., 2007; Cao et al., 2008]. In fact, the infarct size-limiting effects of 
IPC is abolished by inhibition of PI3-Kinase either during IPC (before ischaemia) 
or at the time of reperfusion. During the trigger phase of IPC, it is possible that 
cytosolic PKB/Akt plays a role in protection as a series of studies by Downey and 
others demonstrated that activated PKB/Akt transmitted a signal from PI3-K to 
ERK with eNOS and PKG as downstream substrates, which ultimately activates 
the mitochondrial ATP-sensitive potassium channels (mKATP channels) 
[Housenloy et al., 2005; Downey et al., 2007; Cohen et al., 2007].  The protective 
role of PKB/Akt in the mediator phase of IPC may involve the mitochondria, as 
phosphorylation of PKB/Akt during early reperfusion induces mitochondrial 
translocation of hexokinase [Zuurbier et al., 2005], a PKB/Akt substrate, and also 
inhibits opening of the mPTPs upon reperfusion [Hausenloy et al., 2002; Moon et 
al., 2006].   
 
A substrate of PKB/Akt, GSK-3, showed increased phosphorylation at 10 
minutes of reperfusion after IPC compared to non-IPC hearts. Numerous studies 
showed that phosphorylation at Ser9 of GSK-3, which results in its 
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inhibition, is a key event in signaling mechanisms during IPC [Tong et al., 2002; 
Gross et al., 2004]. Nishihara and co-workers (2006) found a close negative 
correlation between tissue levels of phospho-GSK-3 at 5 minutes after 
reperfusion and infarct size after 2 h reperfusion in rat hearts in vivo.  
Interestingly, Nishihara, et al (2007) has also demonstrated that GSK-3β 
translocates to the mitochondria and physically interacts with adenine nucleotide 
translocase (ANT) and the voltage-dependent anion channel (VDAC), mPTP 
subunits, after ischaemia/reperfusion. A significant correlation between the 
thresholds for mPTP opening in isolated cardiac mitochondria and the ratio of 
phospho-GSK-3β to total GSK-3β was found in mitochondrial samples of the 
heart [Miki et al., 2009]. It is thus suggested that inactivation of GSK-3β through 
PKB/Akt phosphorylation increases the threshold of mPTP opening and tolerance 
to ischaemia/reperfusion injury [Miura et al., 2010]. Although GSK-3 was initially 
discovered and named for its role in regulating glycogen metabolism, Omar and 
co-workers (2010) was the first to link this important effect on myocardial 
metabolism with cardioprotection. Their research highlighted the ability of GSK-3 
to regulate myocardial glycogen and glucose metabolism and demonstrated an 
additional mechanism linking GSK-3 inhibition to enhanced recovery of post-
ischaemic mechanical function. Inhibition of GSK-3 during reperfusion stimulated 
glycogen synthesis which repartitions glucose-6-phosphate away from the 
glycolytic pathway. The reduced rate of glycolysis lessens H+ production from 
glucose metabolism and subsequently reduces Ca2+ overload. These effects limit 
left ventricular dysfunction in early reperfusion and may contribute to 
improvements in mitochondrial function and cell viability.  
 
IPC also induces a significant increase in cyclic AMP (cAMP)-response element 
binding protein (CREB) phosphorylation during 5 and 10 minutes of reperfusion 
when compared to non-IPC hearts. PKB/Akt has been shown in some cell types 
to increase the expression of the antiapoptotic gene, bcl-2 [Skorski et al., 1997; 
Pugazhenthi et al., 2000]. Induction of bcl-2 promotor activity by IGF-1 was 
shown to occur via a PKB/Akt pathway involving CREB. CREB is a direct target 
for phosphorylation by PKB/Akt [Du & Montminy, 1998] and this phosphorylation 
occurs on a site that increases binding of CREB to accessory proteins necessary 
for induction of genes containing cAMP response elements (CREs) in their 
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promoter regions. CREB has also been shown to mediate PKB/Akt-induced 
expression of another antiapoptotic gene, mcl-1 [Wang et al., 1999].  
 
3.4.2 p38 MAPK and Heat Shock Proteins 
 
A significant increase in p38 MAPK activation occurred at 5 and 10 minutes 
reperfusion and was attenuated at 15 and 30 minutes of reperfusion after IPC 
when compared to non-IPC hearts. Although the majority of studies showed p38 
MAPK activation during the triggering phase of IPC [Sato et al., 2000; Nakano et 
al., 2000; Fryer et al., 2001; Housenloy et al., 2005], the role of p38 MAPK as a 
potential mediator of protection in the preconditioned hearts remains 
controversial. The p38α-MAPK isoform appears to be required during IPC-
induced protection of the heart [Sicard et al., 2010]. Potential p38 MAPK-
mediated protective mechanisms include the phosphorylation of small heat shock 
protein, Hsp-27, which stabilizes the actin cytoskeleton during ischaemia [Rouse 
et al., 1994; Li et al., 2008; Clements et al., 2011]. In addition, HSP-27  
decreases the intracellular ROS content and prevent apoptotic cell death, by 
binding directly to cytochrome c [Paul et al., 2002; Samali et al., 2001]. 
 
3.4.3        CAMKII 
 
In the present study no differences in CAMKII activation and expression were 
observed between IPC and Non-IPC at 5 and 10 minutes reperfusion. This is an 
unexpected finding as attenuated activation of CAMKII was shown to be 
cardioprotective [Jingdong et al., 2007]. Since the anti-apoptotic RISK pathway is 
activated in IPC at 5 minutes reperfusion, one would expect CAMKII to be 
attenuated in IPC at this timepoint. Since CAMKII is a pro-apoptotic signaling 
molecule these results suggest that at 10 minutes reperfusion the IPC and Non-
IPC hearts are equally protected against Ischaemia/reperfusion injury. This 
statement can be confirmed by the finding that the anti-apoptotic RISK pathway is 
attenuated in IPC at 10 min reperfusion. These results suggest that IPC-induced 
protection is lost after 5 minutes reperfusion. 
 
Calcium/Calmodulin-dependent protein kinase II (CAMKII) is a multifunctional 
signaling molecule in the heart and activated in response to ß-adrenergic 
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stimulation [Anderson 2009]. Excessive catecholamine exposure and subsequent 
ß-stimulation increases the activation and expression of CAMKII in the heart, 
leading to the expression of hypertrophic  genes. CAMKII therefore participates in 
the transition from early structural heart disease to heart failure and sudden death 
[Anderson 2009]. CAMKII is also activated in response to myocardial infarction, 
heart failure, ischaemia reperfusion injury an myocardial cell death [Mei-ling et 
al., 2012]. Inhibition of CAMKII in cardiomyocytes prevented the maladaptive 
remodeling after myocardial infarction [Zhang et al., 2005; Yang et al., 2006; Wu 
et al., 2006]. Inhibition of CAMKII in Langendorff perfused mouse hearts were 
resistant to ischaemia/reperfusion injury [Li et al., 2006]. 
 
3.4.4 AMPK, the energy sensor of the cell 
 
A significant increase in AMP-activated protein kinase (AMPK) was observed at 5 
and 10 minutes of reperfusion after IPC compared to non-IPC hearts. The energy 
reserve of the heart is rapidly depleted during ischaemia [Nishida et al., 2009]. 
AMPK act as a sensor for energy deprivation, and activation of AMPK mediates 
metabolic adaptation during ischaemia. AMPK plays an important role in 
mediating ischaemia-induced autophagy in cardiac myocytes [Zhang et al., 
1013]. The phosphatidylinositol kinase homolog of the mammalian target of 
rapamycin (mTOR), is a sensor of the nutrient status in the cell and is an 
important negative regulator of autophagy [Meijer & Codogno, 2004]. AMPK has 
been shown to inhibit mTOR and thereby induces protective autophagy 
[Papandreou et al., 2008]. 
 
3.4.5 Autophagy 
 
LC-3II and Beclin-1, two markers of autophagy, were significantly upregulated at 
5 minutes reperfusion after IPC compared to non-IPC hearts. Interestingly, at 10 
minutes reperfusion, LC-3II was attenuated, but upregulated again at 30 minutes. 
No differences in Beclin-1 were observed at 10 and 30 minutes reperfusion. 
Autophagy can be detected under basal conditions in the heart and the level 
increases during ischaemia. It is generally accepted that activation of autophagy 
during ischaemia is protective and important for cell survival and maintenance of 
cardiac function [Decker & Wildenthal, 1980; Matsui et al., 2007]. The level of 
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autophagy further increases during reperfusion and the production of ROS was 
suggested to be the main inducer of autophagy during reperfusion. However, 
activation of autophagy during reperfusion has been shown to be detrimental to 
the heart when it is associated with activation of the autophagy marker Beclin-1. 
[Zhang et al., 1013].  
 
It has been shown recently that autophagy is activated during IPC [Yitzhaki et al., 
2009; Yan et al., 2009]. This is in agreement with our results where we have 
observed a significant increase in the activation of both Beclin-1 and LC-3II at 5 
min reperfusion.  
 
3.4.6 Apoptosis 
 
A significant increase in cleaved caspase-3 was observed at 30 min reperfusion 
after IPC compared with the non-IPC hearts. These results are not in agreement 
with the literature, since it is proposed that IPC has anti-apoptotic effects. 
However, in the present study the RISK pathway which has anti-apoptotic effects 
was attenuated in IPC at 30 min reperfusion compared to non-IPC. These results 
may suggest that when the Risk pathway is attenuated, protection is lost and 
cells are commited to undergo apoptosis. Recent studies have demonstrated that 
the release of cytochrome c from the mitochondria leads to the activation of 
caspase-3 [Zou et al., 1997]. In normal cells, cytochrome c is confined to the 
mitochondria with no activation of caspase-3 [Narula et al., 1999]. The activation 
of caspase-3 usually leads to cleavage of its cytoplasmic substrate PKC-δ and 
cleavage of its nuclear substrate PARP for the induction of apoptosis. PARP 
cleavage however, is not always demonstrated in cardiomyopathic  hearts, 
suggesting a mechanism that links mitochondrial release of cytochrome c to 
activation of caspase-3.  Cytochrome c release and activation of caspase-3 occur 
both in ischaemic and idiopathic dilated cardiomyopathic hearts in a similar way. 
[Narula et al., 1999]. Although cytochrome c release from mitochondria, 
accompanied by caspase activation are almost generally observed during 
apoptosis, the ultrastructural alterations of apoptosis in nuclei as a result of PARP 
cleavage is not always observed [Narula et al., 1999]. Activation of caspase 3 in 
the absence of PARP cleavage as observed in the present study, is therefore in 
agreement with the literature. 
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Figure 3.4: The double edge sword of autophagy (modified from Ryter et al., 2010) 
 
 
 
 
 
• Beneficial role of autophagy: homeostatic turnover of damaged organelles and protein, 
promoting recycling of metabolic building blocks for the generation of energy. 
• Excessive autophagy associated with aberrant degradation of intracellular constituents, 
leading to type II (autophagic) cell death.  
• Relationship between autophagy and apoptosis is incompletely understood – both impaired 
and excessive autophagy can lead to apoptosis. 
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3.5) Conclusion 
 
The aim of this study was to identify possible mediators of IPC during different 
timepoints of reperfusion. The activation patterns of the kinases (Table 3.2), 
suggest that the RISK pathway (PKB/Akt and ERK MAPK) as well as p38 MAPK 
may act as possible mediators of IPC. As already mentioned, some investigators 
measure kinase activation several hours after reperfusion so that infarct size can 
be measured in the same heart. Our results however, demonstrated that 
activation of the RISK pathway is an early event in IPC. Interestingly, p38 MAPK 
activation in IPC at 5 minutes reperfusion was accompanied by activation of the 
RISK pathway. This is an unexpected finding and to our knowledge has never 
been reported before in the setting of IPC and ischaemia/reperfusion damage. In 
addition this was accompanied by activation of HSP-27, CREB, AMPK, LC-3II 
and Beclin-1. These results suggest that activation of p38 MAPK in IPC may be 
potentially beneficial during early reperfusion.  
 
According to Marais and co-workers 2001, IPC-induced protection is associated 
with an attenuation of  p38 MAPK activation and enhanced activation of HSP-27 
during reperfusion in the isolated working rat heart model. In this particular study 
however, the RISK pathway was not investigated and no explanation was offered 
for their observation that HSP-27 activation was accompanied by an attenuation 
of p38 MAPK activation.  
 
Hausenloy and co-workers (2003), utilizing the isolated perfused rat heart model 
demonstrated that IPC results in activation of the RISK pathway at 15 minutes 
reperfusion. In this particular study activation of p38 MAPK and HSP-27 were not 
investigated [Hausenloy et al., 2003] 
 
Results demonstrated that autophagy plays an important role in early (5 min) and 
late (30 min) reperfusion, suggesting that it is could act as a mediator and 
possible end-effector in IPC. Currently there is no consensus as to whether 
activation of autophagy during ischaemia/reperfusion represents a protective or 
detrimental function. It is generally excepted however, that the functional role of 
autophagy during ischaemia represents a beneficial role, as it is normally 
associated with activation of the energy sensor of the cell, AMPK [Ryter et al., 
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2010].  Autophagy during reperfusion is believed to be detrimental, unless it is 
also associated with AMPK.   
 
In the present study, the activation of autophagy in IPC at 5 minutes reperfusion 
was accompanied by activation of AMPK, an inhibitor of the mTOR pathway, 
suggesting the induction of protective autophagy at this timepoint.  Activation of 
autophagy in the Non-IPC hearts at 10 minutes reperfusion, may represent a 
compensatory mechanism to maintain homeostasis during the early stages of 
ischaemia/reperfusion damage. Attenuation of autophagy at 10 minutes 
reperfusion in IPC may indicate a switch between protective autophagy, observed 
at 5 minutes reperfusion to possibly impaired or detrimental autophagy observed 
at 30 minutes reperfusion in IPC. Autophagy in IPC at 30 min reperfusion was 
accompanied by activation of caspase-3. This may suggest impaired or 
detrimental autophagy at this timepoint. Various studies demonstrated that 
apoptosis and autophagy are not always mutually exclusive [Ryter et al., 2010]. 
These 2 processes can sometimes, as a result of impaired or excessive 
autophagy occur simultaneously in the same cell [Galluzzi  et al., 2008; Maiuri et 
al., 2007; Kroemer & Levine 2008; Nishida et al., 2008]. Various studies indicated 
that excessive autophagy directly affects cell death pathways [Levine & Yuan 
2005; Galuzzi et al., 2008; Maiuri et al., 2007] and can lead to cardiac diseases 
[Nishino et al., 2000; Tanaka et al., 2000]. Impaired autophagy was demonstrated 
in hypertrophied hearts [Dammrich & Pfeifer, 1983]. Chronic ischaemia resulted 
in excessive autophagy and the expression of autophagic markers in cardiac 
tissue, reached a maximal response after repeated cycles of ischaemia [Yan et 
al., 2005]. 
 
To conclude, we propose the following activation patterns (signaling pathway) of 
the kinases investigated in this part of the study in IPC during early (5 minute) 
reperfusion as indicated in Figure 3.5.  
 
The PI3-K pathway is triggered by binding of growth factors (GFs) to the receptor 
tyrosine kinase (RTK), thereby activating PI3-K. Activated PI3-K converts PIP2 to 
PIP3 which recruits phosphoinositide-dependent kinase1 (PDK1) and PKB/Akt 
(part of the RISK pathway) to the cell membrane. PKB/Akt is then phosphorylated 
by PDK1 on Threonine 308 and by  mTOR2 on Serine473 .  Activated PKB/Akt in 
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turn, phosphorylates and inactivates tuberous sclerosis complex (TSC) 1/2 
leading to activation of Rheb and consequently mTORC1. AMPK, the energy 
sensor sensitive to changes in the intracellular ATP/AMP ratio, directly 
phosphorylates TSC2, thereby providing the priming phosphorylation for 
subsequent phosphorylation of TSC2 by glycogen synthase kinase 3 (GSK-3) to 
inhibit mTORC1 signalling. When AMPK phosphorylates and activates TSC1/2 
complex, the mTOR1-mediated inhibition of autophagy is relieved and protective 
autophagy is induced. AMPK can also activates SIRT1 which can deacetylate 
and activate several autophagy related proteins such as Atg5, Atg7 and LC3. 
Mitogens and cellular stress activate the MAPKs which include ERK (part of the 
RISK pathway) and p38 MAPK. P38 MAPK activates MAPKAP2 which in turn 
can activate HSP-27 which protects the heart from ischaemia/reperfusion 
damage by stabilization of the actin cytoskeleton. In addition, HSP-27  decreases 
the intracellular ROS content and prevent apoptotic cell death, by binding directly 
to cytochrome c [Paul et al., 2002; Samali et al., 2001]. 
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Figure 3.5 Proposed activation patterns of the kinases during reperfusion after 
IPC compared to Non-IPC hearts.  
 
The PI3-K pathway is triggered by binding of growth factors (GFs) to the receptor tyrosine kinase 
(RTK), thereby activating PI3-K. Activated PI3-K converts PIP2 to PIP3, which then recruits 
phosphoinositide-dependent kinase1 (PKD1) and PKB/Akt to the cell membrane. PKB/Akt (part of 
RISK pathway) is then phosphorylated by PDK1 on Thr308 and by mTORC2 on Ser473. Activated 
PKB/Akt, in turn, phosphorylates and inactivates tuberous sclerosis complex (TSC) 1/2, leading to 
activation of Rheb and consequently of mTORC1. AMPK, a cellular energy sensor of changes in the 
intracellular ATP/AMP ratio, directly phosphorylates TSC2, thereby providing the priming 
phosphorylation for subsequent phosphorylation of TSC2 by glycogen synthase kinase 3 (GSK3) to 
inhibit mTORC1 signaling. When AMPK phosphorylates and activates TSC1/2 complex, the mTORC1-
mediated inhibition of autophagy is relieved, and autophagy is induced. AMPK can also activate 
SIRT1 which can deacetylate and activate several autophagy-related proteins such as Atg5, Atg7 and 
LC3. Mitogens and cellular stress activate the MAPKs, which include ERK (RISK pathway) and p38 
MAPK. p38 MAPK can activate HSP-27 which protects the heart form reperfusion-induced damage. 
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Chapter 4 
 
Two-Dimensional Gel Electrophoresis (2-DE Proteomics) 
 
4.1) Introduction 
 
In the past decade, there has been remarkable progress in the field of protein 
technologies. Mass spectrometry (MS) has emerged as the preferred analytical 
tool for in-depth studies of the components of biological systems [Cravatt et al., 
2007]. Important insights have been gained by these studies regarding functions 
of proteins as well as regulation of molecular complexes and their biological 
pathways. Mass spectrometry based proteomics is now well recognized as a 
powerful technology that has the ability to advance our understanding of the 
dynamics and complex nature of the proteome [Parag & Kuster, 2010].  
 
Proteomic studies are generally accomplished by combining two-dimensional gel 
electrophoresis (2-DE) with mass spectrometry. Although the basic 2-DE 
technique was developed 30 years ago, it is still acknowledged as the core 
technology of choice in the majority of proteomic projects [Jiang & Wang, 2012]. 
2-DE is a gel-based, label-free proteomics technique which allows separation and 
visualization of proteins, followed by mass spectrometry for peptide analysis. 
Peptide files generated from the MS analysis are subjected to different database 
searches to identify the corresponding proteins [Gygi et al., 2000]. The major 
advantage of the 2-DE technique is that the gel analysis is broad-based and 
effectively unbiased from the researcher’s point of view. Since the 2-DE approach 
is non-targeted, it can reveal novel discoveries [Lindsey et al., 2012]. It is an 
established technology  and separates intacts proteins. Another strength of this 
technique is that it provides apparent molecular weight and information regarding 
the iso-electric point (pI) of proteins, therefore allowing the detection of post 
translational modifications. In addition, detailed image analysis of gel spots using 
software such as PDQuest, allows for the identification of significant differences 
between comparison groups. This affords the benefit that subsequent mass 
spectrometry analysis only have to be performed on these spots [Lindsey et al., 
2012]. The limitations of this approach is the dynamic range which is 104. Several 
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strategies can be employed to overcome this: 1) the use of narrow-range pH 
strips to ensure full proteomic coverage; 2) optimizing sample solubility by 
choosing the correct sample detergent combination during tissue 
homogenization; 3) to enrich low abundance proteins by pre-fractionation 
(fractionation into different cell fractions i.e. cytosolic or membrane fractions and 
also fractionation into different organelle fractions i.e. mitochondrial fraction);  4) 
to include technical replicates (each sample has to be run in triplicate). Another 
disadvantage of 2D is that in the absence of any automation (PDQuest connected 
to a robotic spot cutter attached to LC-Ms) it is a labour intensive technique. 
 
2D-DIGE (2D-Differential Gel Electrophoresis), also a gel-based proteomics 
technique, has been developed recently and implemented as another powerfull 
tool to study cardiovascular diseases [Lilley & Friedman, 2004].                      
The advantages of 2D-DIGE is that up to three samples can be separated on one 
gel. It is therefore less labour intensive than 2D. The samples are fluorescently 
labeled with three different fluorochromes; Cy2, Cy3 and Cy5. All 3 samples are 
mixed and run on the same gel with an internal standard. 2D-DIGE allows the 
reliable quantification of difference in protein expression as low as 10%. The 
disadvantage of 2D-DIGE is that membrane proteins are poorly represented by 
this technique and low-abundance proteins are difficult to identify [Lilley & 
Friedman, 2004; Mayr M et al., 2011]. 
 
As part of this research project a 2D proteomics study was conducted on the 
mitochondrial and cytosolic fractions of rat heart tissue. Before discussing the 
results of the present study, an overview of the myocardial metabolism will be 
given.  
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4.2)     Energy metabolism in the aerobic heart  
 
The high energy demand of the heart is met by utilizing a variety of carbon      
substrates, including free fatty acids (FFAs), carbohydrates, amino acids and 
ketone bodies (Figure 4.1) [Stanley et al., 2001]. Free fatty acids and 
carbohydrates are the major substrates from which the heart derives most of its 
energy. Under normal, aerobic conditions, 50-70% of the total energy is obtained 
from fatty acids, while the majority of the rest is obtained from carbohydrates 
(mainly glucose and lactate).  
 
Approximately 60-70% of the ATP obtained is used to supply the energy required 
for contractile shortening, while the rest (30-40%) is mainly used for the 
sarcoplasmic reticulum Ca2+- ATPase and other ion pumps [Suga et al., 1990; 
Gibbs, 1978]. Mitochondrial oxidative phosphorylation is fuelled with energy 
generated from electrons, transferred from carbon fuels by dehydrogenation 
reactions. The reducing equivalents NADH and FADH2 are subsequently 
produced mainly by the beta-oxidation pathway and to a lesser extent from 
glycolysis (Figure 4.1) [Stanley et al., 2005]. A stoichiometric link exists between 
the rate of oxidation of carbon fuels, oxygen consumption, ATP hydrolysis, flux 
through the electron transport chain (ETC), oxidative phosphorylation, actin-
myosin interaction and the external contractile power generated by the heart 
[Stanley et al., 2005]. Therefore, an increase in contractile power, results in a 
concomitant increase in all the components in the system. The regulation of 
myocardial metabolism is linked to arterial carbon substrate concentration, 
hormone concentrations, inotropic state and coronary flow [Taegtmeyer et al., 
2002; Opie 1991].  
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Figure 4.1 Cardiac energy metabolism under normal aerobic conditions.  
Fatty acids are the primary source of energy for the heart, supplying 60–90% 
of the energy for adenosine triphosphate (ATP) synthesis. The balance (10–
40%) comes from the oxidation of pyruvate formed from glycolysis and lactate 
oxidation. Almost all of the ATP formation comes from oxidative 
phosphorylation in the mitochondria; only a trivial amount of ATP (<2% of the 
total) is synthesized by glycolysis. ADP=adenosine [Stanley, 2001]  
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4.2.1) Glycolysis 
 
Glycolysis (“lysis of glucose”) is the biochemical process by which glucose is 
metabolized to pyruvate leading to the production of acetyl-CoA, which is further 
metabolized in the citric acid (Krebs) cycle.  All the enzymes of the glycolysis 
pathway are located in the cytosol. Glycolysis is a unique pathway, since it can 
utilize oxygen when under aerobic conditions, but it can also function in the 
absence of oxygen (anaerobic conditions).  
 
The function of the citric acid cycle (Krebs cycle) is to act as the final common 
pathway for the oxidation of carbohydrates, proteins and lipids (Figure 4.2). The 
enzymes of the citric acid cycle are located in the mitochondrial matrix. The 
Krebs cycle forms an integral part of a process in which much of the free energy 
liberated during oxidation of carbohydrates, lipids and amino acids is made 
available. During the course of oxidation of acetyl-CoA in the cycle, reducing 
equivalents in the form of hydrogen or electrons are formed as a result of the 
activity of specific dehydrogenases.  
 
These reducing equivalents then enter the respiratory chain, where large 
amounts of ATP are generated in the process of oxidative phosphorylation. This 
process is aerobic and therefore absence or partial deficiency of oxygen causes 
total or partial inhibition of the cycle.  
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Figure 4.2 Mitochondrial energy metabolism. 
Reduced nicotinamide adenine dinucleotide (NADH) and reduced 
flavin adenine dinucleotide (not shown) transfer electrons from fatty 
acids, glucose and lactate to the electron transport chain. The process 
of oxidative phosphorylation is driven by the electron transport chain, 
which takes the energy from the oxidation of fatty acids, glucose and 
lactate, primarily via NADH. ADP=adenosine diphosphate; 
ATP=adenosine triphosphate; CoA=coenzyme A; NAD+ = 
nicotinamide adenine dinucleotide [Stanley, 2001].  
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4.2.2)  -oxidation in the aerobic heart 
 
Within the circulation, fatty acids are tightly bound to albumin and represent an 
important, readily available energy source for certain organs like the heart. Entry 
of fatty acids into the myocardial cell is presently thought to be mediated by 
several proteins including fatty acid binding proteins (FABPs) and a myocardial-
specific integral membrane transporter (fatty acid translocase or FAT). The non-
enzymatic FABP also serves as a facilitator of intracellular transport of relatively 
insoluble long-chain fatty acids to sites of metabolic utilization (e.g. mitochondria). 
In mammals, the FABP content in skeletal and cardiac muscle is related to the 
fatty acid oxidation capacity of the tissue [Glatz & Storch, 2001]. 
 
Once in the cytoplasm, long-chain fatty acids (LCFAs) may be transported by 
heart-type fatty acid binding protein (H-FABP) [Binas et al., 1999] and are rapidly 
esterified to acyl-CoA by long-chain acyl-CoA synthase (LCAS). Transport of 
LCFAs into the mitochondria occurs via transesterification by carnitine 
palmitoyltransferase I (CPT-I) and subsequent translocation across the inner 
mitochondrial membrane facilitated by carnitine/acyl-carnitine translocase. CPT-I 
catalyzes a key rate-limiting step in mitochondrial fatty acid flux and, as such, is 
highly regulated at gene transcriptional level [Brown et al., 1995; Brandt et al., 
1998; Mascoró et al., 1998; Steffen et al., 1999] as well as through post-
translational control via reversible binding of the inhibitor, malonyl-CoA, the first 
committed intermediate in the pathway of fatty acid synthesis [McGarry et al., 
1989]. Upon translocation across the inner mitochondrial membrane, long-chain 
acylcarnitines are re-esterified to acyl-CoA derivates by CPT-II and enter the -
oxidation spiral. The initial step in the oxidative spiral is catalysed by:  (1) a family 
of acyl-CoA dehydrogenases (AD) specific for very long-chain (VLCAD), long-
chain (LCAD), medium-chain (MCAD) and short-chain (SCAD) acyl-CoA 
substrates. Subsequent steps involve: (2) hydration by enoyl-CoA hydratase; (3) 
a second oxidation by a 3-hydroxyacyl-CoA dehydrogenase; and then (4) a 
thiolytic cleavage by 3-ketoacyl-CoA thiolase to yield acetyl-CoA and shortened 
acyl-CoAs destined for additional rounds of oxidation. Steps 1 and 3 of the fatty 
acid oxidation (FAO) cycle generate electrons which are ultimately transferred to 
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the electron transport chain where ATP is produced in the presence of oxygen 
(i.e. oxidative phosphorylation). The acetyl-CoA end-product is oxidized via the 
tricarboxylic acid (TCA) cycle. 
 
 
The process of fatty acid oxidation is termed -oxidation, since it occurs through 
the sequential removal of 2-carbon units by oxidation of the -carbon position of 
the fatty acyl-CoA molecule. Each round of -oxidation produces NADH, FADH2 
and acetyl-CoA. The acetyl-CoA, the end product of each round of -oxidation, 
enters the TCA cycle where it is further oxidized to CO2 with the concomitant 
generation of NADH, FADH2 and ATP. The NADH and FADH2 generated during 
fatty acid oxidation and acetyl-CoA oxidation in the TCA cycle will subsequently 
enter the respiratory pathway for the production of ATP. Consequently, the 
oxidation of fatty acids yields more energy per carbon atom than does the 
oxidation of carbohydrates. However, while fatty acids produce more ATP during 
complete aerobic oxidation than glucose, this occurs at the expense of a higher 
rate of oxygen consumption. The supply of oxygen is an important determinant of 
myocardial fuel utilization. 
 
4.2.3) Energy metabolism in the ischaemic and reperfused heart 
 
All of the ATP produced from fatty acid oxidation is dependent on the presence of 
oxygen. In contrast, ATP production from glucose originates from both glycolysis 
(which is not dependent on oxygen) and glucose oxidation (which is dependent 
on the presence of oxygen). During ischaemia, due to restricted oxygen supply to 
the muscle, both fatty acid and carbohydrate oxidation decreases and ATP 
production is impaired (Figures 4.3; 4.4) [Lopaschuk, 1997].  
 
Glycolysis, a minor source of ATP in the aerobic heart, becomes a more 
significant source of energy during ischaemia [Olivier & Opie, 1994]. However, 
pyruvate produced from glycolysis is converted to lactate rather than being 
completely metabolized to CO2 and H2O in the mitochondria. This not only results 
in the accumulation of lactate but also H+s, since H+ produced from hydrolysis of 
glycolytically derived ATP are not taken up by the mitochondria (with pyruvate) 
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where it eventually is used for H2O production. This results in a reduction in 
intracellular pH, the magnitude of which depends on the severity of ischaemia 
[Kloner & Jennings, 2001; Liu et al., 2001]. 
 
During reperfusion of previously ischaemic muscle, there is the possibility of an 
impaired post-ischaemic functional recovery due to a delayed recovery of 
metabolism [Schwaiger et al., 1985]. However, in the reversibly injured 
myocardium, fatty acid oxidation rapidly recovers during reperfusion and 
becomes the dominant source of energy replenishing the ATP pool in the heart 
[Belke & Lopaschuk, 1997]. Glucose oxidation, on the other hand remains 
suppressed due to the fact that increased fatty acid oxidation inhibits glucose 
oxidation via the well known Randle cycle (increase in fatty acid oxidation inhibits 
glucose oxidation in the muscle via inhibiting the rate limiting pyruvate 
dehydrogenase complex of the glucose oxidation pathway) [Kantor et al., 2001. 
Interestingly, glycolysis is unaffected by these high rates of fatty acid oxidation 
and remains elevated during reperfusion resulting in an increase in the 
uncoupling of glycolysis from glucose and a continued H+ accumulation [Liu et al., 
1996]. Activation of AMPK during and following ischaemia is an important 
contributor to these high rates of both glycolysis and fatty acid oxidation. 
 
Proton accumulation during ischaemia and reperfusion can alter cardiac 
efficiency by a number of potential mechanisms. It can lead to intracellular Na+ 
accumulation via Na+/H+ exchange and a subsequent intracellular Ca2+ 
accumulation via Na+/Ca2+ exchange [Liu et al., 1996]. Sudden rises in 
intracellular Ca2+ could potentially cause cell death [Liu et al., 1996]. Proton 
accumulation can also result in a decreased efficiency of the contractile proteins, 
impair functional recovery during reperfusion and decrease cardiac efficiency 
(cardiac work/myocardial O2 consumption).  Liu and co-workers [1996] have also 
demonstrated that decreasing H+ production (by improving uncoupling) and/or 
inhibiting Na+/H+ exchange, improves functional recovery as well as cardiac 
efficiency during reperfusion. Thus, altered metabolism during ischaemia is an 
important contributor to post-ischaemic functional impairment of the heart.  
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Figure 4.3 Cardiac energy metabolism during ischaemia of moderate 
severity (approximately 40% of normal blood flow).  
The up and down arrows indicate the changes compared with normal 
aerobic conditions. Relative to aerobic conditions, ischaemia results in 
an increase in glycolysis without an increase in the rate of pyruvate 
oxidation, thus causing lactate to accumulate in the cell. Despite 
accelerated glycolysis and lactate production, the relatively high rate of 
residual oxygen consumption is fueled primarily by the oxidation of 
fatty acids. ADP=adenosine diphosphate; ATP=adenosine 
triphosphate [Stanley, 2001] 
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Figure 4.4 Pyruvate oxidation during ischaemia.  
There is accelerated glycolysis and lactate production in the cytosol. In 
the mitochondria there is a rise in the ratio of reduced nicotinamide 
adenine dinucleotide (NADH) to oxidized nicotinamide adenine 
dinucleotide (NAD+) due to a decrease in oxygen consumption and 
continued fatty acid oxidation [Stanley, 2001]. 
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4.2.4) AMPK control of fatty acid metabolism during 
ischaemia/reperfusion      
 
AMPK, described as a “cellular fuel gauge”, shuts down the energy consuming 
processes and facilitates energy producing processes during various metabolic 
stresses [Hardie & Hawley, 2001]. Ischaemic stress in the heart leads to an 
increase in AMPK activity [Kudo et al., 1995, 1996]. AMPK modifies two 
important metabolic pathways during and post ischaemia, namely glycolysis and 
fatty acid oxidation. AMPK also inhibit creatine kinase and discourages the 
reverse reaction in which Cr is converted to PCr, and thus makes more ATP 
available for other critical functions of the cell [Ponticos et al., 1998].  
 
AMPK belongs to a family of serine/threonine kinases which have highly 
conserved kinase domains [Lefebvre et al., 2001]. It was originally identified as a 
HMG CoA reductase kinase and an acetyl CoA carboxylase kinase [Carlson et 
al., 1973; Beg et al., 1978; Keith et al., 1979]. However, when it became clear 
that this kinase phosphorylated a number of proteins and was activated by 
5’AMP, it was renamed as AMPK [Ferrer et al., 1985; Carling et al., 1987].  
 
Under normal conditions, fatty acids are the preferred energy source of the 
myocardium contributing to 60-80% of the total ATP production [Belke & 
Lopaschuk, 1997]. Although fatty acid oxidation decreases during ischaemia, it 
rapidly recovers during reperfusion contributing to between 90-100% of the ATP 
production in the heart [Belke & Lopaschuk, 1997]. This increased use of fatty 
acids to support ATP production is due to an increase in circulating fatty acid 
levels, and to subcellular alterations in the control of fatty acid oxidation, where 
AMPK appears to play an important role.  
 
In clinical conditions like myocardial infarction, or during and after cardiac 
surgery, serum fatty acid concentrations increase [Opie, 1975; Mueller & Ayres, 
1987; Lopaschuk et al., 1994; Fragaso et al., 2002]. As a result, cardiac fatty acid 
supply and oxidation could increase several fold under these conditions. 
Inhibition of fatty acid oxidation protects the heart from detrimental effects of 
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heparin [Fragaso et al., 2002], implicating the detrimental effects of elevated fatty 
acid oxidation. Experimental evidence further supports that over-reliance on fatty 
acid oxidation is detrimental to the functional recovery of the heart during 
reperfusion following severe ischaemia [Lopaschuk et al., 1988; 1992]. Thus, it is 
important to understand the mechanisms responsible for alterations in fatty acid 
metabolism during ischaemia/reperfusion. 
 
An important control site of fatty acid oxidation in the heart is at the mitochondrial 
membrane where fatty acids are transported across the membrane as acyl 
carnitine esters. This process is facilitated by acyl carnitine translocase and two 
carnitine palmitoyl transferases (CPT-I and CPT-II) (as discussed earlier). Once 
inside the mitochondria, acyl-CoA undergoes -oxidation in the matrix producing 
several acetyl-CoA molecules which then enter the TCA cycle for complete 
oxidation. Transport of fatty acids by CPT-I across the mitochondria is the rate- 
limiting step in fatty acid oxidation [Kantor et al., 2001]. CPT-I, located on the 
outer mitochondrial membrane, is under the inhibitory control of malonyl-CoA 
[Kantor et al., 2001]. Cellular malonyl CoA levels are in turn regulated by the rate 
of synthesis by acetyl-CoA carboxylase (ACC) and the rate of degradation by 
malonyl-CoA decarboxylase [Sakamoto et al., 2000]. AMPK has a potentially 
important role here, since it has been shown to regulate both ACC and MCD 
activities.  
 
Thus, AMPK could be a potential target for metabolic modulation during 
ischaemia and reperfusion. It is also proposed that activating AMPK in the heart 
may be beneficial since it reduces lipid accumulation and therefore the lipotoxicity 
[Minokoshi et al., 2002]. However, it is important to note that activation of AMPK 
in the heart may also increase fatty acid oxidation and glycolysis which may have 
deleterious effects on the heart especially under conditions where plasma fatty 
acids are already elevated and where the heart utilizes exclusively fatty acids as 
its energy substrate (e.g. in diabetes and myocardial ischaemia).  
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4.3) Motivation leading to the present study 
 
Although the protection elicited by IPC is a powerful response, our results 
demonstrated that some preconditioned hearts have a poor recovery after 
reperfusion. Since kinase activation (as accessed by Western blotting), does not 
always correlate with functional recovery during reperfusion (Chapter 5), it does 
not necessarily contribute to identify the underlying mechanisms involved or 
associated with poor recovery after IPC.  
 
In view of the above, our aims were to identify the underlying mechanisms 
involved contributing to poor recovery of the IPC hearts during reperfusion by 
implementing a more sensitive technique and allowing us to study more that one 
protein at a time. In order to achieve this, we utilized the 2D proteomics 
technique. This technique is well established in our lab and implementing the 
latest IPG strip technology and precast gradient gels during protein separation, 
combined with ESI-MS has proven to yield satisfactory results when separating 
mitochondrial proteins. 
 
Emerging studies suggest that events occurring during the early post-ischaemic 
myocardial reperfusion phase may underlie the cardioprotection elicited by IPC 
[Hauenloy et al., 2005].  Therefore, we decided to study the 15 min reperfusion 
time point. The patterns of kinase activation of the 15 min reperfusion time point 
are shown in chapter 3. Another benefit of studying this time point is that 
functional recovery can be recorded after 15 min reperfusion, thus enabling us to 
correlate functional recovery with biochemical processes in the cell, whereas at 5 
and 10 min reperfusion the heart is still perfused in retrograde mode. 
 
Myocardial cell death due to ischaemia/reperfusion injury is a major cause of 
morbidity and mortality nationwide [Murphy & Steenbergen, 2008]. Mitochondria 
are considered the most important organelle of eukaryotic cells and are the major 
contributers in many cellular as well as extracellular regulatory functions that 
affect the differentiation and survival of living organisms [Jiang & Wang, 2012]. 
The primary function of mitochondria is to converge organic materials into cellular 
energy in the form of ATP. Mitochondria play an important role in many crucial 
metabolic tasks, such as regulation of the cellular redox state, heme and steroid 
Stellenbosch University  http://scholar.sun.ac.za
  136
synthesis, urea cycle, fatty acid oxidation and heat production [Kim et al., 2006]. 
When oxygen availability becomes limited, as during long periods of ischaemia 
alterations to mitochondrial structure can result in mitochondrial dysfunction. 
Mitochondrial structural alterations and dysfunction has proved to have 
deleterious effects on cellular level and have been implicated in numerous forms 
of diseases, including heart disease, ischaemia/reperfusion injury and 
neurological diseases [Hirano et al, 2001; Beal et al., 1997; Yarian 2005]. 
Ischaemic heart disease (IHD) represents a group of pathological disorders, 
characterized by insufficient perfusion (oxygen supply) of the heart [Cadenas et 
al., 2010]. The production of ROS by the mitochondria is an important feature of 
ischaemia. During ischaemia ROS are generated in the myocardium and the 
major sites of ROS production in the mitochondria are complexes I and III of the 
ETC [Zweier & Talukder, 2006; Solani & Harris, 2005; Pacher et al., 2006]. Upon 
reperfusion, the production of ROS initiated by ischaemia is exacerbated. This 
overproduction of ROS coupled with an increase in intracellular calcium is 
thought to be the main cause of reperfusion injury [Cardenas et al., 2010]. The 
ischaemic heart is therefore an important model for studies of cardiovascular 
disease [Jiang & Wang, 2012]. The rapid emerging field of proteomics can now 
provide new insight into the identification and characterization of mitochondrial 
proteins in these processes. In the past mitochondria have been studied using 
classical biochemical methods, but these studies focused only on one particular 
protein involved in the disease processes. Proteomic techniques allow more in-
depth studies involving the whole mitochondrial proteome. A search of the 
literature revealed a lack of proteomics studies involving preconditioning in the 
isolated working heart during reperfusion. Proteomic based studies in the heart 
however, have been utilised to investigate the following aspects; oxidative stress 
in H9C2 cardiomyocytes [Chou et al., 1010]; myocardial ischaemia [Peronnet et 
al., 2006; Kim et al., 2006; Koomen et al., 2006], dilated cardiomyopathy 
[Gramolini et al., 2008; Weekes et al., 1999; Isserlin et al., 2010], hypertrophic 
cardiomyopathy [Buscemi et al., 2005] and heart failure [Chen et al., 2008; Wei et 
al., 2009; Cieniewski-Bernard et al., 2009; Weger et al., 2011; Dai et al., 2012; 
Zhang et al., 2011]. The results of some of these studies will be summarized in 
the Discussion sections (4.7 and 4.8).   
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In view of the above our aims were, to identify the underlying mechanisms 
involved contributing to poor recovery of the IPC hearts during reperfusion by:  
(1) comparing the protein expression profiles of the mitochondrial fractions of rat 
heart tissue between IPC and Non-IPC hearts; (2) comparing the protein 
expression profiles of the cytosolic fractions of rat heart tissue between IPC and 
Non-IPC, by utilizing the 2D proteomics technique (Materials and Methods, 
Chapter 2). 
 
 
 
4.4) Methods 
 
For the proteomic study, the following experimental protocol was used:  
 
(i) Non-preconditioned hearts (Non-IPC).  Isolated rat hearts were stabilized for 
60 min (15 min retrograde, 15 min working heart and 30 min retrograde). These 
hearts were subsequently subjected to 25 min sustained global ischaemia 
followed by 15 min reperfusion (10 min retrograde perfusion, followed by 5 min 
working heart) (Figure 4.5). After 15 min reperfusion hearts were snap-frozen and 
mitochondrial and cytosolic fractions were isolated using two different kits as 
described in the methods section. 
 
(ii) Ischaemic preconditioned hearts (IPC).  Isolated rat hearts were stabilized for 
30 min (15 min retrograde, 15 min working heart) and then preconditioned for 3x5 
min global ischaemia, alternated with 5 min reperfusion. These hearts were 
subjected to 25 min sustained global ischaemia, followed by 15 min reperfusion 
(10 min retrograde perfusion, followed by 5 min working heart) (Figure 4.5). After 
15 min reperfusion, hearts were snap-frozen and mitochondrial and cytosolic 
fractions were isolated using two different kits as described in the methods 
section.   
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 Retrograde     Working heart              Retrograde                   Sustained ischaemia       Retrograde          Working heart              
    
Retrograde     Iscmic preconditioned hearts: 
                                                                                                                                                        Reperfusion 
                                                       Recordings                                             Recordings                      
                                                                                       
ii 
  
 Retrograde    Working heart               Preconditioning             Sustained ischaemia         Retrograde          Working heart          
 
 
                                                                                                                                                       Reperfusion        
                                                                                                                      Recordings  
 
 
 
 
 
Figure 4.5   Experimental protocol according to a timeframe. Mitochondrial and cytosolic fractions were isolated from heart tissue for 
the 2D proteomic study after 15 min reperfusion (indicated by the solid          arrows). Functional recordings were made indicated by 
the dashed arrows, (          ). 
Ischaemic preconditioned  hearts: 
0                  15                 30    35     40    45    50   55     60                                       85      90      95    100   105                115    (time in min) 
Isolation of mitochondrial and cytosolic 
fractions at 15 min reperfusion 
Isolation of mitochondrial and 
cytosolic fractions at 15 min 
Recordings 
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4.5) Results: Cytosolic proteomics 
  
Two dimensional proteomics of the cytosolic fraction of rat heart tissue 
highlighted several differences between Non-IPC and IPC rat hearts after 15 min 
reperfusion (Figure 4.6).  
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 Figure 4.6   A  2D gel-image of cytosolic proteins expressed in rat heart 
tissue.  
 Differentially expressed protein spots (p< 0.05) between Non-IPC and IPC were 
identified by PDQuest software and are indicated by numbers 1-18. These spots 
(spots of interest) were manually excised and subjected to in-gel digestion followed 
by Ms analysis.  Peptide datasets were subjected to the Mascot search engine 
(www.matrixscience.com) and the corresponding proteins were identified, using the 
Swiss-Prot database. 
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The majority of proteins identified (61%) are involved in energy metabolism, 8% 
are structural proteins, 8% are heat shock proteins, while the rest have different 
functions. Several cytosolic proteins involved in energy metabolism were 
differentially expressed (statistically significant) between IPC and Non-IPC hearts 
after 15 min reperfusion (Table 4.1). These data show down regulation of two 
pivotal regulators of glycolysis, glyceraldehyde 3-phosphate (Table 4.1, spot 18) 
and pyruvate dehydrogenase (Table 4.1, spot 5) in the IPC hearts. Another 
energy regulator of glycolysis, pyruvate kinase, was up regulated in the IPC 
hearts (Table 4.1, spot 35).  
 
The indirect energy-regulator lacate dehydrogenase (LDH), is downregulated 
(Table 4.1, spot 28) in the IPC hearts compared to the Non-IPC hearts, whereas 
some of the key regulators of electron transport in the electron transport chain 
(ETC) were down regulated in the IPC hearts.  
 
Enzymes responsible for fatty acid β-oxidation (long chain specific acyl CoA 
dehydrogenase) Table 4.1, spot 21, in the mitochondria were up regulated in the 
IPC hearts, compared to the Non-IPC hearts. Interestingly, fatty acid binding 
protein (Table 4.1, spot 9), which is responsible for the transportation of fatty 
acids in the cell and the uptake of fatty acids into the mitochondria, was down 
regulated in the IPC hearts. 
 
The expression of the Krebs cycle enzyme, isocitrate dehydrogenase [NAD] 
subunit (Table 4.1, spot 12), was decreased in the IPC hearts, while the 
expression of aconitase, another Krebs cycle enzyme (Table 4.1, spot 25), was 
up regulated in the IPC hearts compared to the Non-IPC hearts.  
 
Heat shock protein-60 (HSP-60), Table 4.1, spot 8, was down regulated in the 
IPC hearts, while heat shock protein-beta-6 (Table 4.1, spot 15), was up 
regulated in the IPC hearts, compared to the Non-IPC hearts.  
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Table 4.1  Proteins identified in the cytosolic fraction of rat heart tissue.  
Data represent differentially expressed proteins between control (Non-IPC) and IPC (p<0.05) as identified by the Swiss-prot  database. Only 
proteins that were significantly regulated are reported (p < 0.05). Results are reported as fold increase or decrease compared to control (Non- 
IPC). SSP numbers are assigned by PDQuest Software (Bio-Rad, Hercules CA). 
Spot SSP Mascot
score 
Protein Name Swiss 
Prot 
Accession
Number 
% 
Sequence 
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease 
Functional 
   Group  
      or 
  Function 
   1 1004  278 Cytochrome C 
Oxidase   
  P11240     27%     6  - 2.86 Complex IV 
of the ETC 
   2 2102  395 Myosin light 
chain 3 
  P16409     72%     17  - 1.59 Cardiac 
muscle 
contraction 
  3 2201  400 NADH 
dehydrogenase
(Ubiquinone) 
  P19234      47%     20  -  2.04 Complex 1 
of ETC 
   4 2402  266 Prostaglandin 
reductase 
 Q5BK81      22%      9   - 1.82 Activates 
PPAR-γ 
   5 3401  472 Pyruvate 
dehydrogenase 
  O88989      39%      16    - 4 Glycolysis 
   6 3403  126 Troponin T, 
cardiac muscle 
  P50753      25%      12    - 9.1 Cardaic 
Muscle 
contraction 
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Table 4.1         continued 
 
Spot SSP Mascot 
score 
Protein Name Swiss 
Prot 
Accession
Number 
% 
Sequence
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease
Functional 
   Group  
      or 
  Function 
  7 2906   396 Cytochrome b-c1 complex  Q68FYO     32%     20   - 1.61 Complex III 
of ETC 
  8 7301   573 HSP-60 
Mitochondrial 
 P63039     43%     26   - 1.56 Mitochondrial 
protein  
import 
 
  9 4002   775 Fatty acid binding protein 
heart 
 P07483     66%     30   -  1.3 Transport of 
long chain 
fatty acids  
 
  10 4704   402 Prohibitin  P67779     52%     16    - 1.64 Inhibits DNA 
synthesis 
 
  11 3101   186 Phosphatidylethanolamine
Binding protein 
 P31044     25%       3      1.6 Negative 
regulation of 
Raf/MAPK 
signaling 
  12 4305   258 Isocitrate dehydrogenase 
[NAD] subunit 
 Q99NA5     29%     15    - 1.14 Krebs cycle  
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Table 4.1         continued 
 
 
Spot SSP Mascot
score 
Protein Name Swiss 
Prot 
Accession
Number 
% 
Sequence
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease
Functional 
   Group  
      or 
  Function 
  13 4705  381 Acetyltransferase 
component of 
Pyruvate 
dehydrogenase 
Complex 
 P08461     19%    16   - 1.64 Glycolysis 
  14 4706  252 Myosin-6  P02563     12%    23   - 1.49 Muscle 
contraction 
 
 
  15 6103  107 HSP-beta 6 
 
P97541      29%     6     1.89 Pre-
slaughter 
stress 
 
  16 6302  388 Malate 
dehydrogenase 
 
 O88989      44%    21     1.38 Malate to 
oxaloacetate
  17 9104  462 Alpha crystalline  
B-chain 
 Q9D6J6      59%     26    -1.72 Stabilizes 
actin  
cytoskeleton 
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Table 4.1         continued 
Spot SSP Mascot
score 
Protein Name Swiss 
Prot 
Accession
Number 
% 
Sequence 
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease
Functional 
   Group  
      or 
  Function 
 18 7301  488 Glyceraldehyde 
3- phosphate 
dehydrogenase
 P04797      42%    17   - 1.56 Glycolysis 
 19 7203  383 Enoyl-COA 
hydratase 
mitochondrial 
Proteosome 
 P14604      33%    13    1.31 Lipid 
metabolism 
 20 9705  376 ATP synthase  P15999      28%     22    - 2.86 ATP 
production 
 21 8501  585 Long chain 
specific acyl 
COA 
dehydrogenase
 P15650      42%     20     1.95 Fatty acid 
beta 
oxidation 
 22 2907  496 Transitional 
endoplasmic 
reticulum 
ATPase 
 P46462      33%     29    - 1.61 Reassembly 
of Golgi 
stacks after 
mitosis 
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Table 4.1         continued 
 
Spot SSP Mascot
score 
Protein Name Swiss 
Prot 
Accession
Number 
% 
Sequence 
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease
Functional 
   Group  
      or 
  Function 
  23 5103  924 78 kDa 
Glucose 
regulated 
protein 
P06761 
 
 
     46%     36  - 2.38 Assembly of 
proteins inside 
endoplasmic 
reticulum 
  24 7205  370 Delta (3,5)- 
Delta(2,4)-
Dienoyl-COA 
isomerase, 
mitochondrial 
Q62651      27%    15   - 1.2 Fatty acid 
metabolism 
  25 9908  800 Aconitate 
hydratase, 
mitochondrial 
Q9ER34      43%     42   1.73 Krebs cycle 
 26 8203  1108 Electron 
transfer 
flavoprotein 
subunit alpha  
 P56757      52%     36  -1.96 Transfer of 
electrons to main 
ETC 
 27 1102  434 Peroxiredoxin-
6 
 O35244      59%      25    -2.33 Protects against 
Ischaemia/ 
reperfusion injury 
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Table 4.1         continued 
 
 
 
 
Spot SSP Mascot
score 
Protein Name Swiss 
Prot 
Accession
Number 
% 
Sequence 
Coverage 
 
No of 
Peptides 
  Fold  
Increase  
    or 
Decrease 
Functional 
   Group  
      or 
  Function 
  28 2305  274 L-lactate 
dehydrogenase
  P42123 
 
     39%     17  - 1.5 Glycolysis 
 
 
  29 0205  238 Annexin A5   P14668      39%    15   - 1.22 Anti-
coagulant 
protein 
 
 
  30 4601  476 Alpha enolase   P04764      38%     19    -1.82 Glycolysis 
 
 
  31 4703  454 Protein 
disulfide-
isomerase A3 
  P11598      42%     24     1.3 Heart failure 
 32 6402  479 Isovaleryl CoA 
dehydrogenase
 O35244      43%      25    -1.89 Amino acid 
degradation 
 
 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
  147
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1         continued 
 
 
 
 
 
 
Spot SSP Mascot
score 
Protein Name Swiss 
Prot 
Accession
Number 
% 
Sequence
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease
Functional
   Group  
      or 
  Function 
  33 2304  130 Lactoylglutathione 
lyase 
  P42123 
 
     37%     11   - 1.5 Removes 
toxic 
aldehydes 
 
 
  34 0203  312 HSP -beta 1   P14668      39%    15   - 1.22  
Anti-
apoptotic 
 
  35 8704  576 Pyruvate kinase 
Isozymes M1/M2 
 
  P11980      46%     29     6.96 Glycolysis 
  36 1803  197 Protein DJ-1   O88767      33%     13    -2.38 
 
Sensor of 
oxidative 
stress 
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4.6)  Results:  Mitochondrial proteomics 
          
 
2D proteomic analysis of mitochondrial proteins highlighted several differences 
between Non-IPC and IPC hearts after 15 min reperfusion (Figure 4.7).  
 
 
 
 
           pH5                                                                                                        pH 8    
 
 
 
Figure 4.7   A 2D gel-image of mitochondrial proteins expressed in rat heart tissue. 
Differentially expressed protein spots (p< 0.05) between Non-IPC and IPC were 
identified by PDQuest software and are indicated by numbers 1-18. These spot (spots of 
interest) were manually excised and subjected to in-gel digestion followed by Ms 
analysis. Peptide datasets were subjected to the Mascot search engine 
(www.matrixscience.com) and the corresponding proteins were identified, using the 
Swiss-Prot database. 
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Eighteen differentially expressed (statistically significant) proteins were identified 
between Non-IPC (control) and IPC hearts after 15 min reperfusion. These 
include 15 proteins involved in mitochondrial metabolism, three heat shock 
proteins, Annexin A3 and Mitofilin (Table 4.2). These data show both up- and 
down regulation of key regulators of electron transport in the ETC and 
mitochondrial ATP production.  
 
Enzymes responsible for fatty acid β-oxidation (long chain specific acyl CoA  
dehydrogenase), in the mitochondria were up regulated in the IPC hearts, 
compared to the Non-IPC hearts. ATP synthase responsible for the generation of 
ATP from ADP was downregulated in the IPC hearts. Several enzymes 
responsible for the catabolism of amino acids were upregulated in the IPC hearts.  
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            Table 4.2  Proteins identified in the mitochondrial fraction of rat heart tissue.  
Data represent differentially expressed proteins between control (Non-IPC) and IPC (p<0.05) as identified by the Swiss-prot database. 
Results are expressed as fold increase or decrease compared to control (Non-IPC). Only proteins that were significantly differently regulated 
are reported (p < 0.05). SSP numbers are assigned by PDQuest.  
Spot SSP  Mr 
(Da) 
 
 pI Mascot
score 
Protein Name Swiss 
Prot 
Accession
Number 
% 
Sequence
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease
Functional 
   Group  
      or 
  Function 
 1 0104 27703  6.23  194 Ubiquinone P 12934      18      5   - 1.3 Complex I of 
ETC 
  2 5106 28563 7.14
 
   40 Thioredoxin 
dependent 
peroxide 
reductase 
 
Q920V6       4      2     1.13 Scavenger of 
mitochondrial 
generated 
hydrogen 
peroxide 
  
  3 
 
7303 
  
48242 
 
7.63
  
  248  
Long chain 
specific Acyl-
CoA 
dehydrogenase
 
  P15650 
 
 
     13 
 
 
     5 
   
    1.6 
Fatty acid 
beta 
oxidation 
 
  4 
 
7102 
 
20076 
 
6.76
 
   55 
Alpha crystallin 
B chain 
  
  P23928 
 
      7 
 
     2 
  
   -1.2 
Stabilization 
of  actin 
cytoskeleton 
 
  5 
 
7502 
 
 
 
54574 
 
7.69
  
   40 
Dihydrolipoyl 
dehydrogenase
 
  P23434 
 
      2      
 
 
     2 
   
    1.41 
Catabolism 
of glycine  
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                    Table 4.2 continued 
 
 
       
 
 
Spot SSP  Mr 
(Da) 
 
 pI Mascot
score 
Protein Name Swiss 
Prot 
Accession 
Number 
% 
Sequence
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease 
Functional 
   Group  
      or 
  Function 
  
  6 
 
4204 
 
18809 
 
6.17
  
   51  
ATP Synthase D 
chain 
 
  P31399 
 
     21% 
 
     3 
  
  - 1.52 
ATP 
synthesis 
  
  7 
 
5607 
 
74097 
 
5.97
  
  158 
Heat shock 
protein 70 
 
 
  P63018 
 
    12% 
 
     7 
  
  - 1.82 
Protein 
import 
   
  8 
 
9306 
 
35272 
 
8.62
  
  595 
Electron transfer 
flavoprotein alpha 
 
 
  P13803 
 
     51% 
 
    16 
   
    2.23 
Transfer 
electrons to 
main ETC 
  
  9 
 
8306 
 
45022 
 
8.47
 
  301 
Short chain 
specific Acyl-COA 
dehydrogenase 
 
 
  P15651  
 
     24% 
 
     8 
 
    
    1.95 
Fatty acid 
metabolsim 
  
 10 
 
6208 
 
33205 
 
5.88
 
   81  
Mercaptopyruvate 
sulfurtransferase 
  
  P97523 
 
     9% 
 
     3 
    
    1.56 
Catabolism 
of amino 
acids 
  
 11 
 
4305 
 
36874 
 
5.7 
   
  222 
 
L-lactate 
dehydrogenase 
 
 
  P42123 
     
    25% 
      
     9 
     
    1.65 
Lactate to 
pyruvate 
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                  Table 4.2  continued 
 
Spot SSP  Mr 
(Da) 
 
 pI Mascot
score 
Protein Name Swiss 
Prot 
Accession 
Number 
% 
Sequence 
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease
Functional 
   Group  
      or 
  Function 
  
 
  12 
 
 
3304 
 
 
18809 
 
 
6.17
  
 
   51 
 
Oxoisovalerate 
dehydrogenase
 
 
  P21953 
 
 
       8 
 
 
     3 
  
 
  - 1.22 
Conversion of 
alpha-keto 
acids to Acyl-
CoA and CO2 
 
   
  13 
 
4305 
 
36569 
 
5.96
  
   68 
 
Annexin A3 
 
  P14669 
 
      9 
 
 
     3 
   
  - 1.316 
    Cell 
regeneration 
  
  14 
 
5301 
 
40044 
 
8.88
 
  317 
Isocitrate 
dehydrogenase
[NAD] 
 
 
  P41562 
 
     33 
 
    19 
   
    1.31 
Krebs cycle 
  
  15 
 
9410 
 
43246 
 
6.58
 
  394 
Creatine 
kinase 
  
  P00564 
 
     32 
 
    13 
   
    1.82 
Energy 
shuttle 
 
  16 
 
9605 
 
86121 
 
7.87
 
  118 
 
Aconitase 
 
  Q9ER34 
 
      8 
 
     6 
 
    1.94 
 
Krebs cycle 
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               Table 4.2  continued 
                
               
 
             
Spot SSP  Mr 
(Da) 
 
 pI Mascot
score 
Protein Name Swiss 
Prot 
Accession 
Number 
% 
Sequence
Coverage 
 
No of 
Peptides
  Fold  
Increase  
    or 
Decrease
Functional 
   Group  
      or 
  Function 
   
  17 
 
8402 
 
17296 
 
5.96
  
 924 
 
Nucleoside 
diphosphate 
kinase A 
 
 
 
  Q05982 
 
       2 
 
    13 
     
    1.5 
 
Nucleotide 
biosynthesis
 
   
  18 
 
6502 
 
57015 
 
7.53
  
 638 
 
Aldehyde 
dehydrogenase
 
  P11884 
 
      30 
 
     15 
    
    1.94 
Omega 
oxidation of 
fatty acids 
 
   
  19 
 
3602 
 
61088 
 
5.91
  
 297 
 
Heat shock 
protein 60 
 
  P 63039 
 
 
      25 
 
     15 
   
    -1.5 
Folding of 
new 
proteins 
 
  
  20 
 
3601 
 
82247 
 
618 
  
173 
 
Mitofilin 
  
 Q9NQR4 
   
      11    
 
      7 
    
   -1.724 
Stabilization 
of  actin 
cytoskeleton
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4.7)  Discussion: cytosolic proteomics 
 
Some of the differentially regulated proteins (Table 4.1) will be individually 
discussed in this section. 
 
4.7.1) Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
 
Glyceraldehyde 3-phosphate (GAPDH) is a key energy regulator in the cardiac 
myocyte and the importance of this enzyme in regulating myocardial glycolysis 
has long been recognized. GAPDH catalyzes the oxidation of glyceraldehyde-3-
phosphate (GAP) to 1,3-diphosphoglycerate by utilizing NAD+ as a redox factor  
and concomitantly reduces NAD
+ 
to NADH + H+  .  This makes GAPDH an energy 
regulator that is responsive to the energy demands of the cardiomyocyte through 
its sensitivity to the ratio of NAD
+ 
to NADH (Mochizuki and Neely, 1979). The rate 
of glycolysis at high workloads is also regulated by GAPDH [Koayashi & Neely, 
1979]. 
 
In the present study, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
down regulated in the IPC hearts (Table 4.1, spot 18), suggesting that glycolysis 
is decreased in the IPC group. Down regulation of GAPDH may result in an 
accumulation of GAP, which contribute to enhanced triglyceride synthesis during 
reperfusion [Saddik & Lupaschuk, 1992]. It is well recognized that the production 
of fatty acids during reperfusion is detrimental to the post-ischaemic heart 
[Challoner & Steinberg, 1966]. The downregulation of GAPDH and subsequent 
attenuation of glycolysis is a direct effect of severe ischaemia [Rovetto et al., 
1975]. Downregulation of GAPDH results in an increase in lactate with a 
subsequent decrease in the internal pH by Na+/H+ and Na+/Ca2+. These 
processes lead to a rise in cytosolic calcium with adverse consequences which 
contribute to the overall mechanism of severe ischaemic damage [Cross et al., 
1995]. Therefore the decreased expression of GAPDH in the IPC hearts can 
explain their poor recovery. 
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4.7.2) Pyruvate dehydrogenase (PDH) 
 
Pyruvate dehydrogenase forms part of a multi-enzyme complex collectively 
designated as the pyruvate dehydrogenase complex (PDC), located in the 
mitochondrial inner membrane. PDH stands at the crossroads of glycolysis in the 
cytosol and oxidation of carbohydrates in the mitochondria, thereby linking 
glycolysis and oxidative phosphorylation through the conversion of pyruvate to 
acetyl CoA (Figure 4.6) - this step commits pyruvate to oxidation in the Krebs 
cycle [Depre et al., 1999]. This increases the energy carrying capacity per 
glucose molecule almost fourteen-fold in the absence of the glycolytic NADH 
contribution to ATP. This conversion reaction is a complex process that involves 
the decarboxylation and oxidation of pyruvate to an acetyl molecule bound by 
lipoamide. The acetyl group is consequently transferred to CoA producing acetyl-
CoA, followed by the formation of NADH [Stryer, 1998]. PDC is mainly inactive 
during fatty acid oxidation, but can be activated by enhanced glycolysis, as a 
result of increased work or in response to catecholamine stimulation [Depre et al., 
1999]. It is important that this enzyme complex must be coordinated with the rate 
of glycolysis to avoid the buildup of pyruvate. This makes PDH a crucial energy 
modulator in the setting of glucose oxidation. When expression of this multi-
enzyme complex is down regulated, as during ischaemia, lactate is formed 
especially when the flux of glycolysis is increased [Opie, 1998]. PDH is inhibited 
by its products acetyl CoA and NADH, therefore PDH and glycolysis are inhibited 
not only by a high energy potential but also under conditions of fatty acid 
oxidation.  
 
In the present study, the expression of the PDH is down regulated (Table 4.1, 
spot 5 and spot 13) in the IPC hearts.  As a result of this, the conversion of 
pyruvate to acetyl CoA will be retarded, since PDH is the link between glycolysis 
in the cytosol and oxidative phosphorylation in the Krebs cycle, as explained 
earlier. Pyruvate will therefore not be optimally oxidized to acetyl CoA in the 
Krebs cycle, which could be detrimental to the IPC hearts, as the Krebs cycle is 
fuelled by acetyl-CoA produced from pyruvate. In addition, the downregulation of 
GAPDH (section 4.7.1) impacts negatively on PDH as the accumulation of 
NADH2 in the cytosol means more protons, thus intracellular acidosis is 
promoted. The result is further downregualtion of PDH by NADH2, thereby 
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permiting entry into the Krebs cycle. Subsequently more lactate forms and the 
ratio of NADH2 to NAD increases further. This results in the accumulation of 
NADH2 in the mitochondria with adverse effects, characterized by downregulation 
of the Krebs cycle and a increase in mitochondrial calcium [Lehninger 1978]. 
These adverse processes can explain why the IPC hearts showed poor functional 
recovery. 
 
 
 
 
Figure 4.8 Regulation of pyruvate oxidation under normal aerobic conditions. 
Pyruvate is formed in the cytosol from glycolysis and lactate oxidation 
and is converted to acetyl-coenzyme A (CoA) in the mitochondria by 
pyruvate dehydrogenase (PDH). The acetyl-CoA and reduced 
nicotinamide adenine dinucleotide (NADH) generated by fatty acid 
oxidation inhibit flux through PDH. Pharmacological inhibition of the rate 
of fatty acid oxidation removes inhibition of flux through PDH by NADH 
and acetyl-CoA and results in more pyruvate oxidation and thus more 
glucose and lactate uptake [Stanley, 2011]. 
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4.7.3) Lactate dehydrogenase 
 
Oxidation of lactate occurs through lactate dehydrogenase (LDH) to produce 
pyruvate. This is the reverse direction of the reaction whereby lactate is formed 
during hypoxia or ischemia. The resultant cytosolic NADH molecules have the 
same fate as that of the glycolytic NADH. The pyruvate is subsequently 
converted to acetyl-CoA by PDC with the formation of another NADH molecule. 
The net theoretical yield of ATP per lactate molecule oxidized is 14.75, half the 
amount produced by glucose oxidation [Opie, 1998].  
 
Lactate is formed from pyruvate by LDH in the absence of oxygen, which is 
advantageous in sustaining glycolysis when oxygen levels become reduced. 
Thus, the formation of lactate facilitates a uninterrupted low ATP production 
during ischemia provided that the lactate is removed from the cytosol of the 
cardiomyocyte via the lactate-proton co-transporter (LPC) [Depre et al., 1999]. 
Indeed, during exercise or hypoxia, skeletal muscle and cardiac muscle become 
the major contributors to the elevation of blood lactate levels. In addition to the 
buffering effect on glycolysis, lactate can also be seen as a temporary mobile 
energy store to conserve energy. This is evident from the increased uptake of 
lactate from the blood by the myocardium when sufficient oxygen becomes 
available. Lactate is oxidized to pyruvate with a concomitant reduction of a NAD+    
molecule to NADH. The resultant pyruvate can then be oxidized in the 
mitochondria by the TCA cycle. Lactate competes remarkably well with glucose 
and fatty acids for oxidation by the heart if high levels of lactate are available 
[Opie, 1998; Lloyd et al., 2004; Liedtke et al., 1994]. 
 
In the present study, the expression of cytosolic LDH (Table 4.1, spot 28) was 
down regulated in the IPC hearts, compared to Non-IPC, suggesting that the 
conversion of lactate to pyruvate in the cytosol is retarded. This may result in an 
accumulation of lactate, intracellular acidosis and general disruption of cell 
homeostasis [Stanley et al., 2001]. The detrimental consequences of intracellular 
acidosis was explained in sections 4.7.1 and 4.7.2. These can account for failure 
of recovery of the IPC hearts. 
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4.7.4) Pyruvate kinase (PK) 
 
This energy regulator plays an important role in the final step of glycolysis, where 
PK transfers one phosphate from phosphoenolpyruvate to ADP, thereby forming 
pyruvate and ATP. This irreversible reaction could play an important role in 
glycolytic regulation due to the sensitivity of PK to fructose 1,6 diphosphate 
(F1,6DP). Increased production of F1,6DP by increased activity of PFK1 
enhances the activity of PK and thus pyruvate production (Kiffmeyer et al., 1991). 
This complimentary feed-forward reaction of energy regulators synchronizes the 
activity of PFK1 and PK, thereby preventing the accumulation of glycolytic 
intermediates during normoxia [Depre et al., 1999]. However, during ischemia, 
pyruvate accumulation could result in product-induced inhibition of PK that may 
retard the activity of PK and thus the rate of glycolysis. Removal of this glycolytic 
byproduct from the cytosol to the mitochondria is mediated by the PDH, which 
therefore has a regulatory role in glycolysis. In contrast, during ischemia, PDH 
becomes inhibited and the role of pyruvate removal is conferred to LDH [Kerbey 
et al., 1976; Opie, 1998].  
 
In the present study the expression of PK (Table 4.1, spot 35) is increased in the 
IPC hearts, with the resulting formation of pyruvate in the cytosol. Since 
expression of PDH is down regulated in the IPC hearts the removal of pyruvate 
from the cytosol to the mitochondria (by PDH) will be retarded. Since the 
expression of LDH is also down regulated in the IPC hearts, pyruvate removal by 
LDH from the cytosol to the mitochondria will also be inhibited. As a result of this, 
pyruvate will accumulate in the cytosol. 
 
4.7.5) Complex I, III and IV of the Electron transport chain 
 
Mitochondria contain a series of catalysts known as the electron transport chain 
(ETC) that collects and transports reducing equivalents in a final common 
pathway to direct them in a final reaction with oxygen leading to the formation of 
water. These catalysts comprises of NAD-linked dehydrogenase systems, 
flavoproteins and cytochromes. Also present in the ETC is the machinery 
responsible for trapping the generated free energy as high energy phosphate.  
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Ubiquinone or Q (also known as Complex I or coenzyme Q) is an additional 
carrier present in the ETC linking the flavoproteins to cytochrome b.  Q exists in 
mitochondria in the oxidized quinone form under aerobic conditions and in the 
reduced quinol form under anaerobic conditions. Q is a constituent of 
mitochondrial lipids and the more mobile component of the ETC enabeling it to 
collects reducing equivalents from the more fixed flavoprotein complexes and 
passes them on to the cytochromes. In the present study, expression of four 
electron carrier proteins of the ETC are down regulated in the IPC hearts;  
Complex 1 or Q (Table 4.1, spot  3), Complex III (Table 4.1, spot 7), Complex IV 
(Table 4.1, spot 1) and electron transfer flavoprotein (Table 4.1, spot 26) is also 
down regulated in the IPC hearts. These results suggest that the ETC may be 
slowed down during IPC at 15 min reperfusion with subsequent detrimental 
consequences for the post-ischaemic hearts. An decreased electron transfer 
efficiency resulting from a decreased expression of complexes I and III promotes 
the formation of ROS [Cadenas et al., 1977]. It is well documented that oxidative 
stress play a key role in heart disease. Mitochondria is a major source and target 
of reactive oxygen species (ROS) in the heart, due to the fact that it is the 
principle site of substrate oxidation in cardiomyocytes [Major et al., 2006]. ROS 
can damage cellular DNA, mitochondrial and cytosolic proteins, lipids and 
contractile apparatus thereby disrupting their normal structure and function. 
These results can explain why the IPC hearts are metabolically worse off 
compared to the Non-IPC hearts. 
   
4.7.6) Long chain specific acyl CoA dehydrogenase 
 
Acyl CoA dehydrogenases play a role in β-oxidation of fatty acids in the 
mitochondria as discussed in section 4.2. In the present study, the expression of 
long chain specific acyl CoA dehydrogenase  (Table 4.1, spot 21) is increased in 
the IPC hearts. Interestingly, the expression of fatty acid binding protein (Table 
4.1, spot 9), responsible for the transport of long chain fatty acids in the cell, is 
down regulated in the IPC hearts. This suggests that fatty acids in the IPC hearts 
accumulate in the cytosol because uptake into the mitochondria is retarded.  
Alternatively, down regulation of fatty acid binding protein in the IPC hearts 
suggests that fatty acids are transported by a different mechanism than in the 
Non-IPC hearts. In addition, the enhanced β-oxidation of fatty acids in the IPC 
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hearts could be responsible for the down regulated expression of glycolytic 
proteins. It is well established that enhanced fatty acid oxidation during 
reperfusion is detrimental to the ischaemic heart. Therefore the increased 
expression of long chain specific acyl CoA dehydrogenase in the IPC hearts 
compared to the Non-IPC hearts in the present study, can explain the poor 
functional recovery of the IPC hearts. 
 
4.7.7) Phosphatidylethanolamine binding protein (PEBP) 
 
Phosphatidylethanolamine binding protein (PEBP), also known as Raf kinase 
inhibitory protein, is a cytosolic protein that negatively regulates the mammalian 
mitogen activated protein kinases (MAPKs) [Wilsbacher & Cobb, 2001; Yeung et 
al., 1999]. PEBP inhibits Raf kinase by binding directly to Raf-1, MEK-1 and ERK-
2, leading to inhibition and inactivation of Raf-1 with subsequent inhibition of the 
β-adrenergic receptor [Granovsky et al., 2009]. As a result, downstream MAPK 
signaling is interrupted and attenuated [Keller, 2011]. Expression of PEBP (Table 
4.1, spot 11) is increased in the IPC hearts compared to Non-IPC. The ability of 
PEBP to negatively regulate Raf/MAPK signaling, could explain why activation of 
ERK is downregulated in the IPC hearts compare to the Non-IPC hearts at 15 
min reperfusion (Results section, Chapter 3). 
 
4.7.8) Protein DJ-1 
 
Protein DJ-1 was discovered in 1997 as a novel oncogenic product [Nagakubo et 
al., 1997]. Emerging evidence indicate that this ubiquitously expressed protein 
has mutilpe cellular functions. DJ-1 plays an important role in the oxidative stress 
response by oxidizing itself to a more acidic form, thereby inducing the production 
of glutathione synthesis through an increase in glutamate ligase [Zhou & Freed, 
2005]. Studies demonstrated that over-expression of DJ-1 protects against 
oxidative stress induced injury, whereas knockout of DJ-1 increases the 
susceptibility to oxidative injury [McCoy & Cookson, 2011]. DJ-1 deficient cells 
have higher levels of ROS, dysregulation of mitochondrial function, increased 
fragmentation and altered autophagy. It has been shown that mitochondrial 
fusion followed by fission events are a protective mechanism against oxidative 
stress. DJ-1 deficient cells have lower rates of mitochondrial fusion. A recent 
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study reported that DJ-1 is upregulated in hypoxic preconditioning through the 
activation of ERK p44/p42 [Lu et al., 2012]. 
 
In the present study, the expression of protein DJ-1 (Table 4.1, spot 36) is down 
regulated in IPC compare to Non-IP. It could possibly be due to the increased 
levels of ROS production in IPC, because of the inhibition of the ETC by the 
down regulation of the four electron carriers (Complex I, III, IV and electron 
transfer flavoprotein alpha). It is well documented that oxidative stress play a key 
role in heart disease [Costa et al., 2009], as discussed on page 157. The 
decreased expression of DJ-1 in the IPC hearts in the present study can 
therefore explain their poor functional recovery. 
 
4.7.9) Heat shock protein-beta-6 
 
Heat shock-beta-6, also known as HSP-20, is a member of the small heat shock  
protein family. HSP-20 is an inducible chaperone protein produced by cells in 
response to environmental changes and are expressed in skeletal muscle along 
with other heat shock proteins including alpha B crystalline and HSP-70 
[Golenhofen et al., 2004]. HSP-27 and HSP-20 localize from the sarcoplasm to 
the myofibrils within 30 min after the onset of psychological stress [Golenhofen et 
al., 2004; Huot et al., 1996]. HSP-20 produces a similar response in cardiac 
muscle [Boluyt et al., 2006]. It is well documented that these proteins which 
include HSP-27, HSP-20, HSP-70 and alpha B crystallin are used as markers of 
pre-slaughter stress in a variety of animals [Morgan et al., poster - Carne 
Technologies, New Zealand; Boluyt et al., 2006]. The expression of HSP-20 
(Table 4.1, spot 15) is up regulated in the IPC hearts, compared to the Non-IPC 
hearts, suggesting that the animals in the IPC group experienced pre-slaughter 
stress before the onset of the experiment. A proteomic study utilizing 2D analysis 
followed by MALDI-TOF mass spectrometry, demonstrated that the expression of 
HSP-20 was increased in an experimental model of heart failure [Cieniewski-
Bernard et al., 2008]. Chronic heart failure was induced in male wistar rats by left 
coronary occlusion. The occlusion was permanent and no reperfusion occurred. 
Increased expression of HSP-20 in this study was associated with left ventricular 
remodeling (LVR), a process that occurs in response to myocardial damage 
[Pfeffer & Braunwald, 1990]. During this process the left ventricle undergoes 
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pathological changes when faced with an acute loss of contractile function 
[Yousef et al., 2002]. These results can explain why an increased expression of 
HSP-20 in the IPC hearts in the present study, may contribute to their poor 
functional recovery.  
 
4.7.10) Heat shock protein-60 
 
Heat shock proteins (HSP) are highly conserved proteins that play important 
roles in the cellular response to stress. HSP may enhance the survival rate of 
stressed cells by increasing the tolerance to stress [Iwaki et al., 1993; 
Fehrenbach et al., 2003]. HSP are also important role players in the emergence 
and development of cardiovascular disease [Snoeckx et al., 2001]. Studies 
demonstrated that HSP-60 localizes in the mitochondria where it has a crucial 
role in folding, unfolding and translocation of mitochondrial and cytosolic proteins. 
[Bukau & Horwich, 1998; Fink, 1999].  Interestingly, expression of HSP-60 (Table 
4.1, spot 8) was down regulated in the present study in the IPC hearts compare 
to Non-IPC hearts. HSP-60 is also associated with psychological stress/trauma in 
animals and associated with transport stress, crowding and pre-slaughter stress. 
[Zhu et al., 2009; Bakau & Horwich, 1998]. Therefore, it may be possible that the 
animals in the Non-IPC group experienced psychological stress before the onset 
of the experiment. Since HSP-60 increases the survival rate of stressed cells  by 
increasing the tolerance to stress, the decreased expression of HSP-60 in the 
IPC hearts however, can explain why these hearts showed poor functional 
recovery during reperfusion. In addition, HSP-60 has a crucial function in folding, 
unfolding and translocation of newly synthesized cytosolic and mitochondrial 
proteins. Downregulation of HSP-60 in the IPC hearts, suggests that these crucial 
functions are attenuated in these hearts and may contribute to poor recovery. 
 
4.7.11) Enoyl CoA hydratase 
 
Enoyl CoA hydratase triggers the metabolic breakdown of the following individual 
amino-acids; the branched chain amino-acids (Isoleucine, Valine and Leucine) 
and also Lysine. Degradation of Valine and Isoleucine by Enoyl CoA hydrates 
lead to the formation of Succinyl-CoA, which is coverted to glucose via 
glucogenesis under the influence of glucocorticoids. Metabolic breakdown of 
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Leucine and Lysine by Enoyl CoA hydratase result in the formation of 
acetoacetate, which can be converted to fatty acid biosynthesis in the cytosol. In 
the present study Enoyl CoA hydratase (spot 19, Table 4.1) is upregulated in the 
IPC hearts compared to the Non-IPC hearts, suggesting that the IPC hearts are 
energy depleted (starved) and as a result non-carbohydrates (both amino-acids 
and acetoacetate) are used as fuel to synthesize glucose and fatty acids 
respectively. These results can explain why the IPC hearts in this part of the 
present study showed poor functional recovery. 
 
 
4.7.12) Transitional endoplamic reticulum ATPase (TER ATPase) 
 
Transitional endoplasmic reticulum ATPase is a member of the ATPase family 
[Ye et al., 2001]. It is a cytosolic protein bound to ER membranes that binds and 
transports ubiquitinated proteins from the ER to the cytosol, where they are 
degraded by the proteasome. This is an ATP dependent process, as 
TER ATPase uses ATP hydrolysis to perform this function. Its major function is 
proteasome mediated protein degradation, but TER ATPase is also involved in a 
wide variety of cellular activities. These include membrane fusion, vesicle 
transport and dissociation of an ubiquitinated membrane transcription factor from 
its non-ubiquitinated binding partner. It prevents excessive DNA synthesis and 
limit the incidence of mutations induced by DNA damage [Ye et al., 2001]. 
 
Stimulation of the Gαq-protein-coupled receptors (GPCR’s) activates 
phospholipase C resulting in the formation of the 2nd messenger inositol 1,4,5-
triphosphate (IP3) and Diacylglycerol (DAG). IP3 diffuses into the cytosol and bind 
to the IP3 receptors located in the membranes of the ER, thereby releasing 
calcium from this organelle. IP3 receptors play therefore a pivotal role in 
converting extracellular stimuli into intracellular calcium signals. In response to 
hormonal stimulation of GPCR’s that persistently elevate the concentration of IP3, 
the cellular level of IP3 are rapidly reduced. This process is known as IP3 
downregualtion and has been shown in various mammalian tissues. 
 
Downregulation of IP3 receptors is a protective mechanism that protects cells 
against the harmfull effects of elevated cytosolic calcium levels as a result of 
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alpha-GPCR stimulation. IP3R downregulation is mediated by the ubiquitin-
proteasome pathway (UPP) and is a form of endoplasmic reticulum associated 
degradation [Alzayady et al., 2005]. TER ATPase associates with IP3 receptor in 
response to hormonal stimulation that induce IP3 receptor ubiquitination.  TER 
ATPase is therefore a protective mechanism that protects cells against the 
deleterious effects of chronic elevated calcium levels [Alzayady et al., 2005]. 
In the present study TER ATPase (spot 22, Table 4.1), was downregulated in the 
IPC hearts compared to the Non-IPC hearts, suggesting the Non-IPC hearts are 
protected against calcium overload during reperfusion. These results suggest that 
downregulation of IP3 by TER ATPase in the IPC hearts was suppressed 
compared to Non-IPC. In addition calcium levels might have been elevated in IPC 
during reperfusion and this can explain why the IPC hearts showed poor 
functional recovery.  
 
4.7.13)  78 kDa Glucose regulated protein (GRP78) 
 
Mammalian cells respond to glucose deprivation by synthesizing a set of proteins 
known as the glucose-regulated proteins, GRPs [Shiu et al., 1997]. GRP78 is an 
endoplasmic reticulum protein and a central regulator of ER function. It plays an 
important role in protein folding and assembly, ER calcium binding and the 
targeting of misfolded proteins for degradation [Chang et al., 1987].  Apart from 
its role as an ER chaperone, GRP78 also functions as an anti-apoptotic protein 
[Zhou et al., 2011]. BCL-2-interacting killer (BIK) is a BH3 only protein and a pro-
apoptotic tumor suppresser. It’s function is regulated at the ER where 
endogenous BIK forms selectively complexes with GRP78, but not with other ER 
chaperones [Zhou et al., 2011]. BIK rely on its BH3 domain to interact with 
GRP78. Overexpression of GRP78 blocks BIK-induced apoptosis by inhibiting 
the release of calcium form the ER stores; Bax translocation to the mitochondria, 
the release of cytochrome c into the cytosol, acticvation of caspases, 
mitochondrial permeability transition and consequent apoptosis [Chang et al., 
1987].  
 
In the present study, GRP78 (spot 23, Table 4.1) is downregulated in the IPC 
hearts compared to the Non-IPC hearts. This may suggest that the IPC hearts 
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are undergoing apoptosis and can explain why they showed poor functional 
recovery. 
 
4.7.14)  Protein disulfide isomerase A3  (PDI-A3) 
 
PDI-A3 is a member of the PDI family of proteins of the endoplasmic reticulum 
and is activated in response to cellular stress [Ni & Lee, 2007]. Its expression 
increases following glucose depletion and it also has a role in calcium regulation 
[Appenzeller-Herzog & Ellgaard, 2008; Turano et al., 2011]. Oxidative stress and 
dysregulation of calcium play an important role in heart failure [Afanas’ev, 2011]. 
It is well known that the NADPH oxidases (Nox), xanthine oxidase, mitochondria 
and nitric oxide synthetases (NOS) are sources of ROS and RNS [Afanas’ev, 
2011]. Nox4 increases the mitochondrial level of superoxide, resulting in 
mitochondrial and LV dysfunction [Afanas’ev, 2011]. Calcium leak from the SR 
and decreased blood flow are associated with increased production of superoxide 
radicals in HF. Both oxidative and hypoxic stresses have been shown to increase 
the expression of PDI-A3 [Toldo et al., 2011]. Increased levels of PDI-A3 is 
associated with HF in both human and animal models. This was linked to calcium 
dysregulation and apoptosis, suggesting a role for PDI-A3 in the progression of 
heart disease [Vitello et al., 2012]. In the present study PDI-A3 (spot 31, Table 
4.1) is upregulated in the IPC compared to the Non-IPC hearts. These results 
suggest that ROS and calcium levels may be increased in the IPC hearts with 
detrimental consequences, resulting in poor recovery. 
 
       
4.8)      Discussion:   Mitochondrial proteomics 
 
Some of the differentially regulated proteins (Table 4.2) will be individually, 
discussed in this section. 
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4.8.1)  Long chain specific acyl CoA dehydrogenase 
 
Acyl CoA dehydrogenases play a role in β-oxidation of fatty acids in the 
mitochondria as discussed in section 4.2. In the present study, the expression of 
long chain specific acyl CoA dehydrogenase  (Table 4.2, spot 3) is increased in 
the IPC hearts. As mentioned before, the expression of fatty acid binding protein 
(Table 4.1, spot 9), responsible for the transport of long chain fatty acids in the 
cell, is down regulated in the IPC hearts. This suggests that fatty acids in the IPC 
hearts accumulate in the cytosol because uptake into the mitochondria is 
retarded.  Alternatively, down regulation of fatty acid binding protein in the IPC 
hearts suggests that fatty acids are transported by a different mechanism than in 
the Non-IPC hearts. In addition, the enhanced β-oxidation of fatty acids in the 
IPC hearts could be responsible for the down regulated expression of glycolytic 
proteins. It is well established that enhanced fatty acid oxidation during 
reperfusion is detrimental for the ischaemic heart. Therefore the increased 
expression of long chain specific acyl CoA dehydrogenase in the IPC hearts 
compared to the Non-IPC hearts in the present study, can explain the poor 
functional recovery of the IPC hearts. 
 
4.8.2)   Complex 1 of the Electron Transfer Chain (ETC) 
 
Mitochondria contain a series of catalysts known as the electron transport chain 
(ETC) that collects and transports reducing equivalents in a final common 
pathway to direct them in a final reaction with oxygen leading to the formation of 
water. These catalysts comprises of NAD-linked dehydrogenase systems, 
flavoproteins and cytochromes. Also present in the ETC is the machinery 
responsible for trapping the generated free energy as high energy phosphate.  
 
Ubiquinone or Q (also known as Complex I or coenzyme Q) is an additional 
carrier present in the ETC linking the flavoproteins to cytochrome b.  Q exists in 
mitochondria in the oxidized quinone form under aerobic conditions and in the 
reduced quinol form under anaerobic conditions. Q serves as the entry point of 
elecrons into the ETC and pass them on to complex III and IV. In the present 
study, expression of Complex 1 or Q (Table 4.2; spot 1) of the ETC is down 
regulated in the IPC hearts. Since Complex 1 serves as the entry point of 
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electrons to the ETC, these results suggest that the ETC may be retarded during 
IPC at 15 min reperfusion, with subsequent detrimental consequences for the 
post-ischaemic hearts. 
 
4.8.3)   Complex V (ATP Synthase) 
 
ATP synthase or complex V of the ETC, also known as the proton pumping 
synthase is the most complex structure in the mitochondrial inner membrane. It 
facilitates proton flux to drive ATP synthesis. The endergonic synthesis of ATP 
from ADP and Pi is catalyzed by ATP synthase, which is driven by the electron 
transport process through complexes I, II and IV. A proteomic study utilizing the 
2D-DIGE technique followed by MALDI-TOF mass spectrometry demonstrated 
that expression of ATP synthase was reduced in the spontaneous hypertensive 
rat, which confirmed the deprivation of ATP production in the very early stages of 
left ventricular hypertrophy before hypertension [Meng et al., 2005]. In the 
present study ATP synthase (spot 6, Table 4.2) is downregulated in the IPC 
hearts compared to the Non-IPC hearts. These results suggest that the ETC is 
not functioning in the IPC hearts, since Complex I, II and IV are also 
downregulated in the IPC hearts. Since the generation of ATP by the ETC is 
crucial for pump function and functioning of the ion channels, these results can 
explain why the IPC hearts showed poor functional recovery in the present study. 
 
4.8.4)   Mitofilin 
 
Mitofilin exists as a large protein complex in the narrow space between the inner 
boundary and the outer mitochondrial membrane where it controls mitochondrial 
cristae morphology. Downregulation of mitofilin was shown to be associated with  
increased apoptosis and abnormal mitochondrial function [John et al., 2005]. 2D 
analysis of mitochondrial proteins in a Langendorff model, using rabbit hearts 
demonstrated that mitofilin was downregulated in IPC hearts compared to Non-
IPC hearts, after 60 min reperfusion [Kim et al., 2006]. These results support the 
results of the present study in which mitofilin (spot 20, table 4.2) was 
downregulated in the IPC hearts compared to the Non-IPC hearts. The increased 
expression of mitofilin in the Non-IPC hearts can be explained as a protective 
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recovery mechanism against ischaemia/reperfusion injury of the mitochondria 
[Kim et al., 2006]. Increased expression of mitofilin is associated with  
maintainance of normal mitochondrial function during stress and protective 
against the collapse of main mitochondrial function. This can offer a possible 
explanation why the Non-IPC hearts (with an increased expression of mitofilin) in 
the present study are metabolically better off than the IPC hearts. 
 
4.8.5)  Heat shock protein 60 (HSP-60) 
 
Heat shock proteins (HSP) are highly conserved proteins that play important 
roles in the cellular response to stress. HSP may enhance the survival rate of 
stressed cells by increasing the tolerance to stress [Iwaki et al., 1993; 
Fehrenbach et al., 2003]. HSP are also important role players in the emergence 
and development of cardiovascular disease [Snoeckx et al., 2001]. It was 
demonstrated that HSP-60 localizes in the mitochondria where it has a crucial 
role in folding, unfolding and translocation of mitochondrial and cytosolic proteins. 
[Bukau & Horwich, 1998; Fink, 1999].  A proteomic study utilizing 2D analysis, 
followed by MALDI-TOF mass spectrometry demonstrated that HSP-60 was 
upregulated in cardiomyocytes by sustained levels of adrenalin [Costa et al., 
2009]. The same study showed that when cardiomyocytes were subjected to  a 
combination of sustained levels of adrenalin and increased levels of ROS, HSP-
60 expression was decreased. The protocol did not include any reperfusion 
[Costa et al., 2009] Interestingly, expression of HSP-60 (Table 4.2, spot 19) was 
down regulated in the present study in the IPC hearts compare to Non-IPC 
hearts. HSP-60 is also associated with psychological stress/trauma in animals 
and associated with transport stress, crowding and pre-slaughter stress. [Zhu et 
al., 2009; Bakau & Horwich, 1998]. Therefore, it may be possible that in the 
present study the animals in both groups (IPC and Non-IPC) experienced 
phsycological stress before the onset of the experiment. Since HSP-60 increases 
the survival rate of stressed cells by increasing the tolerance to stress, the 
decreased expression of HSP-60 in the IPC hearts however, can explain why 
these hearts showed poor functional recovery during reperfusion. 
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4.8.6)  Creatine Kinase M-type (mitochondrial type) 
 
In cardiac muscle the enzyme creatine kinase transports high energy phosphates 
between ATP and creatine. It forms part of a creatine phosphate shuttle that 
transports high energy phosphates from the mitochondria to the sarcolemma. In 
the myocardium this shuttle may be important in affording immediate protection 
against the effects of infarction. A proteomic study utilyzing 2D analysis, followed 
by MALDI-TOF mass spectrometry, demonstrated that the expression of creatine 
kinase M-type was increased in cardiomyocytes subjected to sustained elevated 
levels of adrenaline. This was accompanied by decreased expression of 
glycolytic enzymes and the protective HSP-60, HSP-70 and Alpha ß-Crystallin 
[Costa et  al., 2009]. The protocol did not include any reperfusion. In the present 
study the expression of creatine kinase was increased in the IPC hearts (spot 15, 
Table 4.2) compared to the Non-IPC hearts.  
 
4.8.7)  Aconitase 
 
Mitochondrial Aconitate hydratase (Aconitase) catalyzes the reaction of reversible 
isomerization of citrate to isocitrate. This reaction is the initiating step of the TCA 
cycle. Aconitase bind the mitochondrial chaperones HSP-70, HSP-60 and HSP-
40, very specificly, resulting in the formation of a stable complex [Matasova & 
Poppova, 2008]. The function of Aconitase is mainly to regulate citrate 
accumulation and to direct it to lipogenesis. There upon it affects the level of free 
fatty acids. Aconitase also functions as a neurotransmitter. Aconitase is very 
sensitive to ROS and can influence the formation of ROS under conditions of 
oxidative stress, such as ischaemia in the following ways: (1) inhibition of the 
initiating stage of the TCA (2) change the reduction of the carriers of the 
mitochondrial respiratory chain, (3) influence the intensity of lipogenesis and the 
pool of free fatty acids and as a result provide uncoupling of respiration and 
phosphorylation [Matasova & Popova]. A proteomic study utilizing 2D-DIGE 
followed by MALDI -TOF mass spectrometry demonstrated that Aconitase was 
upregulated in spontaneous hypertensive rats. This study showed that the 
increased expression of Aconitase contributed to the development of cardiac 
hypertrophy [Meng et al., 2009]. A different proteomic study utilizing 2D 
Stellenbosch University  http://scholar.sun.ac.za
  170
proteomics, followed by MALDI-TOF mass spectrometry, showed that the 
expression of Aconitase was upregulated in cardiomyocytes subjected to 
sustained elevated levels of adrenalin. The protocol did not include any 
reperfusion [Costa et al., 2009]. The sustained levels of catecholamines and ROS 
are well recognized hallmarks of several pathological conditions like  
ischaemia/reperfusion injury and heart failure [Behonick et al., 2001; Bindoli et 
al., 1992]. In this particular study the  increased expression of Aconitase  was 
associated with pathological levels of adrenaline [Costa et al., 2009]. In the 
present study Aconitase is upregulated in the IPC hearts (spot 25, Table 4.2)       
compared to the Non-IPC hearts. These adverse effects of increased  expression 
of Aconitase can explain why the majority of ETC carriers are downregulated in 
the IPC hearts. It can also explain the increase in generation of free fatty acids in 
the IPC hearts, with the subsequent decrease in glycolytic enzymes. The 
increase in fatty acids can lead to uncoupling of respiration from oxidative 
phosphorylation in the IPC hearts. Taken together this can explain why the IPC 
hearts are comprimized  at a metabolic level.  
 
4.8.8)    Heat shock protein-70 (HSP-70) 
 
HSP-70 is a member of the heat shock protein family as discussed and serves as 
a molecular chaperone. It plays a major role in protecting cells against different 
cellular stressors, such as heat, hypoxia, oxidative stress, ultraviolet irradiation, 
apoptosis and necrosis [Zhang et al., 2012].  Despite its protective functions, 
HSP-70 is also used as a marker of pre-slaughter stress in animals [Bao et al., 
2008; 2002; Cvoro et al., 1998]. A proteomic study utilizing 2D-DIGE followed by 
MALDI-TOF mass spectrometry demonstrated that HSP-70 was upregulated in 
34 patients suffering from chronic heart failure [Wei et al., 2009]. This increased 
expression of HSP-70 in the cardiac tissue was accompanied by an elevation of 
circulating HSP-70 in heart failure patients. These patients suffer from the 
following cardiomyopathies; arrhythmogenic right ventricular cardiomyopathy 
(ARVC), dilated cardiomyopathy (DCM) and ischaemic cardiomyopathy (ICM). A 
different proteomic study utilyzing 2D proteomics followed by MALDI-TOF mass 
spectrometry, demonstrated that HSP-70 was downregulated in cardiomyocytes 
subjected to sustained pathological levels of adrenaline [Costa et al., 2009]. The 
protocol did not include reperfusion [Costa et al., 2009]. In the present study, 
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HSP-70 expression (Table 4.2, spot 7) was down regulated in IPC compared to 
Non-IPC. Since the present study was carried out with normal healthy animals 
these results suggest that the animals in both groups (IPC and Non-IPC) 
experienced psychological stress before the onset of the experiment. The Non-
IPC hearts had the ability to induce a protective strategy by increasing the 
expression of the protective HSP-70 family of proteins. The IPC hearts, on the 
other hand were unable to increase the expression of the protective HSP-70 
family of proteins, possibly due to the increased formation of ROS as a result of 
the multiple episodes of ischaemia. These results can explain the poor recovery 
of the IPC hearts. 
  
4.8.9)  Alpha β-Crystallin  
 
Alpha β-crystallin is a member of the small heat shock protein family that 
functions as chaperones contributing to cell survival. It also acts as an anti-
oxidant and free radical scavenger. The expression levels of alpha β-crystallin 
are high in cardiac muscle. It comprises 3% of total cardiac protein content. It is 
well documented that the heat shock protein family are upregulated in response 
to psychological  stress. A proteomics study, utilizing 2D analysis combined with 
MALDI-TOF mass spectrometry demonstrated increased expression of alph ß-
Crystallin in the presence of sustained levels of adrenaline in a cardiomyocyte 
model without reperfusion [Costa et al., 2009]. In the same study the expression 
of alpha β-Crystallin was decreased when sustained levels of adrenaline was 
combined with increased levels of ROS [Costa et al., 2009]. The expression of 
alpha β-crystalline (Table 4.2, spot 17) is upregulated in Non-IPC compared to 
IPC. The pro-survival functions of alpha β-crystalline mentioned above can 
explain why the Non-IPC hearts are metabolically advantaged compared to the 
IPC hearts. Interestingly, alpha β-crystallin was shown to be activated by p38 
MAPK [Aggeli et al., 2008] and in the present study, p38 MAPK was significantly 
activated in Non-IPC compared to IPC at 15 min reperfusion. This finding [Aggeli 
et al., 2008] therefore supports our results. 
 
4.8.10)  Short Chain Specific Acyl-CoA dehydrogenase 
 
Fatty acids can be metabolized by different mechanisms. Long chain fatty acids 
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are degraded by β-oxidation in the mitochondria, while short chain fatty acids are 
degraded by omega oxidation. It is normally a very minor pathway and  involves 
P-450 in the endoplasmic reticulum [Wanders et al., 2010]. Short chain specific 
acyl-CoA dehydogenases play a role in this process. Short chain specific acyl 
CoA is upregulated in IPC hearts (Table 4.2, spot 9), compared to Non-IPC, 
suggesting that fatty acids are metabolized by omega-oxidation in IPC. β-
oxidation is the preferred pathway for the metabolism of fatty acids and yield 
more high energy phosphates, but omega oxidation becomes important when β-
oxidation in the mitochondria is impaired [Wanders et al., 2010], as seen in IPC in 
the present study. These results can explain why the IPC hearts are metabolically 
disadvantaged compared to the Non-IPC hearts in the present study. 
 
4.8.11)  Aldehyde dehydrogenase 
 
The expression of aldehyde dehydrogenase (Table 4.2, spot 18) is up regulated 
in IPC compared to Non-IPC. Aldehyde dehydrogenase is also involved in omega 
oxidation of fatty acids in the endoplasmic reticulum [Nelson & Cox, 2005], in light 
of the above mentioned, this result supports our earlier finding that beta oxidation 
is compromized in the IPC hearts, resulting in the accumulation of fatty acids 
during reperfusion. These results can explain why the IPC hearts are 
metabolically compromized in the present study. 
 
4.8.12)  Malate dehydrogenase 
 
Cytosolic malate dehydrogenase is involved in gluconeogenesis by catalyzing  
the production of oxaloacetate from malate. Malate is produced from 
oxaloacetate in the mitochondria and diffuses from the mitochondria into the 
cytosol where it is converted back to oxaloacetate, leading to the formation of 
phosphoenolpyruvate. Phosphoenolpyruvate is involved in the reversal of 
glycolysis resulting in the production of glucose. This process forms part of the 
gluconeogenesis pathway, whereby non-carbohydrates are converted to glucose 
under energy deprived situations when glycolysis is inhibited.  
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A proteomic study utilizing 2D-DIGE followed by MALDI -TOF mass spectrometry 
demonstrated that Malate dehydrogenase was upregulated in spontaneous 
hypertensive rats. This study showed that the increased expression of Malate 
dehydrogenase contributed to the development of cardiac hypertrophy [Meng et 
al., 2009]. A different proteomic study utilizing 2D analysis combined with MALDI-
TOF mass spectrometry demonstrated that expression of Malate dehydrogenase 
was upregulated in myocytes subjected to sustained elevated levels of 
adrenaline. The protocol did not include reperfusion [Costa et al., 2009]. In the 
present study, expression of malate dehydrogenase (Table 4.1, spot 16) was 
upregulated in IPC compared to Non-IPC, suggesting that IPC utilized the 
gluconeogenic pathway in order to replenish the shortage of glucose. Since 
gluconeogenesis is the preffered metabolic pathway in the IPC hearts instead of 
glycolosis, this can explain why the IPC hearts are metabolically disadvantaged 
in the present study. These results also suggest that animals in both groups (IPC 
and Non-IPC) experienced psycological stress, but the Non-IPC hearts could 
adapt by upregulation of the glycolytic enzymes.  
 
4.8.13)  Nucleoside Diphosphate kinase 
 
Nucleoside Diphosphate kinase (NDPK) catalizes the non-substrate specific 
conversion of nucleoside diphosphates to nucleoside triphosphates [Zhou & 
Artman, 2001]. It has been found in the hearts of many species, where it 
participates in a wide range of biological functions including gene regulation, 
development, growth and signal transduction [Heidbuchel et al., 1992]. The 
expression and activation of NDPK in the heart is regulated by β-adrenergic 
signaling [Lutz et al., 2003]. NDPK catalizes the transfer of terminal phosphate 
groups from 5’-triphosphate to 5’-diphosphate nucleotides. The main reaction is 
the synthesis of GTP from ATP, to maintain levels of GTP, required for activation 
of G proteins [Otero 1990; Kimura 1993; Piacentini & Niroomand 1996]. A study 
by Niroomand and his group demonstrated that both expression levels and 
activation of NDPK are significantly increased in failing human hearts compared 
to normal non-failing controls [Lutz et al., 2001]. Patients treated with β-blockers 
who underwent cardiac surgery had a 65% lower DNPK content compared to 
those who had no β-blocker therapy [Lutz et al., 2001]. The lower levels of DNPK 
were associated with a reduced DNPK- dependent Gi-mediated inhibition of 
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adenylyl cyclase activity. Rats treated with a β-adrenergic agonist, isoproterenol 
developed myocardial hypertrophy. This was accompanied by an increase in 
DNPK levels by 60%. Treatment with the β-blocker propranolol prevented the 
development of cardiac hypertrophy and DNPK levels did not rise [Lutz et al., 
2001]. Taken together, these results demonstrated that chronic stimulation of the  
β-adrenergic receptors increase DNPK levels. This pathway provides a 
mechanism that compensates in part for the downregulation of β-receptors that 
paralleled chronic β-stimulation in order to modulate cAMP levels independent of 
receptor-G-protein interaction [Zhou & Artman, 2001]. In the present study, the 
expression of DNPK (spot 17, Table 4.2] was upregulated in the IPC hearts 
compared to the Non-IPC hearts. This finding may suggest that the IPC hearts 
underwent chronic β-stimulation followed by desensitization of the β-receptors. 
This can explain the poor functional recovery (contractile function) of the IPC 
hearts.  
 
4.8.14)  Generation of amino acids 
 
The expression of proteins involved in the metabolic breakdown of amino acids 
was up regulated in IPC compare to Non-IPC. Expression of dihydrolipoyl 
dehydrogenase (Table 4.2, spot 5) is up regulated in IPC and similarly the 
expression of mercaptopyruvate sulfurtransferase (Table 4.2, spot 10). Amino 
acids can fuel the Krebs cycle by entering the cycle at several entry points and 
thereby enhance glucose biosynthesis via gluconeogenesis as a result of  
glucocorticoid secretion. This supports the rest of the data which demonstrate 
that glycolosis is attenuated in the IPC hearts and can explain why the IPC hearts 
is metabolically disadvantaged in the present study. 
 
 
4.8.15)   Annexin A3 
 
The annexins are a family of proteins which are involved in a variety of cellular 
processes, including inflammation, apoptosis, membrane fusion, proliferation and 
differentiation [Gerke et al., 2002].  Annexin A3 is a physiological regulator of 
angiogenesis [Park et al., 2005]. Angiogenesis is the process whereby new blood 
vessels are generated from existing ones. It occurs under normal, but also 
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pathological conditions. Physiological angiogenesis is critical for wound healing, 
development and reproduction [Park et al., 2005]. Studies demonstrated that 
annexin A3 induces the migration and tube formation of human umbilical vein 
endothelial cells. In addition, expression of annexin A3 activates HIF-1 activity, 
suggesting that annexin A3 promotes up regulation of the HIF-1 signaling 
pathway which is also involved in angiogenesis [Park et al., 2005]. HIF-1 
prevents cardiac and tissue damage as a result of ischaemia by inducing 
angiogenesis thus increasing oxygen delivery to the area. In the present study, 
expression of annexin A3 (Table 4.2, spot 13] is increased in Non-IPC compare 
to IPC, suggesting that oxygen delivery to the post-ischaemic area may be  
increased in Non-IPC hearts.   
 
Taken together, the results from the cytosolic and mitochondrial data generated 
in the present study suggest the following modifications of the metabolism in the 
IPC hearts: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which is a 
key energy regulator of glycolysis in the cardiomyocyte is down regulated in the 
IPC hearts (Table 4.1, spot 18). This enzyme is normally down regulated during 
ischaemia since ischaemia uncouples glycolysis from oxidative phosphorylation 
[Opie, 1998]. This is due to the low oxygen levels that suppress the ETC, which 
in turn inhibits the transfer of NADH and H+ to the mitochondria.  Accumulation of 
NADH and H+ in the cytosol inhibits GAPDH and thus glycolysis [Opie, 1998]. 
Removal of NADH from the cytosol to the mitochondria during early reperfusion is 
thus essential to maintain the levels of GAPDH and thus sustain glycolysis.  
Transfer of NADH from the cytosol to the mitochondria is normally facilitated by 
lactate dehydrogenase (LDH), which is down regulated (Table 4.1, spot 28) in the 
IPC hearts. As a result NADH will accumulate in the cytosol, which inhibits LDH 
further and thus GAPDH and glycolysis, resulting in damage to the myocardium 
[Neely & Grotyohan, 1984].  The protective mechanism of LDH mediated removal 
of NADH is sometimes limited as a result of poor waste removal when the 
myocardium is inadequately reperfused. Since this study was carried out at 15 
min reperfusion, it is expected that waste removal (lactate accumulated during 
ischaemia), in the now perfused myocardium of the IPC hearts should have been 
sufficient. In addition, lactate inhibits PDH and inhibits glucose uptake [Depré, 
Rider & Hue, 1998]. Therefore, different substrates (fatty acids, amino acids and 
lactate) are utilized by the IPC hearts as an alternative source of energy. In 
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addition, down regulation of PDH may switch pyruvate metabolism towards 
oxaloacetate in order to replenish the Krebs cycle intermediates and switch the 
cycle towards glucose biosynthesis via gluconeogenesis as a result of 
glucocorticoid (corticosterone) stimulation [Stanley et al., 1997; Taegtmeyer 
1994].   
 
Another factor that can contribute or might be responsible for the down regulation 
of glycolysis in the IPC hearts is the upregulation of the oxidation of fatty acids. 
The fatty acid transporter is downregulated in the IPC hearts, suggesting that 
fatty acids may accumulate in the cytosol. Since it is generally accepted that fatty 
acids decrease cardiac efficiency [Challoner & Steinberg, 1966], the build-up of 
fatty acids in the cytosol may be detrimental to the IPC hearts.  
 
Studies in the isolated working heart demonstrated that fatty acid oxidation 
inhibits glycolysis to a greater extent than what glycolysis can inhibit fatty acid 
oxidation; however, the heart functions best when it oxidizes two substrates 
simultaneously [Taegtmeyer et al., 1980]. It is generally accepted that fatty acids 
decrease cardiac efficiency [Challoner & Steinberg, 1966].  The main reason for 
contractile dysfunction is thought to be the delayed clearance of protons from the 
cell. One hypothesis is that increased glucose oxidation during reperfusion 
reduces the proton load and improves functional recovery [Challoner & Steinberg, 
1966; Burkhoff et al., 1991]. 
 
In the present study, four mitochondrial proteins associated with electron transfer 
in the ETC are down regulated in the IPC hearts, suggesting that the ETC and 
oxidative phosphorylation may be attenuated. Oxidative phosphorylation in the 
mitochondria is the main source of ATP generated for cardiac contractile function 
[Bugger et al., 2010]. It is well documented that impairment of mitochondrial 
function contributes to mechanical dysfunction in numerous cardiac disease 
states [Bugger et al., 2009; Rosca et al., 2008; Lesnefsky et al., 2001]. These 
results could offer a possible explanation of the underlying causes (mechanisms 
involved) or factors contributing to poor functional recovery of the IPC hearts after 
15 min reperfusion.  
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In addition, results from this study demonstrated that the gluconeogenesis 
pathway is upregulated in IPC compare to Non-IPC. Gluconeogenesis is 
stimulated by the glucocorticoids, which is known to inhibit glycolysis. It is well 
documented that the production of corticosterone is enhanced in animals during 
stressfull events, such as crowding, transportation and pre-slaughter stress. 
Alpha β-crystallin, HSP-27, HSP- 60, HSP-70 associated with pre-slaughter 
stress are upregulated in Non-IPC and HSP-20 associated with pre-slaughter 
stress is upregulated in IPC.  These results indicate that animals in both groups 
experienced psychological stress before the hearts were excised, but the Non-
IPC could counteract the stress, as indicated by the unaltered metabolism.  
 
Expression of NDPK was increased in the IPC hearts: This pathway provides a 
mechanism that compensates in part for the downregulation of β-receptors that 
paralleled chronic β-stimulation in order to modulate cAMP levels independent of 
receptor-G-protein interaction [Zhou & Artman, 2001].  The contractile proteins 
Troponin T and Myosin Light chain 3 were downregulated  in the IPC hearts, 
supporting possible downregulation of the β-receptor.   
 
Expression of anti-apoptotic proteins were increased in Non-IPC hearts compare 
to IPC hearts, suggesting that apoptosis was induced in IPC hearts.  
 
4.9)  Conclusion 
 
Here we demonstrated the use of 2-DE proteomics for detection of significant 
differences in protein expression levels between IPC and Non-IPC hearts during 
early (15 min) reperfusion. It is generally believed that IPC is a β-receptor 
dependent process [Lochner et al., 1999; Kovanecz et al., 1996]. Previous 
studies supported these findings that stimulation with the β-agonists 
norepinephrine or isoproterenol mimics IPC [Asimakis et al., 1994]. Studies 
performed in our laboratory showed no evidence that the α-adrenergic receptor 
or the PKC signal transduction pathway is involved in IPC-induced protection 
[Moolman et al., 1996]. 
 
Results from the present study however, suggest that animals in the IPC group 
experienced chronic β-stimulation, as a result of psychological stress, followed by 
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downregulation and desensitizing of the β-receptors. This resulted in signaling 
through α-adrenergic receptors which was accompanied by suppression of 
contractility and a subsequent attenuation of  MAPK signaling in IPC hearts. The 
α-adrenergic receptor is a G-protein-coupled receptor (GPCR) associated with 
the Gq heterotrimeric G-protein. The catecholamines like noreprinephrine 
(noradrenaline) and epinephrine (adrenaline), which are known β-receptor 
agonists also signal through the α-adrenergic receptor. Upon activation of the 
alpha-Gq receptor by norepinephrine and epinephrine the 2nd messenger inositol 
1,4,5-triphosphate (IP3) and Diacylglycerol (DAG) is generated. IP3 diffuses into 
the cytosol and bind to the IP3 receptors located in the membranes of the ER, 
thereby releasing calcium from this organelle. Under normal conditions 
downregulation of the IP3 receptor occur to protect the cell against the harmfull 
elevated levels of calcium. The results from the present study indicate that 
downregulation of the IP3 receptor failed, resulting in calcium overload in the IPC 
hearts.  
 
In addition, results suggest that the ETC and oxidative phosphorylation may be 
attenuated. Oxidative phosphorylation in the mitochondria is the main source of 
ATP generated for cardiac contractile function [Bugger et al., 2010]. It is well 
documented that impairment of mitochondrial function contributes to mechanical 
dysfunction in numerous cardiac disease states [Bugger et al., 2009; Rosca et 
al., 2008; Lesnefsky et al., 2001]. Mitochondrial dysfunction gives rise to the 
accumulation of ROS and causes oxidative stress. As a result oxidative stress 
stimulates cardiac hypertrophy through a variety of hypertrophy signaling 
cascades and transcription factors [Takimoto & Kass 2007; Sabri et al., 2003]. 
Studies have shown that downregulation of complexes I, III, IV and V in 
mitochondria were the source of elevating damaging free radicals [Roche et al., 
2009] and was associated with elevated blood pressure and decreased ATP 
synthesis [Lopez-Campistrous et al., 2008]. Studies have shown that the 
following factors, a decrease in cellular ATP levels, accumulation of hydrogen 
ions, calcium overload and the production of ROS, contribute to 
ischaemia/reperfusion injury [French et al., 2006; Zweier et al., 2006].  
 
Taken together, the data from the present study suggest that the IPC hearts 
experienced extreme or even possibly irreversible ischaemia, whereas the Non-
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IPC hearts experienced only mild and reversible ischaemia. During early 
ischaemia in animals models, there is a variable and possibly predominant 
element of reversibility with eventually irreversibility. The term ischaemia was first 
used by Rudolf Virchow in 1858. The concept was described as the limitation of 
blood supply with an increased resistance to flow. Myocardial ischaemia exists 
when the reduction of coronary flow is so severe that the oxygen supply to the 
myocardium is inadequate to meet the required demands of the cardiac tissue. 
Two phases of the adaptation of the oxygen deficient tissue are proposed: 
namely short-term defence and long term rescue [Hochachka et al., 1996]. The 
aim of short term defence is to achieve a new balance between oxygen demand 
and supply. This is achieved by a combination of a downregulation of contraction 
and upregulation of anaerobic energy production by glycolosis to compensate in 
part for oxidative metabolism. The aim of long term rescue is to enduce a series 
of cellular signals that lead to protective genetic reprogramming. These long term 
adaptations may account for unexpected protective reactions to ischaemia, such 
as the synthesis of new proteins, as demonstrated in the Non-IPC hearts. The 
metabolic consequences of myocardial ischaemia can be divided into 2 major 
processes: 1) those caused by inadequate oxygen supply 2) and those caused 
by inadequate washout of the metabolites of ischaemia. Common to both 
processes is an increase of cytosolic calcium. 
 
In animal models there is rapid recovery from ischaemia that is not accompanied 
by contracture. The period after potentially reversible ischaemia (early 
reperfusion) is associated with an intracellular accumulation of protons as well as 
sodium and calcium ions. Decreasing the proton load during early reperfusion by 
implementing sodium-proton exchange inhibitors have shown a more rapid 
recovery from ischaemia. These results from numerous studies suggest that 
operation of this exchanger help to normalize the cell’s pH [Liu et al., 1996; 
Vandenberg 1993]. Several metabolic changes occur during recovery from 
ischaemia (early reperfusion); 1) Mitochondrial metabolism is depressed (as seen 
in the IPC group);  2) fatty acids appear to compete better than glucose for this 
residual metabolism (as seen in the IPC group); 3) Glycolysis is depressed (as 
seen in the IPC group). Glycolysis is beneficial and not harmfull during 
reperfusion, since it supply energy for the calcium uptake pump of the 
sarcoplasmic reticulum, thereby decreasing the internal calcium load 
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accumulated during ischaemia [Jeremy, 1992]. A study by Sebbag and 
coworkers in 1996, indicated that a decrease in glycolysis markedly accelerated 
cell death in dogs  after coronary occlusion. Thus a decrease of glycolysis during 
reperfusion is postulated to be a crucial factor in the progression of reversible 
ischaemia to ischaemic cell necrosis. The upregulation of glycolytic enzymes in 
the Non-IPC hearts in the present study suggest beneficial effects. The 
mechanisms whereby reversible ischaemic damage developes into irreversible 
infarction are: 1) loss of a critical amount of ATP; 2) membrane damage induced 
metabolically or mechanically; 3) formation of free radicals; 4) calcium overload 
and 5) sodium pump inhibition. Inhibition of the sodium pump may result in an 
excess of internal sodium, which in turn leads to an increase in osmotic pressure, 
which helps to rapture the cell membrane and to cause irreversible damage. The 
proposed cause of pump failure was an inadequate synthesis of sufficient 
glycolytic ATP for the functioning of the sodium pump [Cross, 1995]. Membrane 
damage includes 1) accumulation of free fatty acids inside and outside of 
ischaemic cells. Part of the membrane damage results from the action of 
phospholipases that brake down membrane lipids. The resulting 
lysophosphoglycerides further promote membrane damage 2) lipid peroxide 
formation by oxygen free radicals. Free radicals are derived in part from 
neutrophils particularly during the reperfusion phase of ischaemic damage and in 
part from damaged cardiomyocyte mitochondria. The concept of calcium 
overload resulting in irreversible ischaemic damage has received special 
prominence in relation to conditions of massive calcium overload, such as 
catecholamine stimulation and severe reperfusion damage. This was illustrated 
by the experimental condition described as the calcium paradox. This entails the 
total removal of extracellular calcium after which calcium is re-introduced, 
causing massive cellular damage. The basic concept of calcium overload is that 
the mitochondria takes up calcium from the cytosol, thereby acting as a  buffer. 
This process requires a considerable amount of energy. When energy depletion 
is enhanced, the energy required for maintenance of of ionic gradients becomes 
inadequate and membrane integrity is lost. During ischaemia cytosolic calcium 
levels increase and this is accompanied by activation of phospholipases, 
increasing resting tension and promotion of fatal arrhythmias [Lubbe 1992]. 
Therefore, irreversible injury probably depends on no single metabolic event, but 
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may be a complex phenomenon resulting from the simultaneous operation of 
many diverse mechanisms. 
 
Earlier studies identified emotional and physical stress as triggers in up to half of 
the cases of AMI in humans, as a result of increased adrenergic activation, 
originating from either intense arousal or severe physical exercise [Tofler, 1990].    
Later studies revealed a link between psychological stress and sudden death, 
resulting from cardiac complications [Lampert, 2009]. The mechanisms for the 
adverse adrenergic effects as a result of chronic beta stimulation, may include a 
series of events which include 1) an increased heart rate and contractility 
increases oxygen demand (MVO2) and promotes ischaemia; 2) Increased arterial 
blood pressure which is associated with an increased cardiac output which 
increases alpha-adrenergic mediated peripheral vascular resistance which 
axaggerates ischaemia and damages the vascular endiothelium and 3) The 
increased circulation of free fatty acids have harmful effects on membranes and 
promote platelet aggregation. All these links to the onset of AMI and even if AMI 
is not triggered, there is an early increase in circulating catecholamine levels. 
Much evidence supports the concept that excessive beta-adrenergic activation 
can exaggerate the degree of myocardial ischaemia [Verrier et al., 1974; Lown et 
al., 1973; Corbalan et al., 1976]. An increase in heart rate increases the severity 
of ischaemic injury [Schaper, 1987; Verrier et al., 1974] and increases the 
incidence of reperfusion arrhythmias [Lederman, 1987]. Studies indicated that 
two agents known to reduce heart rate, namely propranolol and the calcium 
antagonist diltiazem, decreased reperfusion calcium uptake in the case of 
propranolol [Miyazawa 1986] and reperfusion arrhythmias [Tosaki & Hearse, 
1987]. 
 
Energy metabolism is enhanced in animals during stressful events and is a 
characteristic of the “fight or flight” response and lead to deprivation of energy 
stores as seen in the IPC hearts (glycolosis is attenuated and glucose and fatty 
acid biosynthesis is enhanced). Since the animals in both groups experienced 
psychological stress and only the IPC group are energy deprived, it could be that 
the multiple short episodes of ischaemia of the IPC protocol, utilized or consume 
more energy via anaerobic glycolosis and depleted the energy stores of the IPC 
hearts compared to the Non-IPC hearts. As a result the IPC hearts had lower 
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energy stores at the start of sustained ischaemia to keep the ischaemic tissue 
viable via anaerobic glycolosis during the 25 min of sustained ischaemia.  
 
These results indicate that animals in both groups experienced psychological 
stress before the hearts were excised, but the non-IPC could reverse the stress, 
as indicated by the unaltered metabolism and also by upregulating the protective 
heat shock proteins and anti-apoptotic proteins. The results suggest that 
psychological stress may cause the IPC hearts to be more susceptible to 
ischaemic damage during the period of sustained ischaemia and increased 
oxidative stress compared to non-IPC hearts. In addition, we could also identify 
the proteins responsible for the downregulation of the MAPK signaling pathway in 
the IPC hearts.  
 
Taken together, these results demonstrated that an IPC heart which failed after 
ischaemia /reperfusion is metabolically compromized and “worse off” compared 
to a non-IPC heart. To our knowledge this is the only study that investigated this 
aspect in the context of IPC during reperfusion. 
 
In addition, the results from this part of the study suggests that enhanced 
psychological stress and consequent increase in sympathetic stimulation (before 
repetitive short episodes of ischaemia) can result in poor recovery of the heart, 
after a prolonged period of sustained ischaemia.  
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Chapter 5 
 
An investigation of the variable signaling patterns of 
kinase activation before and after IPC and in control 
hearts before and after an ischaemic insult. 
 
5.1)  Introduction 
 
Studies addressing the signal transduction pathways involved in cardioprotection 
by ischaemic preconditioning have focused increasingly on the role of the 
prosurvival kinases, including the PI3-kinase pathway and the extracellular 
signal-regulated kinases (ERK1/2). This is not surprising, since Hausenloy and 
co-workers (2005) have demonstrated that the cardioprotective effects of 
ischaemic preconditioning is completely abolished by inhibition of the RISK 
pathway. Furthermore, there is also increasing evidence that the cardioprotection 
afforded by preconditioning occurs during the early reperfusion phase after index 
ischaemia [Hausenloy et al., 2007]. 
 
The golden standard of the effectiveness of preconditioning is the reduction of the 
infarct size. However, there is also a series of other benefits obtained from 
preconditioning and among these is better recovery of post-ischaemic left 
ventricular function [Shiki & Hearse, 1987; Przyklenk, 2000; Yellon & Downey, 
2003]. 
 
According to the literature, functional recovery of the ischaemic heart in IPC is 
associated with an attenuation of p38 activation after 30 min reperfusion [Marais 
et al., 2001]. However, our results did not follow the expected pattern of p38 
MAPK activation, but showed variable responses between different animals. 
PKB/AKT also showed variable responses of activation between different 
animals, but to a lesser extent as p38 MAPK. However, in some groups of 
animals activation of the RISK pathway followed the same trend as activation of 
p38 MAPK.  
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This may suggest that:  
 
(1) an attenuation of p38 MAPK kinase activation in IPC during reperfusion is 
detrimental to the ischaemic heart. The results in Chapter 3 of the thesis 
demonstrated that an attenuation of p38 MAPK in the IPC group after 15 min 
reperfusion is associated with an attenuation of both the protective PKB and 
HSP-27. This was accompanied by an attenuation in glucose metabolism and an 
upregulation of fatty acid metabolism, as demonstrated in Chapter 4 of the thesis.  
 
(2) activation of the protective RISK pathway in the IPC group during 30 min 
reperfusion is not associated with functional recovery. The results in Chapter 3 of 
the thesis demonstrated that the RISK pathway was activated in the non-IPC 
hearts at 30 min reperfusion and was therefore associated with failing hearts. 
 
In view of the above and to confirm the results obtained in Chapters 3 and 4, the 
aims of this part of the study were: 
 
1) to correlate kinase activation with functional recovery in the IPC groups at 30 
min reperfusion, 
 
2) to investigate and identify the factors responsible for (or relating to) the 
variable responses of kinase activation observed in: (a) the IPC groups after 
reperfusion and directly after the IPC protocol before sustained ischaemia (b)  
Control hearts before and after sustained ischaemia. 
 
5.2  Methods (Figure 5.1) 
 
(i) Control: Hearts were stabilized for 60 min (15 min retrograde, 15 min working 
heart and 30 min retrograde). The haemodynamic parameters of the hearts were 
recorded after 15 min working heart as indicated by the dashed arrows, as 
indicated in Fig. 5.1. Hearts were snap-frozen for Western blotting analysis, as 
indicated by the solid arrows (Fig.5.1).  
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ii) 25 min sustained ischaemia: Hearts were stabilized for 60 min (15 min 
retrograde, 15 min working heart and 30 min retrograde), followed by 25 min 
global sustained ischaemia. The haemodynamic parameters of the hearts were 
recorded after 15 min working heart, as indicated by the dashed arrows (Fig. 5.1). 
Hearts were snap-frozen for Western blotting analysis, as indicated by the solid 
arrows (Fig.5.1).  
 
iii) Ischaemic preconditioning (IPC): Hearts were stabilized for 30 min (15 min 
retrograde, 15 min working heart) and then preconditioned by 3x5 min global 
ischaemia, alternated with 5 min reperfusion. Hearts were subjected to 25 min 
sustained global ischaemia, followed by 30 min reperfusion (10 min retrograde 
perfusion and 20 min working heart). After 30 min reperfusion, the 
haemodynamic parameters of the hearts were recorded (indicated by the dashed 
arrows) and hearts were snap-frozen for Western blotting analysis, as indicated 
by the solid arrows in Fig.5.1. The haemodynamic parameters of the hearts were 
recorded after 15 min working heart, as indicated by the dashed arrows (Fig. 5.1). 
In order to investigate shorter reperfusion periods, hearts were snap-frozen at 5 
and 10 min reperfusion, as indicated by the solid arrows in Fig. 5.1.  In order to 
study events during the IPC period in the absence of sustained ischaemia and 
reperfusion, hearts were snap-frozen directly after the IPC period, indicated as 
3xIPC (solid arrows in Fig.5.1).  
 
iv) Non-preconditioning (non-IPC): Hearts were stabilized for 60 min (15 min 
retrograde, 15 min working heart and 30 min retrograde perfusion). 
Haemodynamic recordings were made at 15 min working heart as indicated by 
the dashed arrows in Fig. 5.1. Hearts were subsequently subjected to 25 min 
sustained global ischaemia followed by 30 min reperfusion (10 min retrograde 
perfusion and 20 min working heart). After 30 min reperfusion, haemodynamic 
recordings were made (dashed arrows) and hearts were snap-frozen for Western 
blotting analysis, as indicated by the solid arrows in Fig.5.1. 
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 Control, 25 min sustained ischaemia and non-IPC hearts:                                                                      Recordings 
                                                                                                                           Retrograde             Working heart                                           
 Retrograde     Working heart                Retrograde                           Sustained ischaemia                        Reperfusion       
  Retrograde     Iscmic preconditioned hearts: 
 
                                                                                                                                                                    non-IPC  30 min reperfusion 
                                Recordings                           Control              25 min sustained ischaemia                        
 
                                                                                                                                                                         Recordings 
  
 Retrograde     Working heart               Preconditioning                     Sustained ischaemia        Retrograde             Working heart                
                                                                                                                                                                    Reperfusion 
 
 
                                        Recordings               3xIPC                                            5 min            10 min                             30 min reperfusion 
 
 
                                                                                              
                                                                  
Figure 5.1 Experimental protocol according to a timeframe (min) indicating at which time intervals (indicated by solid arrows,   ), hearts were 
snap-frozen for western blot analysis. Functional recordings  were made after 15 min working heart and 30 min reperfusion as 
indicated by the dashed arrows (    ).   
Ischaemic preconditioned  hearts: 
0                  15                  30    35    40    45     50    55    60                                      85      90      95     100    105               115   min 
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5.3)  Results 
 
5.3.1  The variable patterns of p38 MAPK activation in three IPC groups 
after 30 min reperfusion (Figures 5.3.1 A, B and C). 
 
Results from the present study did not follow the expected pattern of MAPK 
activation after 30 min reperfusion, but showed variable responses between 
different animals. All of these hearts (n=23 animals), from three different IPC 
groups showed functional recovery after the ischaemic insult. 
 
5.3.2  The variable patterns of p38 MAPK, ERK and PKB/Akt activation in a 
fourth IPC group after 30 min reperfusion (Figures 5.3.2 A, B and C). 
 
Results from the present study, showed variable patterns of p38 MAPK activation 
after 30 min reperfusion, as indicated in Fig. 5.3.2 A. All of these hearts showed 
functional recovery after the ischaemic insult (n=8 animals). The percentage (%) 
functional recovery is indicated for each heart. The corresponding activation of 
ERK MAPK and PKB/Akt (denoted as the RISK pathway) is indicated in Fig. 
5.3.2 B and Fig. 5.3.2 C respectively. 
 
5.3.3  The variable patterns of p38 MAPK, ERK and PKB/Akt activation in a 
fifth IPC group after 30 min reperfusion (Figures 5.3.3 A, B and C). 
 
The results demonstrated the variable patterns of p38 MAPK activation after 30 
min reperfusion in a different set of animals, indicated in Fig. 5.3.3 A. All of these 
hearts showed functional recovery after the ischaemic insult (n=8 animals). The 
percentage (%) functional recovery is indicated for each heart. The 
corresponding activation of ERK MAPK and PKB/Akt (denoted as the RISK 
pathway) is indicated in Fig. 5.3.3 B and Fig. 5.3.3 C respectively. 
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5.3.4  The variable patterns of p38 MAPK, ERK and PKB/Akt activation in an 
IPC group that showed functional recovery and failed respectively, after 30 
min reperfusion (Figures 5.3.4 A, B and C). 
 
The results demonstrated the variable activation patterns of p38 MAPK  
activation in the IPC group after 30 min reperfusion, indicated in Fig. 5.3.4 A. The 
percentage (%) functional recovery is indicated for each heart. Some hearts did 
not recover (failed) after the ischaemic insult, indicated by 0% (zero percent 
recovery). The corresponding activation patterns of ERK MAPK and PKB/Akt is 
indicated in B and C respectively. Interestingly, hearts that showed 49% and 50% 
functional recovery, showed in some animals the same level of p38 MAPK 
activation as failed hearts (Figure 5.3.4 A). Furthermore, PKB/AKT activation 
was more pronounced in failed hearts from some animals than in hearts that 
showed functional recovery (Figure 5.3.4 C). 
 
5.3.5  The variable patterns of p38 MAPK, ERK and PKB/Akt activation in an 
IPC group that failed after 30 min reperfusion (Figures 5.3.5 A, B and C). 
 
The results demonstrated the variable patterns of p38 MAPK activation in the IPC 
group after 30 min reperfusion, indicated in Fig. 5.3.5 A. These IPC hearts did 
not precondition and failed after 30 min reperfusion (indicated by 0 %). 
Interestingly hearts from this group of animals (n=8 animals) also showed a 
variable pattern of p38 MAPK activation (Fig. 5.3.5 A). The RISK pathway (Fig. 
5.3.5. B) and (Fig. 5.3.5 C) was also activated in this group.  
 
5.3.6  The variable patterns of p38 MAPK, ERK and PKB/Akt activation in a 
non-IPC group after 30 min reperfusion (Figures 5.3.6 A, B and C). 
 
The results indicated the variable patterns of p38 MAPK activation in the non-IPC 
hearts after 30 min reperfusion, indicated in Figure 5.3.6 A. These hearts (n=8 
animals) did not show functional recovery after 30 min reperfusion (indicated by 
0%). Even more intriguing was the finding that the RISK pathway was also 
activated in the non-IPC hearts after 30 min reperfusion (Figures 5.3.6 B and C). 
In addition the small heat shock protein-27 (HSP-27) was also activated in the 
non-IPC group. 
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5.3.7  Activation patterns of p38 MAPK and the RISK pathway between an 
IPC group and non-IPC group at 30 min reperfusion (Figures 5.3.7  A, B, C 
and D). 
 
The results in Figure 5.3.7 A demonstrated that at 30 min reperfusion p38 MAPK 
was significantly attenuated in IPC compared to non-IPC hearts (1.015±0.5167 vs 
2.662±0.1096; p<0.05). Activation of PKB/Akt was significantly lower in IPC 
compared to non-IPC (1.501±0.07889 vs 3.550±0.2426; p<0.05), indicated in 
Figure 5.3.7 B. ERK p44 was significantly decreased in IPC compared to non-
IPC (1.344±0.07658 vs 3.063±0.1312; p<0.05). Similarly ERK p42 was also 
significantly attenuated in IPC compared to non-IPC (1.896±0.1168 vs 
3.958±0.1678; p< 0.05), indicated in Figure 5.3.7 C. HSP-27 was also 
significantly attenuated in IPC compared to non-IPC (1.166±0.02704 vs  
2.810±0.2270; p <0.05) indicated in Figure 5.3.7 D. 
 
5.3.8  Functional recovery and the RISK pathway (Figures 5.3.8 A, B and C) 
 
The results from the present study indicated (Figure 5.3.8a) that no correlation  
(r= -0.376) exists between activation of PKB/Akt  and functional recovery in the 
IPC group after 30 min reperfusion. The results in Figure 5.3.8b indicated that 
there was no correlation (r= 0.0738) between ERK p44 activation at 30 min 
reperfusion and functional recovery in the IPC group after 30 min reperfusion. 
Similarly no correlation (r= -0.07296) was observed between activation of ERK 
p42 and functional recovery in the IPC group at 30 min reperfusion (Figure 
5.3.8c).  
 
5.3.9  Functional recovery and p38 MAPK (Figures 5.3.9) 
 
Interestingly, there was also no correlation (r= -0.0637) between activation of p38 
MAPK and functional recovery in the IPC group at 30 min reperfusion (Figure 
5.3.9a). 
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5.3.10  Correlation of the RISK pathway with haemodynamic parameters 
(Figures 5.3.10 a to 5.3.10 j) 
 
Results from the present study indicated that activation of PKB/Akt in the IPC 
group at 5 min reperfusion correlated negatively (r= -0.8734) with the aortic 
diastolic pressure at baseline/stabilisation (15 min working heart), Figure 
5.3.10a. In addition, activation of PKB/Akt in the IPC group at 5 min reperfusion 
correlated positively (r= 0.7517) with dP/dTmin measured at baseline/stabilisation 
(15 min working heart), Figure 5.3.10b. Activation of PKB/Akt did not correlate 
with any other haemodynamic parameters in the IPC group at this particular time 
point, but correlated positively (r= 0.7650) in the IPC group at 10 min reperfusion 
with PSP measured at baseline/stabilisation (15 min working heart), Figure 
5.3.10c. In addition, activation of PKB/Akt after the IPC protocol (3xIPC)  
correlated negatively (r= -0.7633) with PSP measured at baseline/stabilisation  
(15 min working heart), (Figure 5.3.10d) and correlated positively (r= 0.7855) 
with the Aortic diastolic pressure at baseline/stabilisation (15 min working heart), 
Figure 5.3.e. Interestingly, activation of PKB/Akt in the IPC group at 30 min 
reperfusion correlated positively (r= 0.578) with heart rate at baseline/stabilisation 
(15 min working heart), Figure 5.3.10f.  
 
Activation of ERK p42 after the IPC protocol (3xIPC) before sustained ischaemia, 
correlated negatively (r= -0.8131) with aortic output (AO) measured at 
baseline/stabilisation (15 min working heart), Figure 5.3.10g. Activation of 
ERKp42 after the IPC protocol (3xIPC) before sustained ischaemia, correlated 
negatively (r= -0.7073) with coronary output (CO) measured at 
baseline/stabilisation (15 min working heart), (Figure 5.3.10h). In addition, 
activation of ERK p42 in the IPC group at 30 min reperfusion correlated 
negatively (r= -0.64) with total work measured at baseline/stabilisation (15 min 
working heart ), Figure 5.3.10i. At the same timepoint (30 min reperfusion), 
activation of ERK p42 in the IPC group correlated positively (r= 0.58) with heart 
rate measured at baseline/stabilisation (15 min working heart), Figure 5.3.10j. 
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5.3.11  Correlation between p38 MAPK, HSP and haemodynamic parameters 
            (Figures 5.3.11a, b, c, d, & e) 
 
The results from the present study demonstrated that activation of p38 MAPK 
after 25 min ischaemia, correlated positively (r= 0.7089) with aortic output (AO)  
measured at baseline/stabilisation (15 min working heart), Figure 5.3.11a. In 
addition, activation of p38 MAPK after the IPC protocol (3xIPC) before sustained 
ischaemia correlated negatively (r= -0.7265) with total work measured at 
baseline/stabilisation (15 min reperfusion), Figure 5.3.11b. 
 
Expression of HSP-70 after 30 min retrograde perfusion (control) correlated 
negatively (r= -0.7119) with dP/dTMin measured at baseline/stabilisation (15 min 
working heart), Figure 5.3.11c. Expression of HSP-70 after 30 min retrograde 
perfusion (control) correlated negatively (r= 0.7464) with heart rate measured at 
baseline/stabilisation (15 min working heart), Figure 5.3.11d. Interestingly, 
expression of HSP-70 in the IPC group after 10 min reperfusion correlated 
positively (r= 0.7911) with heart rate measured at baseline/stabilisation (15 min 
working heart), Figure 5.3.11e. 
 
5.3.12  Correlation between CREB and haemodynamic parameters 
           (Figure 5.3.12) 
 
The results from the present study demonstrated that activation of CREB after 25 
min sustained ischaemia correlated positively (r= 0.7097) with dP/dTMax 
measured at baseline/stabilisation (15 min working heart), Figure 5.3.12.  
 
5.3.13  Correlation between GSK-3β and haemodynamic parameters 
            (Figure 5.3.13) 
 
Activation of GSK-3β in the IPC group after  30 min reperfusion correlated 
positively (r= 0.62) with heart rate measured at baseline/stabilisation (15 min 
working heart), Figure 5.3.13.  
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5.3.14  Correlation between AMPK and haemodynamic parameters 
           (Figure 5.3.14 a,b & c)  
 
Activation of AMPK after 30 min retrograde perfusion (control) correlated 
negatively (r= -0.8127) with dP/dTMax measured at baseline/stabilisation (15 min 
working heart), Figure 5.3.14a. Activation of AMPK after the IPC protocol (3xIPC) 
before sustained ischaemia correlated positively (r= 0.7488) with aortic diastolic 
pressure measured at baseline/stabilisation (15 min working heart), Figure 
5.3.14b. In addition, activation of AMPK after the IPC protocol (3xIPC) correlated 
negatively (r= -0.7753) with peak systolic pressure measured at 
baseline/stabilisation (15 min working heart), Figure 5.3.14c. 
 
5.3.15  Correlation between CAMKII and haemodynamic parameters 
          (Figure 5.3.15a, b & c) 
 
Activation of CAMKII in the IPC group at 30 min reperfusion correlated negatively 
(r = -0.6303) with aortic output (AO) measured at 30 min reperfusion 
(Figure 5.3.15a). Activation of CAMKII in the IPC group at 30 min reperfusion 
also correlated negatively (r = -0.6259) with coronary output measured at 30 min 
reperfusion (Figure 5.3.15b). In addition, this activation of CAMKII in the IPC 
group correlated negatively (r = -0.6610) with total work measured at 30 min 
reperfusion (Figure 5.3.15c). 
 
5.3.16 Heart rate and ejection fraction at baseline/stabilisation (15 min 
working heart) in the IPC group after 30 min reperfusion (Figure 5.3.16 A & 
B)  
 
Results from the present study demonstrated that heart rate (HR) measured  at 
baseline/stabilisation (15 min working heart) was significantly increased in the 
IPC group that failed after 30 min reperfusion, compared to the IPC group that 
showed functional recovery after 30 min reperfusion (Figure 5.3.16A). Figure 
5.3.16B indicates the differences in ejection fraction between the same hearts as 
in A. Results demonstrated that the ejection fraction measured at  
baseline/stabilisation (15 min working heart) was significantly decreased in IPC 
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hearts that failed after 30 min reperfusion, compared to IPC hearts that showed 
functional recovery after 30 min reperfusion (Figure 5.3.16B). 
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Fig. 5.3.1. A, B and C.  The variable patterns of p38 MAPK kinase activation in IPC 
hearts after 30 min reperfusion. All of these hearts (n=23 animals) showed functional 
recovery after the ischaemic insult. The corresponding Total p38 and β-Tubulin blot is 
shown for each pospho-p38 blot. 
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Fig.5.3.2   The variable patterns of p38 MAPK activation in IPC hearts after 30                    
min reperfusion, indicated in A. The percentage (%) functional recovery is indicated 
for each heart. All of these hearts (n=8 animals) showed functional recovery after the 
ischaemic insult. The corresponding activation of ERK MAPK and PKB/AKT is indicated 
in B and C, respectively. β-Tubulin is shown in D. 
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Fig. 5.3.3   The  variable patterns of p38 MAPK activation in IPC hearts after                 
30 min reperfusion, indicated in A. The percentage (%) functional recovery is 
indicated for each heart. All of these hearts (n=8 animals) showed functional recovery 
after the ischaemic insult. The corresponding activation of ERK MAPK and PKB/AKT is 
indicated in B and C, respectively. β-Tubulin is shown in D. 
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Fig. 5.3.4 The variable patterns of p38 MAPK activation in IPC hearts after                 
30 min reperfusion, indicated in A. The percentage (%) functional                 
recovery is indicated for each heart. Some hearts did not recover (failed) after the 
ischaemic insult (indicated by 0%). The corresponding activation of ERK and PKB/Akt is 
indicated in B and C, respectively. β-Tubulin as loading control is shown in D. 
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Fig. 5.3.5  The variable patterns of p38 MAPK activation in IPC hearts which                  
failed (0% recovery) after 30 min reperfusion, indicated in A. The                  
corresponding activation of ERK MAPK and PKB/Akt is shown in B and C                    
respectively. β-Tubulin as loading control is shown in D. 
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Fig. 5.3.6 Variable patterns of p38 MAPK activation in non-IPC hearts after 
30 min reperfusion, indicated in A. The corresponding activation of ERK, PKB/Akt 
and HSP-27 is shown in B, C and D respectively. β-Tubulin as loading control is shown 
in E. 
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Fig. 5.3.7.  Activation of p38 (A), ERK (B), PKB/Akt (C) and HSP-27 (D) 
between non-IPC (n=4 animals) and IPC hearts (n=4 animals); p<0.05.  IPC 
hearts showed functional recovery after 30 min reperfusion.  β-Tubulin as loading control 
is shown in E. 
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5.3.8 Functional recovery and the RISK pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.8a Correlation of PKB/AKT with functional recovery in the IPC group at 30 min 
reperfusion (n=28 animals). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.3.8b Correlation of ERKp44 with functional recovery in the IPC group at 30 min                 
   reperfusion (n= 24 animals). 
r  = - 0.376 
0 10 20 30
0
1
2
3
4
Functional recovery (Aortic output ml/min)A
ct
iv
at
io
n 
of
 P
K
B
/A
K
T 
(F
ol
d 
in
cr
ea
se
)
 
0 10 20 30 40 50
0.0
0.5
1.0
1.5
Functional recovery (Aortic output ml/min)A
ct
iv
at
io
n 
of
 E
R
K
p4
4 
M
A
PK
 (F
ol
d 
in
cr
ea
se
)
r  =  0.0738 
Stellenbosch University  http://scholar.sun.ac.za
  202
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.8c Correlation of ERKp42 with functional recovery in the IPC group at 30 min 
reperfusion (n = 24 animals). 
 
 
5.3.9 Functional recovery and p38 MAPK 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.9a Correlation of p38 MAPK with functional recovery in the IPC group at 30 min 
reperfusion (n=26 animals).  
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5.3.10 Correlation of the RISK pathway with haemodynamic parameters 
 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.10a Correlation of PKB activation in the IPC goup after 5 min reperfusion with 
Aortic diastolic pressure measured at baseline/stabilisation (15 min working 
heart), n=8. 
 
                           
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5.3.10b Correlation of PKB activation in the IPC goup after 5 min reperfusion with 
dP/dT min measured at baseline/stabilisation (15 min working heart) (n=8). 
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Figure 5.3.10c Correlation of PKB/Akt activation in the IPC group at 10 min reperfusion, with 
PSP measured at baseline/stabilisation (15 min working heart), n=8. 
 
 
After the IPC protocol, before sustained ischaemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.10d Correlation of PKB activation after 3x IPC with peak systolic pressure (PSP) 
measured at baseline/stabilisation (15 min working heart), n=8.      
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     Fig. 5.3.10e       Correlation of PKB activation during 3xIPC with Aortic diastolic pressure 
                               measured at baseline/stabilisation (15 min working heart), n=8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.10f      Correlation of PKB activation in the IPC group at 30 min reperfusion with heart  
rate measured at baseline/stabilisation (15 min working heart), n=8. 
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                 After the IPC protocol before sustained ischaemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.10g Correlation of ERK p42 activation after 3X IPC with Aortic output measured at 
baseline/stabilisation (15 min working heart), n=8. 
 
               After the IPC protocol before sustained ischaemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.10h Correlation of ERK p42 activation after 3x IPC with cardiac output measured 
at  baseline/stabilisation (15 min working heart), n=8. 
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Figure 5.3.10i Correlation of ERK p42 activation in the IPC group at 30 min reperfusion with 
total work measured at baseline/stabilisation (15 min working heart), n=8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.10j Correlation of ERK p42 activation in the IPC group at 30 min reperfusion with 
heart rate measured at baseline/stabilisation (15 min working heart), n=8. 
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5.3.11 Correlation between p38 MAPK, HSPs and haemodynamic 
parameters 
 
                                              After  25 min ischaemia 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.11a Correlation of p38 activation after 25 min global ischaemia with aortic output 
measured at baseline/stabilisation (15 min working heart), n=8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              
Figure 5.3.11b Correlation of p38 activation after 3xIPC with total work measured at 
baseline/stabilisation (15 min working heart), n=8. 
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                              Control  (30 min retrograde perfusion) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.11c Correlation of HSP-70 expression after 30 min retrograde perfusion with 
dP/dT min measured at baseline/stabilisation (15 min working heart), n=8. 
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Control  (30 min retrograde perfusion) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.11d Correlation of HSP-70 expression after 30 min retrograde perfusion with heart 
rate measured at baseline/stabilisation (15 min working heart), n=8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.11e Correlation of HSP-70 expression in the IPC group at 10 min reperfusion with 
heart rate measured at baseline/stabilisation (15 min working heart), n=8. 
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5.3.12   Correlation between CREB and haemodynamic parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5.3.12 Correlation of CREB after 25 min sustained ischaemia with dP/dTMax 
measured at baseline/stabilisation (15 min working heart), n=8. 
 
 
5.3.13  Correlation between GSK-3β and haemodynamic parameters 
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Figure 5.3.13 Correlation of GSK-3β in the IPC group at 30 min reperfusion with heart rate 
measured at baseline/stabilisation, 15 min working heart, n=8. 
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5.3.14   Correlation between AMPK and haemodynamic parameters  
 
                                     Control (30 min retrograde perfusion) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.14a Correlation of AMPK after 30 min retrograde perfusion with dP/dTmax 
measured at  baseline/stabilisation (15 min working heart), n=8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.14b Correlation of AMPK after 3xIPC with Aortic diastolic pressure measured at 
baseline/stabilisation (15 min working heart), n=8. 
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5.3.14   Correlation between AMPK and haemodynamic parameters 
 
 
 
 
 
 
 
 
 
 
 
 
            Figure 5.3.14c  Correlation of AMPK after 3xIPC with PSP measured at 
baseline/stabilisation (15 min working heart), n=8. 
 
 
5.3.15   Correlation between CAMKII and haemodynamic parameters 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.15a  Correlation between CAMKII after 30 min reperfusion and aortic   
output at 30 min reperfusion (n=8). 
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5.3.15   Correlation between CAMKII and haemodynamic parameters 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.15b  Correlation between CAMKII after 30 min reperfusion and cardiac   
output at 30 min reperfusion (n=8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.15c  Correlation between CAMKII after 30 min reperfusion and total work at 
30 min reperfusion (n=8). 
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5.3.16   Comparison of the heart rate and ejection fraction obtained for the 
             IPC group at baseline/stabilisation and functional recovery at 30 min 
           reperfusion.  
                      
        
 
                      A 
 
 
 
 
 
 
 
 
 
 
 
                    B 
 
 
 
 
 
 
 
 
 
Figure 5.3.16  Heart rate and ejection fraction, measured at baseline/stabilisation (15 min 
working heart), between IPC hearts which showed functional recovery       and failed     
respectively, after 30 min reperfusion (n=20). 
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5.3.17   Comparison of the heart rate and total work obtained for the IPC 
group at baseline/stabilisation and functional recovery at 30 min 
reperfusion.  
 
 
 
           A 
 
 
 
 
 
 
 
 
 
           B  
 
 
 
 
 
 
 
 
 
 
Figure 5.3.17 A & B  Correlation of heart rate with total work, measured at 
baseline/stabilisation (15 min working heart), between IPC hearts which showed 
functional recovery (indicated in A) and failed respectively (indicated in B), after 30 min 
reperfusion (n=8). 
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5.4) Discussion 
 
Several studies demonstrated the involvement of various MAPK signaling 
cascades in the cardioprotective mechanism of IPC. The p38 MAPK pathway is 
the most controversial pathway studied in the context of IPC. The published data 
are inconsistent and therefore the role of p38 in IPC still remains unclear. 
However, it is generally believed that in the isolated working rat heart model, an 
attenuation of p38 activation is associated with IPC-induced functional recovery, 
after 30 min reperfusion [Marais et al., 2001]. Our results however, did not follow 
the expected pattern of p38 MAPK activation, but showed variable responses 
between different animals, as indicated in Figure 5.3.1 A, B &C, Figure 5.3.2 A, 
B & C and Figure 5.3.3 A, B & C. PKB/Akt also showed variable responses 
between different animals, but to a lesser extent compared to p38 MAPK. 
 
It is also well established that the prosurvival kinases, PKB/AKT and ERK 
p44/p42 are associated with IPC induced protection. It has been shown that 
PKB/AKT and ERK p44/p42 are phosphorylated during early (15 min) reperfusion 
[Hausenloy & Yellon, 2004]. These two prosurvival kinases are denoted as 
“reperfusion injury salvage kinase” (RISK) pathways and are reported to protect 
the myocardium against ischaemia/reperfusion damage. Although Hausenloy & 
Yellon [2004] have reported a biphasic activation of PKB just after IPC and after 
15 min reperfusion, it might be that at 30 min reperfusion PKB returned to 
baseline levels, which is in agreement with our results. 
 
The next aspect that was investigated in the present study was the activation 
patterns of p38 MAPK and the RISK pathway in the IPC group, between hearts 
from animals that showed functional recovery after 30 min reperfusion and hearts 
that failed (Fig. 5.3.4. A, B & C).  
 
Interestingly, hearts that showed 49% and 58% functional recovery, showed in 
some animals the same level of p38 MAPK activation as failed hearts (Figure 5. 
3.4 A), whereas some failed hearts showed lower levels of p38 MAPK activation 
as those that showed 49% and 58% recovery (Figure 5.3.4 A). Furthermore, 
PKB/AKT activation was more pronounced in failed hearts from some animals 
than hearts that showed functional recovery (Figure 5.3.4 C).   
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A further aspect that was investigated was the patterns of p38 MAPK activation 
and involvement of the RISK pathway in IPC hearts which failed after 30 min 
reperfusion (Figure 5.3.5 A, B & C). Hearts from this group of animals also  
showed a variable pattern of p38 MAPK activation (Figure 5.3.5 A). The RISK 
pathway Figure 5.3.5  B & C was also activated in this group, which is quite 
unexpected, since the IPC hearts showed no functional recovery after 30 min 
reperfusion and according to the literature activation of the RISK pathway is 
associated with cardioprotection (Hausenloy & Yellon, 2004].  
 
Even more intriguing was the finding that the RISK pathway was also activated in 
the non-IPC hearts after 30 min reperfusion (Figures 5.3.6 B & C). In addition  
the small heat shock protein-27 (HSP-27), associated with cardioprotection, was 
also activated in the non-IPC group (Figure 5.3.6 D). 
 
Our results indicated that in the majority of animals (85%), there were no 
significant differences in the activation of p38 MAPK between the IPC group and 
non-IPC group after 30 min reperfusion. This resulted in no significant differences 
in activation of the RISK pathway and HSP-27 between IPC and non-IPC (data 
not shown). 
 
In some groups of animals (15%) however, significant differences were observed 
in p38 MAPK activation between the  IPC group and non-IPC group after 30 min 
reperfusion (Figure 5.3.8 A). This was accompanied by significant differences in 
the activation of the RISK pathway and HSP-27 after 30 min reperfusion. p38 
MAPK activation was increased in the non-IPC group (Figure 5.3.8 A), as 
expected. Interestingly, the RISK pathway (Figure 5.3.8 B and C) and HSP-27 
(Figure 5.3.8 D) activation was also increased in the non-IPC group, compare to 
the IPC group. 
 
Our data consistently show an attenuation of PKB/AKT activation at 15 min 
(Chapter 3, Figure 3.3.1(b)C and 30 min reperfusion (Chapter 3, Figure 
3.3.1(b)D in the IPC groups, compared to the non-IPC groups. This reduced 
activation of PKB/Akt was always associated with a significant attenuation of p38 
MAPK, ERKp44/p42 and HSP-27 in the IPC groups compared to the non-IPC 
groups. These results may suggest that an attenuation of p38 MAPK kinase 
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activation in the IPC group after reperfusion is detrimental to the ischaemic heart, 
since activation of the protective RISK pathway follow the same pattern as p38 
MAPK activation. Alternatively, these results may suggest that activation of the 
RISK pathway in the IPC group after 30 min reperfusion is not associated with 
functional recovery of the ischaemic heart.  
 
In order to investigate these aspects, correlation studies were performed with the 
IPC groups, to establish whether functional recovery in the IPC group correlated 
with an attenuation of p38 MAPK activation and subsequent activation of the 
RISK pathway. Results from the present study showed no correlation between 
ERKp44 and ERKp42 activation respectively, in the IPC group at 30 min 
reperfusion and functional recovery at 30 min reperfusion. Similarly, no 
correlation was observed between ERKp42 activation in the IPC group at 30 min 
reperfusion and functional recovery at 30 min reperfusion. Interestingly, no 
correlation was observed between activation of PKB/Akt in the IPC group at 30 
min reperfusion and functional recovery at 30 min reperfusion. According to the 
literature, PKB/Akt and ERK MAPK denoted as the RISK pathway is associated 
with functional recovery in IPC during reperfusion [Hausenloy et al., 2005], in 
which case a positive correlation (r = +1) is expected in the present study. No 
correlation however, was observed between functional recovery during IPC at 30 
min reperfusion and activation of the RISK pathway at 30 min reperfusion. In 
addition, the results also failed to show any correlation between p38 MAPK 
activation at 30 min reperfusion and functional recovery in the IPC group at 30 
min reperfusion. According to the literature functional recovery in the IPC group 
at 30 min reperfusion correlates with an attenuation of p38 MAPK activation 
[Marais et al., 2001], in which case one would expect a negative correlation (r = -
1) in the present study. No correlation however, was observed between p38 
MAPK and functional recovery in IPC at 30 min reperfusion. 
 
The second aim for this part of the study was to investigate the variable signaling 
patterns of kinase activation in the IPC group, observed at all time points of 
reperfusion and also in control hearts before and after sustained ischaemia. 
Since the variable patterns of kinase activation could not be attributed to 
differences in functional recovery the aim of this part of the study was to identify 
the parameters associated with the variable signaling responses. 
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The results demonstrated that the following haemodynamic parameters 
measured at baseline/stabilisation (15 min working heart) and thus before the 
start of the experiment, had a significant effect on kinase activation or 
attenuation: Aortic output (AO), Coronary output (CO), Heart Rate (HR), Aortic 
diastolic pressure, Peak systolic pressure (PSP), Ejection, Total work (Wt), 
dP/dTMin  and dT/dTMax. The results from the present study demonstrated that 
these parameters effect kinase activation and attenuation in control hearts, after 
25 min sustained ischaemia, after the IPC protocol (3xIPC), IPC after 5, 10 and 
30 min reperfusion. 
 
The results from this part of the study demonstrated that activation of the RISK 
pathway (PKB/Akt & ERK p42) and GSK-3β in the IPC group at 30 min 
reperfusion correlated positively with heart rate measured at baseline/stabilisation 
(15 min working heart). These results implicate that the activation of PKB/Akt, 
ERK p42 and GSK-3β correlate positively with nervous system (sympathetic) 
stimulation. This is a novel finding and not reported in the literature. This finding 
can explain why activation of PKB/Akt and ERK MAPK generally show a similar 
activation pattern during reperfusion. This can also explain why GSK-3β show a 
similar activation pattern as PKB/Akt during reperfusion. These results implicate 
that the higher heart rate measured at baseline/stabilisation increases the 
phosphorylation of PKB/Akt, ERK p42 and GSK-3β at the end of reperfusion. 
Increased activation of PKB/Akt is known to be anti-apoptotic and 
phosphorylation and subsequent inactivation of GSK-3β will close the 
mitochondrial permeability transition pore (mPTP). Since closure of the mPTP is 
associated with cardioprotection, these results could  explain the cardioprotection 
(measured as functional recovery) seen in this group of IPC hearts. On the 
contrary, as demonstrated in Fig. 5.3.16 a significant increase in heart rate 
measured at baseline/stabilisation (15 min working heart) in the IPC group 
resulted in failing of the hearts after 30 in reperfusion. An increase in heart rate 
will enhance the metabolic demand on the heart during ischaemia. A higher 
metabolic demand during ischaemia has been associated with reduced functional 
recovery as a result of an increase in infarct size. This could explain why these 
hearts (indicated in Fig.5.3.16) failed after 30 min reperfusion. These results 
implicate that a moderate increase in heart rate measured at 
baseline/stabilisation accompanied by a moderate activation of PKB/Akt in the 
Stellenbosch University  http://scholar.sun.ac.za
  221
IPC group is cardioprotective. On the contrary, a significant increase in heart rate 
at baseline/stabilisation accompanied by overstimulation of PKB/Akt could result 
in failure of the heart after 30 min reperfusion.  
 
In addition, activation of ERK p42 after the IPC protocol (3xIPC), showed a 
negative correlation with aortic output (AO) and cardiac output (CO). This 
indicates that a decrease in the output (performance of the heart) as measured at 
baseline/stabilisation (15 min working heart) is associated with an increased 
phosphorylation of ERK p42 after the IPC protocol (3xIPC). These results 
indicate that the attenuation of ERK p42 activation after the IPC protocol (3xIPC) 
is a measure of how well the heart was performing at baseline/stabilisation. 
These results implicate that an increased activation of ERK p42 after 3xIPC is not    
due to the effect of IPC, but correlates with the performance of the heart at 
baseline/stabilisation (15 min working heart). Since activation of ERK p42 is 
affected by sympathetic stimulation (positive correlation with heart rate at 
baseline/stabilisation), an increase in heart rate could affect the ejection of the 
hearts at baseline/stabilisation (15 min working heart) negatively, resulting in 
decreased performance (aortic and cardiac output) which correlate with an 
increased phosphorylation of ERK p42. Interestingly, ERK p44 
activation/attenuation showed no correlation with the haemodynamic parameters 
in the present study.  
 
Phosphorylation of PKB/Akt in the IPC group after 5 min reperfusion correlated 
negatively with aortic diastolic pressure and correlated positively with the 
minimum rate of contraction (dP/dTMin). These results implicate that an 
increased phosphorylation of PKB/Akt correlates with a decrease in aortic 
diastolic pressure, which is the lowest pressure in the aorta before the ejection of 
blood from the left ventricle. These results implicate that an increase in 
phosphorylation of PKB/Akt will therefore promote (enhance) relaxation and 
adequate refilling of the left ventricle in order to eject blood into the aorta. These 
results suggest that a moderate activation of PKB/Akt is beneficial to the heart, as 
overstimulation of PKB/Akt will decrease the diastolic pressure in the aorta below 
normal levels.  At 10 min reperfusion however, phosphorylation of PKB/Akt 
correlated positively with peak systolic pressure (PSP) at baseline/stabilisation 
(15 min working heart). The pressure in the aorta rises when the left ventricle 
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ejects blood into the aorta. The maximum aortic pressure following ejection is 
known as the systolic pressure. These results implicate that an increased 
phosphorylation of PKB/Akt correlates with an increase in systolic pressure in the 
aorta, which is associated with the ejection of blood into the aorta. 
Phosphorylation of PKB/Akt after the IPC protocol (3xIPC) correlated positively 
with aortic diastolic pressure and negatively with peak systolic pressure (PSP) 
measured at baseline/stabilisation (15 min working heart). These results implicate 
that a decrease in PKB/Akt after the IPC protocol (3xIPC) correlates with a 
decrease in aortic diastolic pressure. The decreased diastolic pressure in the 
aorta is associated with relaxation and filling of the left ventricle, just before 
ejection of blood into the aorta. These results implicate that moderate activation 
of PKB/Akt may facilitate adequate filling and ejection of blood from the left 
ventricle. On the contrary, overstimulation of PKB/Akt may be detrimental to the 
heart, as the increased activation of PKB/Akt will increase the aortic diastolic 
pressure, thereby preventing adequate refilling and ejection of blood from the left 
ventricle into the aorta. These results may explain the controversies regarding 
PKB/Akt activation during IPC and early reperfusion. These results are novel and 
not available in the literature.  
 
Expression of HSP-70 during IPC at 10 min reperfusion, correlated positively with 
heart rate at baseline/stabilisation (15 min working heart). These results suggest 
that phosphorylation of these kinases and HSP-70 expression are influenced by, 
or associated with nervous system stimulation. HSP-70 is a member of the heat 
shock protein family and serves as a molecular chaperone. It plays a major role 
in protecting cells against different cellular stressors, such as heat, hypoxia, 
oxidative stress, ultraviolet irradiation, apoptosis and necrosis [Zhang et al., 
2012]. Despite its protective functions, HSP-70 is used as a marker of pre-
slaughter stress in animals [Bao et al., 2008; Cvoro et al., 1998], as discussed in 
Chapter 4 (section 4.8.8) of this thesis. Interestingly, in the present study, HSP-
70 expression correlated negatively with heart rate and minimal rate of 
contraction (dP/dTMin) at baseline/stabilisation (15 min working heart) in control 
hearts before IPC. This indicates that expression of HSP-70 is attenuated with 
increased heart rate and increased minimum rate of contraction (dP/dTMin) in 
control hearts before IPC. After the IPC protocol (3xIPC), its expression is altered 
in such a way that it correlates positively with heart rate. This may suggest that 
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overexpression of HSP-70 in the IPC group may be detrimental to the heart, as 
indicated in the present study (Figure 5.3.16) where an increased heart rate at 
baseline/stabilisation (15 min working heart) before IPC, is detrimental to the 
heart and results in failing of the IPC hearts. HSP-27 showed no correlation with 
haemodynamic parameters in the present study. 
 
The results from this part of the study demonstrated that activation of p38 MAPK 
after 25 min ischaemia correlated positively with aortic output at 
baseline/stabilisation (15 min working heart). As p38 MAPK is activated by heat 
and ischaemia as well as during sustained ischaemia, great care was taken to 
keep the temperature constant at 36.5oC for 25 min during the period of 
sustained ischaemia. Thus in the absence of any variation in temperature the 
circumstances were ideal to measure p38 MAPK activation. There was no 
correlation between p38 MAPK activation and heart rate in the present study. 
Therefore these results can be interpreted that when the aortic output of the 
hearts increase in working heart mode, the activation of p38 MAPK also 
increases. This is also a novel finding and no data in literature exist to confirm or 
refute this finding. Once activated p38 MAPK phosphorylates its downstream 
substrate MAPKAP2 which in turn phosphorylates the small heat shock protein 
27 (HSP-27), which is associated with cardioprotection. HSP-27 stabilizes the 
integrity of the cytoskeleton during ischaemia, thereby exerting a protective role. 
In addition, p38 MAPK is known to enhance glycolysis. Increased activation of 
p38 MAPK during 25 min sustained ischaemia, may provide energy via anaerobic 
glycolysis to sustain the ischaemic heart in the absence of oxygen. 
 
In addition, results demonstrated that activation of CREB after 25 min ischaemia 
showed a positive correlation with the maximum rate of contraction (dP/dTMax) 
at baseline/stabilisation (15 min working heart). These results implicate that 
increased activation of CREB correlates with the increased rate of ventricular 
pressure rise in early systole. Increased activation of CREB is therefore an 
indication of increase in left ventricular pressure.  
 
Furthermore, phosphorylation of AMPK in control hearts (before sustained 
ischaemia or IPC) correlated negatively with the maximum rate of contraction 
(dP/dTMax) at baseline/stabilisation (15 min working heart). In addition, 
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phosphorylation of AMPK after 3xIPC correlated negatively with peak systolic 
pressure and correlated positively with aortic diastolic pressure. These results 
implicate that phosphorylation of AMPK is associated with an increase in aortic 
diastolic pressure. Increased phosphorylation of AMPK will therefore decreased 
the relaxation and filling of the left ventricle, resulting in inadequate ejection of 
blood from the ventricle into the aorta. These results are also novel and not 
available in the literature. 
 
Stenslokken and co-workers (2009) investigated the effect of harvesting, 
preparing and perfusing isolated mouse and rats hearts on kinase 
phosphorylation. They compared three different modes of perfusion: Langendorff-
perfusion without an intraventricular balloon, Langendorff-perfusion with an 
intraventricular balloon and working heart mode. Their study demonstrated that 
phosphorylation of ERK p44/p42, JNK and p38 MAPK increased both by excising 
the heart and the mode of perfusion [Stenslokken et al., 2009]. Harvesting of the 
heart and mounting it onto the perfusion system were the least important 
determinants of kinase activation. The mode of perfusion however, plays an 
important role in kinase phosphorylation. Langendorff-perfusion with the 
intraventricular balloon induced the strongest effect on kinase phosphorylation in 
both rats and mice. Perfusion in working heart mode caused less phosphorylation 
than Langendorff perfusion with the balloon. They concluded that working heart 
modus may be a better model than Langendorff-perfusion for studies on IPC and 
postconditioning [Stenslokken et al., 2009]. No correlation studies regarding 
kinase activation and the haemodynamic parameters of the heart were conducted 
in their study [Stenslokken et al., 2009]. 
 
Results from this part of the study demonstrated that phosphorylation of CAMKII 
in the IPC group after 30 min reperfusion correlated negatively with aortic output 
(AO), cardiac output (CO) and total work (Wt) at 30 min reperfusion. These 
results indicate that an attenuation of CAMKII activation after 30 min reperfusion 
is associated with improved functional recovery, measured as AO and CO during 
IPC. This is also a novel finding and to our knowledge has never been reported 
before. According to the literature, CAMKII is activated in the myocardium by 
excessive catecholamine exposure, followed by chronic β-adrenergic stimulation 
[Anderson 2009]. Enhanced activation and expression of CAMKII is associated 
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with ischaemia/reperfusion injury, cardiac hypertrophy, myocardial cell death and 
heart failure [Mei-ling et al., 2012]. Attenuation of CAMKII activation protects 
against excessive β1- adrenergic induced apoptosis [Zhu et al., 2003; Zhang et 
al., 2005; Yang et al., 2006]. Therefore the results from the present correlation 
study combined with what is known in the literature, suggest that hearts with 
decreased functional recovery after IPC at 30 min reperfusion and increased 
activation of CAMKII, were exposed to excessive catecholamine stimulation or 
chronic β-adrenergic activation.  
 
To confirm this, we investigated the parameters between IPC hearts (used in this 
correlation study) that showed improved functional recovery during IPC after 30 
min reperfusion and IPC hearts that did not recover after 30 min reperfusion. As 
indicated in Figure 5.3.16 A & B the results demonstrated that the only 
significant differences in the haemodynamic parameters between these two sets 
of hearts were that heart rate measured at 15 min working heart was significantly 
increased in the failed hearts compared to the hearts that recovered. Accordingly, 
the ejection fraction measured at 15 min working heart was significantly 
decreased in the failed hearts compared to the ejection fraction of the hearts that 
showed functional recovery. Additionally, the increased heart rate of the failed 
IPC hearts showed a positive correlation with the total work (Wt) performed at 15 
min working heart (Figure 5.3.17 B). The IPC hearts that showed functional 
recovery at 30 min reperfusion however, showed no correlation with the total 
work (Wt) performed at 15 min working heart (Figure 5.3.17 A). These results 
suggest that an increased heart rate (as in failed hearts) influences the ejection of 
the heart negatively; therefore the heart has to increase its performance (total 
work) to be able to eject blood. In the hearts that showed functional recovery 
however, the ejection fraction was effective enough as a result of the decreased 
heart rate, to eject blood from the left ventricle without affecting the work load on 
the heart.   
 
5.5) Conclusion 
 
In this part of the present study our aims were to correlate activation of the RISK 
pathway, p38 MAPK and kinases investigated in Chapter 3 of the thesis with 
functional recovery during IPC at 30 min reperfusion. The second aim was to 
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investigate the variable signaling patterns of kinase activation during IPC and to 
identify the parameters involved or responsible for the variability in kinase 
activation observed during al time points investigated. 
 
Results from the present study confirm that activation of the majority of the 
kinases investigated in Chapter 3, do not correlate with functional recovery during 
IPC after 30 min reperfusion, but correlate positively or negatively with the 
haemodynamic parameters of the heart, as measured after 15 min working heart. 
Since this time point is directly after the stabilisation phase before the start of the 
experiment (before IPC), it may suggest that IPC per se, does not induce or 
activate these kinases, which includes the RISK pathway, but that their activation 
patterns are induced by events before the experiment commences.  
 
Activation of the majority of the kinases at different time points, correlate with 
heart rate before the start of the experiment as measured after 15 min working 
heart (before the IPC protocol, or sustained ischaemia). This indicates that 
activation of these kinases are influenced by nervous system stimulation before 
the experiment starts and while the animals are still alive. 
 
In addition, the correlation results explain the variable signaling patterns of kinase 
activation observed at the different time points before and after sustained 
ischaemia, after the IPC protocol and also during the different reperfusion time 
points in the present study. The variable signaling patterns could be attributed to 
differences in heart rate and the effect thereof (ejection fraction, minimum and 
maximum rate of contraction), as a result of stress related processes in the 
animals before slaughtering. Since the animals utilized in the present study, were 
randomly assigned to different groups (IPC and non-IPC) before slaughtering and 
not exposed to any physical or emotional stress induced procedures such as 
maternal separation, foot shocks, transport or food and water deprivation, we 
hypothesize that increases in heart rate is due to emotional stress experienced 
by the animals in the laboratory as a result of pre-slaughter stress.  
 
The results from the proteomic study discussed in Chapter 4 of the thesis 
demonstrated that the non-IPC hearts possess over the remarkable ability to 
activate protective processes to overcome the damaging effects of sustained 
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ischaemia. Therefore we suggest that non-IPC hearts are not the ideal negative 
controls for IPC hearts, in order to investigate the mechanism of IPC induced 
protection. Subsequently in this part of the study, we compared IPC hearts which 
showed functional recovery with IPC hearts that failed. Results demonstrated that 
IPC hearts failed as a result of increased heart rate leading to a decreased in 
ejection fraction. As a result of this, these hearts have to increase their 
performance (total work and dP/dT Max) to be able to eject blood from the left 
ventricle and may end up with low glucose levels before the start of sustained 
ischaemia. Since anaerobic glycolosis is the only soure of ATP generation during 
ischaemia, an attenuation of glycolosis during ischaemia and reperfusion are 
detrimental to the ischaemic heart as fatty acid oxidation will dominate (discussed 
in Chapter 4 of the thesis). The results in this part of the study therefore support 
the results obtained in Chapter 4. 
 
In addition, we identified CAMKII as a marker of functional recovery after IPC. 
Results from this part of the study demonstrated that an attenuation of CAMKII 
activation during IPC at 30 min reperfusion is associated with functional recovery 
of the ischaemic heart. According to our results attenuation of CAMKII activation 
is a more sensitive and reliable indicator or marker of functional recovery than 
p38 MAPK. This is a novel finding and to our knowledge has never been reported 
before.  
   
Importantly, the results presented in this part of the study could also explain the 
controversies in the literature regarding activation/attenuation patterns of the 
different protein kinases at different time points of reperfusion, as discussed in 
the literature review (Chapter 1 of the thesis). 
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Chapter 6 
 
Final conclusions and future studies 
 
In the present study, one of the most important observations made was that 
activation of the majority of the protein kinases investigated, are associated with 
the haemodynamic parameters of the heart instead of functional recovery at the 
end of reperfusion. This is a novel finding and to our knowledge has never been 
reported before. Importantly, this has major implications for cell based research 
studies where kinase activation/attenuation is associated with IPC-induced 
cardioprotection in a specific context, without the necessary contribution of 
mechanical functional recovery measurements and haemodynamic parameters. 
 
The results from the present study can explain the variable signaling patterns of 
kinase activation observed at the different time points before and after sustained 
ischaemia, after the IPC protocol and also during the different reperfusion time 
points investigated in the present study. Results indicated that the variable 
signaling patterns could be attributed to differences in heart rate and the effect 
thereof (ejection fraction, minimum and maximum rate of contraction), as a result 
of sympathetic stimulation due to psychological stress in the animals before 
slaughtering. These results suggest that IPC does not induce activation 
/attenuation of these kinases, including the RISK pathway, but their activation 
patterns is a result of sympathetic stimulation when the animal is still alive.  
 
Importantly, these novel findings could help explain the controversies in the 
literature regarding activation/attenuation patterns of the different protein kinases 
during IPC, as discussed in the literature review (Chapter 1 of this manuscript). 
Therefore, data should be interpreted with great caution especially where 
activation /attenuation of the RISK pathway and p38 MAPK are investigated. 
 
Proteomic data revealed an important role for proteins related and also unrelated 
to cardiac metabolism. The expression of the protective HSP’s implicated in 
protein import and protein folding under stress conditions is increased in non-IPC 
and interestingly, these HSP’s are also associated with pre-slaughter stress. Of 
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particular interest was the observation that the expression of Annexin A3, 
implicated in cell regeneration was upregulated in non-IPC compared to IPC. The 
upregulation of Annexin A3 may induce protective processes, leading to the 
increased expression of proteins related to cardiac metabolism, as observed in 
non-IPC.  
 
These results suggest that non-IPC has an endogenous protective mechanism, 
which comes into play under various stress situations, whereby the induction of 
the protective HSP’s and Annexin A3 are upregulated when oxygen and nutrients 
are re-introduced in the post-ischaemic early reperfusion phase. The non-IPC 
possess the remarkable ability to induce adaptive processes to reverse the 
damaging effects of sustained ischaemia and the adverse effects of enhanced 
sympathetic stimulation.  
 
It is well documented that the diseased heart cannot be preconditioned [Cokkinos 
et al., 2003; Moolman et al., 1992]. Results from the present study however, 
suggest that the preconditioned heart is more susceptible to the adverse effects 
of chronic beta stimulation than a non-IPC heart, probably as a result of the 
repetitive short episodes of ischaemia during the IPC protocol.  This may result in 
poor functional recovery or failure of the IPC hearts, as a result of the altered 
metabolism, demonstrated by the attenuation of glycolysis and the altered 
transport of fatty acids. This is a novel finding and to our knowledge has never 
been reported before. It is well established, however, that an increased heart rate 
increases the severity of the ischaemic injury [Shaper 1987] and chronic β-
adrenergic receptor stimulation increases oxidative stress, leading to 
catecholamine-induced cardiotoxicity [Zhang et al., 2005; Remondino et al., 
2003;  Zhang et al., 2007]. 
 
Taken together, these results demonstrated that an IPC heart which failed after 
ischaemia /reperfusion is metabolically compromised and “worse off” compared 
to a non-IPC heart. To our knowledge this is the only study that investigated this 
aspect in the contect of IPC during reperfusion. In addition, the results from this 
part of the study suggests that chronic beta stimulation (before a period of 
sustained ischaemia) can result in poor recovery of the ischaemic heart.  
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In addition, we identified CAMKII as a novel marker of functional recovery after 
IPC. The results demonstrated that an attenuation of CAMKII activation during 
IPC at 30 min reperfusion is associated with functional recovery of the ischaemic 
heart. According to our results attenuation of CAMKII activation is a more 
sensitive and reliable indicator or marker of functional recovery than p38 MAPK. 
This is a novel finding and to our knowledge has never been reported before.  
 
Shortcomings of the present study 
 
When we set out to do this study, parts of our aims were:  
 
a) to do a Proteomic study on the membrane fraction of IPC and Non-IPC heart 
tissue to measure the density of beta receptor population.  
b) to confirm HSP-60, HSP-70, AMPK, CREB GSK-3ß and CAMKII activation 
and expression during IPC at 15 min reperfusion with Western blots.  
Unfortunately these tissue samples were accidently destroyed by a colleague and 
lack of this data is definitely part of the shortcomings of the study.   
 
Measurement of corticosterone, adrenalin, vasopressin and T-BARS levels in 
plasma and fatty acid determinations in tissue would have contributed to the 
novelty of the study. These measurements are not routinely done and since the 
proteomic study was an example of “data-mining” it was impossible to know 
beforehand which proteins are differentially regulated between IPC and non-IPC 
hearts.  
 
Future studies 
 
These novel findings do not only explain the possible differences that exist at 
protein level between an IPC that failed or showed poor functional recovery at 
reperfusion and non-IPC, but demonstrated that non-IPC hearts possess over the 
remarkable ability to reverse the adverse effects of sympathetic stimulation as 
well as the damaging effects of sustained ischaemia. Therefore, this protective 
mechanism of non-IPC is an ideal or promising model for future investigations of 
cardioprotective strategies. It is highly recommended to measure corticosterone, 
adrenalin and vasopressin levels in the plasma of animals as indicators of 
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psychological stress before sacrificing and to correlate it with HSP-20 and HSP-
70 expression levels as markers of pre-slaughter stress. It is also important to 
evaluate signaling events during early (5 min and 10 min) and late (30 min) 
reperfusion time points in combination with haemodynamic and functional 
recovery parameters to correlate with hearts that failed or showed functional 
recovery. Proteomic technologies can also contribute to these findings. This is 
essential for the clinical application of cardioprotective stategies in the future. 
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